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ABSTRACT

RENAL BASOLATERAL TRANSPORT OF
GLUCURONIDES AND OTHER ORGANIC ANIONS
IN RAT IN VITRO MODELS
by Sarah L. Miles
Glucuronidation is a common Phase II biotransformation reaction that increases the
hydrophilicity, and thus elimination, of toxins, xenobiotics, and endogenous compounds.
Previous studies suggest that the kidney can secrete glucuronide conjugates, but the renal
transport mechanisms for glucuronide secretion have not been determined. Based on the
chemical nature of glucuronide metabolites, it is hypothesized that organic anion transporter
(OAT) proteins along the basolateral membrane of the renal proximal tubule promote renal
accumulation of glucuronide conjugates. The purpose of this study was to develop a rat renal
proximal tubule model which demonstrates OAT activity and by which the contribution of OAT in
the renal accumulation of glucuronide metabolites could be assessed. In the current study two in
vitro models were established; freshly isolated renal proximal tubules (IRPTs), and renal cortical
slices (RCSs) from the male Fischer 344 rat. These models demonstrate time-, temperature- and
probenecid-sensitive uptake of prototypical OAT1 and OAT3 substrates fluorescein (FL) and 14Cp-aminohippuric acid (PAH), and the prototypical OAT 3 selective substrate 3H-estrone sulfate
(ES). Accumulation of 14C-4-acetamidophenyl-β-D-glucuronide (AG) was found to be timedependent, but not temperature- or probenecid-sensitive in IRPTs. In the RCSs, AG uptake was
time-dependent,
but
only
minimally
temperatureand
probenecid-sensitive.
Accumulation/inhibition studies with FL, PAH, ES and AG indicate very limited interaction
between AG and OAT. PAH uptake was not affected by other glucuronides (i.e. testosterone
glucuronide, methylumbelliferyl glucuronide) in IRPTs or RCSs. Studies using RCSs from
Sprague-Dawley rats yielded comparable results to those found in Fischer 344 rat. In all models,
accumulation of 14C-AG was not inhibited by excess unlabeled AG. These results suggest that in
these rat models, AG does not appear to be a substrate for renal basolateral membrane OAT
proteins; that the contribution of OAT in the basolateral membrane transport of AG (and
potentially other glucuronide metabolites) is minimal; and accumulation of AG does not appear to
be a protein carrier-mediated process. Thus, rat renal proximal tubular cells do not appear to
facilitate the accumulation of glucuronide conjugates, and thus do not appear to contribute to the
renal secretion of glucuronide conjugates.
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CHAPTER I
Introduction
1.1 Glucuronides and renal organic anion transport
Glucuronidation is a major Phase two biotransformation reaction that
increases the hydrophilicity, and thus elimination of toxins, xenobiotics and
endogenous compounds. While the liver is the primary site of glucuronidation,
this reaction also takes place in other organs including the kidney. Until recently,
glucuronidation has been considered a detoxification pathway. However, recent
findings have shown that certain reactive glucuronide conjugates have the
potential for covalent binding within tissues.

Many drugs are metabolized to

glucuronide conjugates with potential for inducing toxic reactions.

Several

analgesics (such as diclofenac, sulindac, and ibuprofen) which are metabolized
to glucuronide conjugates have been shown to cause various forms of renal
toxicity. However, the mechanism of nephrotoxicity for these metabolites has not
been fully established.
Results from previous studies suggest that the renal proximal tubule (PT)
has the ability to secrete glucuronide conjugates. Currently, the transport
mechanisms within the kidney for glucuronide conjugate transport have not been
established. Because of the anionic nature of the glucuronide metabolite, the
primary transporters of interest are the organic anion transporter (OAT) proteins
(specifically, OAT1 and OAT3).

The major site of localization of these

transporters in the kidney is along the basolateral membrane of the PT. While
OAT transporters exist on the luminal membrane of the PT as well, the
basolateral OATs are more likely to be of major importance in the role of
glucuronide secretion by the kidney.

These OAT proteins transport
1

organic

anions (OAs) from the blood into the proximal tubular cells as the initial step in
secretion. This initial transport step in secretion is of importance in determining
how renal proximal tubular cells contribute to the accumulation of glucuronide
metabolites within the kidney cells. The second step in glucuronide secretion
involves efflux across the luminal membrane into the luminal fluid. The luminal
membrane also contains numerous transporters, both from the OAT family, as
well as others such as multidrug resistance transporters (MRP) which direct the
efflux of compounds out of the cell and into the luminal fluid for removal from the
kidney. With increased understanding of the role of the basolateral OATs to
glucuronide accumulation, we may better understand the role of these
metabolites in the potential renal toxicity of compounds which are metabolized to
glucuronide conjugates.
1.2 Hypothesis
It is hypothesized that the first step of renal secretion of glucuronide
conjugates involves organic anion transporters along the basolateral membrane
of the PT.
1.3 Selection of animal species and in vitro models
The Fischer 344 rat was chosen as the primary animal model in this study
due to the fact that the rat shares numerous similar anatomical and physiological
characteristics similar to humans as well as metabolic pathway similarities,
allowing

for

comparisons

in

absorption

excretion

and

distribution

of

pharmacologic compounds (Kacew and Festing, 1996). Additionally, the Fischer
344 rat strain is an inbred strain which remains genetically consistent for many
generations. This provides greater data uniformity. Sprague-Dawley (SD) rats
were chosen as a secondary animal model for comparison to the Fischer 344 rat
because the SD rat has been indicated to demonstrate renal secretion of
2

acetaminophen glucuronide (AG) (Galinsky and Levy, 1981). Freshly isolated
renal proximal tubules (IRPTs) were chosen as a study model because this in
vitro model provides an enriched population of PT segments where cells are able
to maintain communication and metabolism.

Access to the basolateral

membrane of the PT and the contribution of this portion of the kidney to the
secretion of compounds can be separated from other components of the kidney
in this model. Most importantly, one can study the handling of molecules by the
basolateral membrane of the PT without having to consider a significant
contribution of the apical membrane.

Isolation of PT fragments involves

enzymatic collagenase digestion of the cortical tissue. Once separated from the
cortical tissue, tubules collapse and access to the luminal membrane is not
available. This is important because it enables the separation between secretion
(basolateral) and reabsorption (luminal) processes of the PT.

Renal cortical

slices (RCSs) were chosen as a secondary in vitro model to assess glucuronide
secretion. The use of RCSs also allows for access to the basolateral membrane
without significant interference from the apical membrane since in this model,
again, the lumens of the tubules collapse. The RCS model is useful in addition to
the IRPT model in that it provides a heterogeneous cell population, the
orientation of the cortical nephron is maintained, cellular communication and
metabolism is maintained and no enzymatic digestion is required in the
establishment of the model (all cellular proteins should be undamaged by any
enzymatic digestion). Both IRPTs and RCSs have frequently been used as in
vitro models to study renal transport of xenobiotics in various animal models.
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CHAPTER II
Review of Literature
2.1 Glucuronides
2.1.1 Glucuronidation and its Role in Bioactivation
Glucuronidation is a major Phase II drug-metabolizing reaction.

The

glucuronidation pathway is catalyzed by UDP-glucuronosyltransferases (UGTs).
Currently, there are approximately 20 distinct UGTs known in both humans and
rats. This superfamily of UGT proteins is divided into 2 families (UGT1, UGT2)
based on sequence homologies.

UGTs, which catalyze the conversion of

hydrophobic substrates to hydrophilic glucuronides are found in hepatic and extra
hepatic tissues. This superfamily yields a range of isozymes, each possessing
different physical and catalytic properties (Mulder et al., 1990). Most vertebrates
are capable of generating UGT-directed glucuronides from a number of
structurally divergent substances (Tukey and Strassburg, 2000). Conservation in
exon/intron organization is maintained in rodents as several UGT2 genes have
been characterized and shown to contain the same exon/intron branch points
(Haque et al., 1991; Makenzie and Rodbourn, 1990). The human UGTs range
from 529 to 534 amino acids in length, with several highly conserved domains
that are important for membrane targeting and activity. UGT activity has also
been shown to be inducible. Several xenobiotics cause the induction of UGT and
are broken down into two major classes; (1) the polycyclic aromatic hydrocarbon
induced UGT and (2) the Phenobarbital induced (PB) UGT (Mulder et al., 1990).
These compounds result in an increase in UGT enzyme protein as a result of
increased mRNA levels. Due to the overlapping substrate specificity of UGTs,
4

the glucuronidation of some aglycones may be induced by more than one
inducer.
Glucuronidation involves the transfer of the glucuronic acid group from
UDP-glucuronic acid (UDPGA) to an acceptor group on a substrate by the
enzyme UGT (Fig. 2.1). UDPGA is a highly water-soluble compound.

The

formation of UDPGA involves a two step reaction in the cytosol. UDPGA is
synthesized from the precursors glucose-1-phosphate and uridine triphosphate
(UTP) to form UDP-glucose (UDPG).
dehydrogenase to UDPGA.

UDPG is oxidized by UDPG

UDPGA must be synthesized in the cell where

glucuronidation takes place since it is not likely to be taken up by intact cells
(Mulder et al., 1990).
Glucuronidation is a microsomal reaction which takes place in the smooth
endoplasmic reticulum and serves as an important step in converting lipophillic
substrates into hydrophilic glucuronide metabolites. Glucuronide metabolites are
then eliminated from the body through the bile and urine. The mechanism of
glucuronidation is an SN2 reaction, the acceptor group of the substrate attacking
the C1 carbon of the pyranose ring to which uridine diphosphate (UDP) is
attached in an α-glycosidic bond (Fig. 2.2). The resulting glucuronide has the βglycosidic configuration. Glucuronides can be formed through hydroxyl (alcoholic,
phenolic), carboxyl, sulfuryl, carbonyl, and amino (primary, secondary, and
tertiary) linkages (Mulder et al., 1990; Tukey and Strassburg, 2000). Examples of
various chemical substrates (shown as functional groups) that undergo
glucuronidation are shown in Table 1.

The reactivity of a given substrate will

depend on the structure, due to both electronic and steric factors (Mulder et al.,
1990). In addition to structural requirements, substrates for glucuronidation must
also be sufficiently lipid soluble. The thickness or bulkiness of the substrate
molecule is important in determining which UDPGT forms will glucuronidate a
given substrate (Mulder et al., 1990). Extensive analysis of specific catalytic
activities attributed to recombinant UGT proteins has demonstrated broad
overlap of substrates targeted for glucuronidation.
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2NAD+
H2O
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dehydrogenase

UTP

phosphorylation
Cytoplasm

2NADH, 2H+
Transport across the endoplasmic reticulum

COO

O

O

-

OR
UDP-glucuronosyl
transferase

OH
HO

O-R

OH
HO

O
HO

Lumen

COO-

UDP

-

HO

UDP

β-glucuronide

UDP-α-D-glucuronic acid
(UDPGA)

Figure 2.1 Mechanism of glucuronidation. Glucuronidation involves the transfer of
the glucuronic acid group from UDP-glucuronic acid (UDPGA) to an acceptor group on a
substrate by the enzyme UDP-glucuronosyltransferase. It is synthesized in the cytosol from the
precursors glucose-1-phosphate and uridine triphosphate (UTP) to form UDP-glucose (UDPG).
UDPG is oxidized by UDPG dehydrogenase to UDPGA and transported into the smooth
endoplasmic reticulum. The mechanism of glucuronidation is a SN2 reaction, the acceptor group
of the substrate attacking the C1 carbon of the pyranose ring to which UDP is attached in a αglycosidic bond. The resulting glucuronide has the β-glycosidic configuration. Glucuronide
metabolites are then eliminated from the body through the bile and urine
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While the liver is one of the primary sites of glucuronidation based on
UDPGT activity, UDPGT is also localized in the kidney, mainly in the proximal
tubular cells (Mulder, 1990; Tukey and Strassburg, 2000). It has been reported
that in the rat, the kidney lacks some of the major UDPGT activities present in
the liver (Lucier and McDaniel, 1977), in particular testosterone (Lucier and
McDaniel, 1977) and morphine (Rush et al., 1983). In humans, UDPGT activity
is present in the kidney, where bile acids are readily conjugated (Matern et al.,
1984; Parquet et al., 1985)

High levels of glucuronidation also occur in the

intestinal mucosa. In the rat intestine, the major UDPGT enzyme present is the
planar phenol UDPGT, which is the major xenobiotics-metabolizing form
(Hartiala, 1973; Koster et al., 1986). Most other organs and tissues also possess
glucuronidation activity, although it may be very low (Mulder et al., 1990).
It is important to note that the kidney has the potential to come in contact
with glucuronides formed at both extrarenal sources such as the liver and small
intestine, as well as at intrarenal sources by conjugation of the parent xenobiotic
within the PT cell. Until recently, glucuronidation has been accepted to be a
detoxification reaction that terminated the biological activity of both endogenous
compounds as well as xenobiotics.

As opposed to the previously accepted

detoxification mechanism, some glucuronides (particularly those of the acyl
classification) are now understood to be potentially reactive intermediates (Smith
et al., 1990; Van Breemen and Fenselau, 1986; Hyneck et al., 1988). Many of
these reactive glucuronide metabolites have been shown to covalently bind to
tissue and serum proteins, and will be discussed in greater detail in the next
section.
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Figure 2.2. Formation of acetaminophen and diclofenac glucuronides.
Conjugation of acetaminophen with glucuronic acid leads to the formation of an
ethereal glucuronide moiety, while conjugation of diclofenac with glucuronic acid
leads to the formation of an acyl glucuronide moiety. Both conjugates are readily
excreted in the urine.
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Table 1. Types of glucuronides formed from various chemical substrates.

O-glucuronide substrates
OH

phenols
R

alcohols

C OH
OH

carboxylic acids

C
O

hydroxylamines
hydroxamic acids

N OH

S-glucuronide substrates
SH

thiophenols

R

thiols

C SH
SH

carbamic acids

C
S

N-glucuronide substrates
aromatic amines
hydroxylamines

N H
C

tertiary amines

N C
C

(thio)carbamate

O(or S)
NH C
NH
H

sulfonamides

O
O

C-glucuronide substrates

S NH
H

O

1,3 dicarbonyl
compounds

C
CH
C
O
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2.1.2 Toxicity Associated with Glucuronides
As shown in Fig 2.2, glucuronidation of a hydroxyl group results in an
ether-type glucuronide while glucuronidation of a carboxy group results in an
ester-type (acyl) glucuronide.

While it has previously been accepted that

glucuronidation was a detoxification mechanism, in the past several years, many
published reports have indicated that some acyl glucuronides are potentially
reactive intermediates that undergo not only hydrolysis and intramolecular acyl
migration, but also bind reversibly to proteins in vivo and in vitro (Faed, 1984; van
Breemen and Fenselau, 1985; Spahn-Langguth and Benet, 1992).

Acyl

glucuronides have been found to be electrophiles, reacting with sulfhydryl and
hydroxyl groups resulting in covalent binding of the molecule to tissue and
plasma proteins (Stogniew and Fenselau, 1982).
Covalent binding to protein can occur by two mechanisms, the first being
nucleophillic displacement where a protein functional group reacts at the
carboxylic (acyl) carbon of the acyl glucuronide leaving the protein irreversibly
bound to the drug moiety and releasing glucuronic acid (Fig 2.3). The second
mechanism is via an acyl migration by which the aglycone migrates from the 1hydroxyl group of the glucuronic acid to the 2,3 and 4-hydroxyl groups of the
glucuronic acid portion. The aldehyde group of the ring open tautomer then
condenses with a lysine group on the protein to form an imine. At the completion
of the reaction, the irreversibly bound product still contains a glucuronic acid
which acts as a covalent link between protein and drug (Fig. 2.3). In spite of the
presence of glucuronic acid in other types of glucuronides (N-, S-, C-, or ether
glucuronides) they do not undergo acyl migration and therefore no ring opening
and aldehyde formation are possible.

Covalent binding to protein has been

found for a number of compounds forming acyl-glucuronide metabolites. Studies
have demonstrated that in vivo binding to plasma proteins of tolmentin (Hyneck
et al., 1988), fenoprofen (Volland et al., 1991), diflunisal and probenecid
(McKinnon and Dickinson, 1989) is correlated with exposure to the reactive acyl
10

glucuronide metabolites of these xenobiotics. Clofibric acid was also shown to
irreversibly bind to rat liver tissue in vivo in a dose dependent manner (Sallustio
et al., 1991). King and Dickinson (1993) have further demonstrated the covalent
binding of difluinisal via its acyl glucuronide metabolite to plasma proteins, as
well as kidney, small intestine and large intestine tissues of rat, with such binding
increasing with the duration of dosing.

Other studies have demonstrated

irreversible covalent binding of suprofen to renal tissue of rat (Smith and Liu,
1995). This study by Smith and Liu (1995) further demonstrated that enhanced
exposure of a particular organ to reactive acyl glucuronides due to excretion by
or metabolism within the organ may result in enhanced covalent binding to
tissues within that organ. McGurk et al. (1996) also demonstrated irreversible
binding of mefenamic acid via its acyl glucuronide metabolite to human serum
albumin as well as cellular proteins in culture. Mefenamic acid, a nonsteroidal
anti-inflammatory drug (NSAID) commonly used to relieve pain, has been
implicated in several cases of nephrotoxicity including acute renal failure and
tubulointerstitial nephritis (Woods, 1981; Jenkins et al., 1988).
Covalent binding of reactive acyl glucuronide metabolites to cellular
constituents can result in acute toxicity, hypersensitivity reactions, mutagenesis
or carcinogenesis, although binding can occur without any harmful effects (Faed,
1984). From studies reported in the literature, there is evidence that antibodies
occur in the blood of patients at low levels following administration of
acetylsalicylic acid and valproic acid (Amos et al., 1971; Williams et al., 1992). An
immunological mechanism may be the basis for anaphylactic reactions as well as
organ toxicity, since covalent binding may be followed by antigen-antibody
formation. Thus, acyl glucuronides may act as haptens, which upon binding to
proteins become immunogens and induce antibody production (Zia-Amirhosseini,
1994).
It is important to note that an unacceptably high incidence of significant
adverse drug reactions has been reported for NSAIDs of the aryl-alkyl acid class.
Six of the 25 drugs removed from the U.S. and British market between 1964 and
11

1983 because of severe toxicity were acid compounds, five of which were
NSAIDs (Spahn-Langguth and Benet, 1992).

All six of these drugs

(benoxaprofen, ticrynafen, ibufenac, zomepirac, indoprofen and aclofenac) are
metabolized by humans to acyl glucuronides, i.e., reactive intermediates (Bakke
et al., 1984). For zomepirac, the common NSAID toxicities of gastric irritation,
nephritis, and acute renal failure were not a major factor in its withdrawl from the
market. Removal was rather due to a high incidence of anaphylactic or
anaphylactoid reactions (Corre and Rothstein, 1982; O’Brien and Bagby, 1984).
Case reports have also described such reactions for tolmentin (Rossi and Knapp,
1982), sulindac, ketoprofen, acetylsalicylic acid and ibuprofen (O’Brien and
Bagby, 1984). Additionally, in 1987, suprofen was withdrawn from the market due
to cases of unexplained acute renal toxicity (Strom et al., 1989; Hart et al., 1987).
Furthermore,

disease

states

which

compromise

the

excretion

of

acyl

glucuronides may enhance exposure of the body to these reactive metabolites
and lead to increased irreversible binding to tissue proteins. Whether such
enhanced exposure with subsequent covalent binding is a causative factor
observed in toxicity to that organ (where binding occurs) is still unknown.
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Figure 2.3. Role of glucuronidation in the activation of xenobiotics to toxic
metabolites. Covalent binding to protein can occur by two mechanisms, the first being
nucleophillic displacement where a protein functional group reacts at the carboxylic (acyl) carbon
of the acyl glucuronide leaving the protein irreversibly bound to the drug moiety and releasing
glucuronic acid. The second mechanism is via an acyl migration by which the aglycone migrates
from the 1-hydroxyl group of the glucuronic acid to the 2,3 and 4-hydroxyl groups of the
glucuronic acid portion. The aldehyde group of the ring open tautomer then condenses with a
lysine group on the protein to form an imine. In this mechanism the glucuronic acid acts as a
bridge between the acyl residue and the protein becoming part of the adduct.
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2.1.3 Renal Formation of Glucuronide Conjugates
Immunohistochemical studies conducted in human and rat indicate that
the highest concentration of renal UDPGTs is in the PT (Lock and Reed, 1998).
Renal glucuronide formation has been confirmed in studies using perfused
kidneys

from

both

rats

and

humans

for

a

number

of

phenols

(4-

dimethylaminophenol, p-nitrophenol, paracetamol) (Elbers et al., 1980; Diamond
and Quebbemann, 1981; Emslie et al., 1981). Renal glucuronidation varies for
different species and substrates.

For example, in humans clearance of

indomethacin occurs primarily by renal glucuronidation (Moolenaar et al., 1992).
Vree and Van der Ven (1999) have shown that the acyl glucuronide metabolite of
furosemide is also formed in part by the kidney tubules in humans. However,
human renal synthesis of acetaminophen glucuronide from acetaminophen is
negligible (Morris and Levy, 1984). In rat, it has been found that acetaminophen
glucuronide is synthesized from acetaminophen by the kidney and secreted into
the urine (Newton et al., 1982; Li et al., 2004). Li et al. (2004) demonstrated that
8.66 ± 2.99 % of the administered dose of acetaminophen appeared in the urine
as the glucuronide conjugate. This is in close agreement with Hart et al. (1980),
who demonstrated in isolated perfused rat kidney that 10% of paracetamol
appeared in the urine as the glucuronide conjugate.

It has also been

demonstrated that estradiol-17β-D-glucuronide (E2-17βG) is also formed within
the kidney and undergoes tubular secretion (Kanai et al., 1996). It can be seen
that the kidney has the ability to contribute to the glucuronidation of numerous
compounds. Thus total renal clearance of glucuronide conjugates must consider
the renal contribution to glucuronide metabolites found in the urine. When the
liver and the kidneys metabolize a drug into identical products and the kidney
excretes these products in the urine, the differences in metabolic pathways are
not detectable. Therefore, there is the potential for the resulting calculation of
renal clearance (CLRE) to be too high (Vree et al., 1992).
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2.1.4 Renal Handling of Glucuronide Conjugates
It has been well established that the kidney has the ability to efficiently
excrete glucuronide conjugates (Braun et al.,. 1957; Schachter and Manis, 1958:
Yuan, 2002). While glucuronide conjugates can enter the proximal tubular filtrate
via glomerular filtration, it has also been indicated that the kidney has the ability
to secrete glucuronides (Duggin and Mudge, 1975; Galinsky and Levy, 1981;
Watari et al., 1983; Somogyi et al., 1993; Van Crugten et al., 1991; Schachter
and Manis, 1958).

Since glucuronide conjugates in general are ionized at

physiological pH and are highly polar chemical species, glucuronides are subject
to a diffusional barrier in their movement across biological membranes (Evans,
1996). Glucuronide conjugates are generally acidic compounds and are generally
more hydrophilic than their parent aglycones. Most glucuronide conjugates have
pKa values of between 3-4, regardless of the pKa of the parent compound (Smith
and Williams, 1966). Therefore, at physiological pH they are almost entirely
ionized and are highly polar.

Given their polarity, movement of glucuronide

conjugates between the primary site of formation (hepatocytes), the systemic
circulation, and target cells (renal proximal tubular cells in this discussion) may
be restricted by their limited ability to passively diffuse across membrane barriers
and may depend on carrier-mediated transport systems that are present in the
cellular

membranes.

The

movement

of

glucuronide

conjugates

across

membranes has only recently begun to be investigated. Cellular transport of
glucuronide conjugates has primarily been studied in the hepatocyte, the primary
site of glucuronide formation (Sallusito et al., 2000). It has been shown that
glucuronide metabolites are substrates for organic anion transporting polypeptide
(oatp) transporters and multispecific organic anion transporter (OAT) proteins in
the basolateral (sinusoidal) membrane of the hepatocyte (Sallusito et al., 2000).
Sallusito et al. (2000) demonstrated that the sinusoidal uptake of gemfibrozil acyl
glucuronide occurs against a 50 fold concentration gradient and is inhibited by
the organic anion dibromosulophthalein (DBSP), a substrate for the oatp/OATP
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transporter proteins. Additionally the uptake of bilirubin acyl glucuronide into rat
hepatocyte sinusoidal membrane vesicles is saturable, temperature dependent,
trans-stimulated, osomotically sensitive, electrogenic, Na+ independent and
competitively inhibited by bromosulfopthalein (BSP), another substrate for
oatp/OATP proteins (Adachi et al., 1990).
While the hepatic handling of glucuronide conjugates has begun to be
investigated, currently very little is known about how the kidney secretes
glucuronide conjugates, and more specifically, what transport protein(s) along the
basolateral membrane of the PT cells are involved in transporting glucuronide
conjugates from the blood across the basolateral membrane and into the PT
cells. The kidney possesses several of the same OAT proteins as those found in
hepatocytes (Kusuhara et al., 1999; Sekine et al., 1998). Isern et al. (2001)
showed that Oatp1 expressed in Xenopus oocytes transports estradiol-17-βglucuronide (Km ~ 5 µM). Multispecific organic anion transporter 3 (hOAT3), has
also been shown to mediate the transport of estradiol-17-β-glucuronide (Cha et
al., 2000). These and other OAT proteins in the kidney may potentially contribute
to the renal secretion of glucuronide conjugates along the renal PT.
2.2 Role of the Kidney in Organic Anion Excretion
2.2.1 Renal Excretion
Maintenance of fluid and electrolyte homeostasis is a critical function of
the kidney.

The kidney also plays an important role in the elimination of

numerous xenobiotics and endogenous compounds.

Three processes are

involved in the renal handling of drugs; glomerular filtration, tubular reabsorption
and tubular secretion. The functional units of the kidney, the nephrons (Fig 2.4),
determine the degree of renal elimination of compounds through a balance of
filtration, reabsorption and secretion (Fig. 2.5).
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Renal clearance (CLREN) is defined as the hypothetical volume of plasma
from which a substance is completely removed per unit of time (usually one min)
in one pass through the kidney.

Clearance of a compound depends on

glomerular filtration rate (GFR), the rate of tubular secretion and the rate of
tubular reabsorption of that compound.
Glomerular filtration is passive filtration of the blood as the blood flows
through the glomeruli of the kidney.

The extent to which a drug or drug

metabolite is filtered depends on the molecular size and protein binding. GFR is
determined or estimated by measuring the clearance of a filtered substance that
is not reabsorbed, metabolized or secreted and is calculated as:
Clearance * Plasma concentration = Urine concentration * Urine volume
GFR= Urine concentration* Urine volume/ Plasma concentration
If ClREN depends only on filtration,
ClREN = GFR * fu
where fu is the unbound fraction of drug and GFR is the glomerular filtration rate
(normal human GFR = 125 ml/min). When this number is compared to renal
blood flow (1200 ml/min) it can be seen that only ~25% of blood is filtered at the
glomerulus.
The pores within the capillary endothelium and the ultrafiltration
membrane of the glomerulus allow only small molecules (less than 400 – 600 A
in diameter or about 5 kDa molecular weight) to be filtered into the tubular fluid.
Large molecules such as most proteins, and therefore the drugs bound to them,
cannot pass through the glomerulus, leaving only small, unbound compounds to
be filtered at the glomerulus. General kidney function can also greatly affect
glomerular filtration. Glomerular filtration is generally estimated by measuring
creatinine clearance (CLCR).

Creatinine is an endogenous compound that is

freely filtered at the glomerulus and is not protein bound (fu = 1). Therefore, for
creatinine
ClCR = GFR
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However, it is important to note that measures of renal drug clearance using
CLCR do not account for tubular secretion or reabsorption of drugs (Perri et al.,
2003).

An additional problem with using creatinine to estimate GFR is that,

although freely filtered by the glomerulus, creatinine is also secreted in small
amounts by the renal tubules. The extent of tubular secretion varies from one
individual to another, as does renal function, which may introduce large errors in
individuals with impaired renal function. Another more accurate measure of GFR
can be obtained through the measurement of inulin clearance.

Inulin is a

polymer of fructose which is freely filtered at the glomerulus and is neither
reabsorbed nor secreted by the renal tubules.

It is metabolically inert and

cleared only by the kidney.
Tubular reabsorption also affects the renal clearance of a compound. The
tubular epithelium is the site of reabsorption of many substances, with molecules
being reabsorbed (by transport or diffusion) across the luminal membrane of the
tubules from the filtrate into the intracellular cytoplasm.

From there, the

molecules can pass across the basolateral membrane (by transport or diffusion)
back into the plasma. As solutes are reabsorbed from the tubular lumen, water
follows. While GFR is about 120 ml/min, reabsorption of solutes and water along
the proximal, distal, and collecting ducts of the kidney is so extensive that only 1
– 2 ml/min of the filtered water is eliminated as urine. Reabsorption is important
for many endogenous substances (e.g., glucose) as well as some xenobiotics.
Compounds may be reabsorbed either by passive diffusion, if the compound is
lipid soluble and nonionized, or by carrier-mediated transport if it is a charged
molecule. It is important to note that the pH of the tubular lumen can also affect
reabsorption by affecting the ratio of drug in non-ionized and ionized form. With
tubular reabsorption, the clearance of a compound may then seem smaller than
expected by glomerular filtration alone (Perri et al., 2003).
The third process of tubular function is secretion. Tubular secretion can
effectively increase the renal clearance of a compound (as compared to
glomerular filtration alone) by actively secreting a compound into the proximal
18

tubular lumen.

Secretion involves transport of drugs against a concentration

gradient, thereby concentrating the compound in the tubular lumen. This
transport mechanism is energy dependent and involves carrier-mediated
transport by way of cotransporter and/or counter transporter proteins along the
tubular epithelia. The rate of tubular secretion depends solely on the protein
transporters involved.

Saturation of these transport mechanisms, and

competition between compounds that use them, may affect the rate of drug
elimination, and can thereby lead to drug interactions (Perri et al., 2003). While
some drug interactions may be beneficial, acting to prolong the duration of action
of a beneficial drug by decreasing its elimination via the kidney (e.g., probenecid
treatment prevents the elimination of penicillin in the urine), this same
mechanism can also lead to the accumulation of a toxic compound in the body.
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S1
S2
S3

Figure 2.4. Structure of the renal nephron.
The proximal tubule is divided into three sections; S1 (proximal convoluted), S2
(proximal convoluted) and S3 (proximal straight). The S1 portion of the nephron is
nearest the glomerulus, with the S3 segment nearest the Loop of Henle.
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Figure 2.5. A simplified overview of proximal tubular function.
The proximal tubule plays an important role in the elimination of biotransformation
products through a balance of filtration, secretion and reabsorption.

2.2.2 Drug Elimination by the Kidney
While all portions of the nephron can contribute to the elimination of
compounds from the kidney, the PT is the portion of the nephron that plays the
most significant role in drug elimination. To accomplish this elimination, the
kidney possesses numerous transport proteins that are primarily localized to the
proximal tubular epithelial cells of the nephron. Many of these transporters utilize
adenosine triphosphate (ATP) or transmembrane ion gradients to drive
movement of substrate compounds across the cell membrane in either a
secretory or reabsorptive direction. The structural requirements for interaction of
21

drugs with renal transport mechanisms normally include either an electronegative
(anionic) or an electropositive (cationic) charge, and a hydrophobic backbone. In
the kidney, only a few uptake systems for organic anions have been proposed
that interact with a variety of xenobiotics (Ullrich et al., 1997; Pritchard and Miller,
1993). These systems primarily include the multispecific organic anion transport
proteins (OAT1 and OAT3). These and other systems will be discussed in
greater detail in later sections. Despite the increasing knowledge of the molecular
identity of individual transport proteins, and transporter substrate specificities, the
overall knowledge regarding the role of these transporters in the renal handling of
drugs and their metabolites is limited.
2.2.3 Tubular Secretion of Organic Anions
Tubular secretion of xenobiotics, especially organic anions, has been
extensively studied (Pritchard and Miller, 1993; Moller and Sheikh, 1982;
Brendayan, 1996). Organic anions are weakly acidic compounds that are ionized
at physiological pH. A major system for net tubular secretion of hydrophobic
organic anions exists in the PTs of almost all vertebrates. Mechanisms of organic
anion transport in the kidney PTs have been studied over the past several
decades. In addition to in vivo experiments, studies have also used tissue slices,
isolated tubules, perfused tubules, cultured cells, membrane vesicles and
peritubular capillary perfusion to study how the kidney handles various
xenobiotics (Moller and Sheikh, 1982; Pritchard and Miller, 1993). The results of
these studies indicate that the secretion of organic anions from the blood into the
urine is accomplished sequentially. Tubular secretion involves a molecule (e.g.,
an organic anion) first passing from the blood into the interstitial fluid and then
across the basolateral membrane into the renal tubular cells. Once inside the
tubular epithelial cells, the molecule is then moved from the cell across the
luminal membrane and into the tubular lumen for excretion in the urine.

To

accomplish secretion, two distinct transporters are required; one at the
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basolateral membrane of the cell (to accept organic anions from the blood into
the cell), and one at the apical membrane (luminal membrane) to excrete organic
anions from the cell into the tubular fluid (urine).
When organic anion secretion was studied in isolated perfused renal PTs
from various species, the steady-state concentration of organic anions (OA) in
the tubule lumen was found to be greater than that in the peritubular bathing
medium and the concentration in the cell was greater than in either the lumen or
the peritubular bathing medium (Dantzler, 2002). Because the inside of the cell
is negatively charged (-70 mV) as compared to the lumen (-3 mV), and the
peritubular fluid (0 mV), and because OA are negatively charged at physiological
pH and do not appear bound inside the cells, this pattern of OA accumulation is
compatible with transport into the cells against an electrochemical gradient at the
basolateral membrane, with movement from the cell into the lumen down an
electrochemical gradient (Dantzler, 2002).

Membrane permeability studies in

various models have shown that (1) the permeability of the luminal membrane for
efflux of OAs is greater than that of the basolateral membrane; (2) backflux of
OAs across the epithelium from lumen to the peritubular fluid is small; and (3)
any backflux that does occur crosses the cells from the luminal membrane
across to the basolateral membrane (Dantzler, 2002).

In the renal PT, the

general direction of movement of OAs is in a secretory direction. This involves
transporters along the basolateral membrane, as OAs must move against an
electrochemical gradient to enter the cell. However, once inside the cell, OAs
move easily across the luminal membrane for excretion in the urine. Any OAs
that move back across the basolateral membrane (back flux) generally are those
reabsorbed from the luminal fluid and are intended to be returned to the general
circulation by crossing the basolateral membrane and reentering the blood.
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2.2.4 Transport of organic anions across the basolateral membrane
The first step in tubular secretion of OAs is the uptake from blood across
the basolateral membrane of epithelial cells in the PT. Transporter-mediated
systems have been shown to play a significant role in endogenous and
exogenous OA uptake in the PT. Entry of OAs along the basolateral membrane
of proximal tubular cells is of primary importance because it leads to the entry of
potentially reactive compounds into the proximal tubular (PT) cell.

As these

compounds accumulate within the cells, potentially toxic reactions can result.
Several transporters from the OAT family have been localized to the basolateral
membrane of renal PT cells (Fig 2.6). These transporters include the
multispecific organic anion transport proteins 1, 2 and 3 (OAT1, OAT2 and
OAT3). The model organic anion used for studying OAT transport is paminohippurate (PAH).

PAH is nearly completely removed from the blood

entering both kidneys and by calculating the rate of PAH clearance, can be used
to approximate renal blood flow. PAH is extensively protein bound and must
enter the luminal fluid via secretion. In general, transepithelial renal secretion of
a wide range of hydrophobic OAs involves transport into the cell of the PTs
against

an

electrochemical

gradient

at

the

basolateral

membrane

by

countertransport for α-ketoglutarate moving down its electrochemical gradient
(Fig 2.6). This step is the dominant rate limiting step in the secretory process. In
the following sections, each transporter contributing to the basolateral uptake of
OAs into the proximal tubular cells will be discussed in detail and is shown in
Figure 2.6.
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Figure 2.6 Model of organic anion transporters in the renal proximal tubule.

Uptake of organic anions (OA-) across the basolateral membrane is mediated by the
classic sodium-dependent organic anion transport system, which includes α-ketoglutarate
(α-KG2-)/OA- exchange via the multispecific organic anion transporter (OAT1) and
sodium-ketoglutarate cotransport via the Na+/dicarboxylate cotransporter (NaDC3). A
second sodium-independent uptake system for OA- has been identified only in human
proximal tubules (OAT2) and is not a dicarboxylate exchanger. OAT3 has been shown to
transport bulky OA- and has recently been demonstrated to be a dicarboxylate
exchanger. Intracellular accumulation of substrates of both transport systems has been
demonstrated in both mitochondria as well as vesicles of unknown origin. The apical
(brush-boarder) membrane contains various transport systems for efflux of OA- into the
lumen or reabsorption from the lumen into the cell. The multidrug resistance transporter,
MRP2, mediates primary active luminal secretion. The organic anion transporting
polypeptide, OATP1, and the kidney-specific OAT-K2 and OAT-K1 might mediate
facilitated OA- efflux but could also be involved in reabsorption via an exchange
mechanism. URAT1 functions as an exchanger mediating reabsorption of uric acid, but
can also transport OAs. OAT4 is present only in human kidney, and its mechanism is
unknown. The human type I sodium-dependent inorganic phosphate transporter, NPT1,
originally thought to function primarily in the reabsorption of phosphate from the
glomerular filtrate, has since been determined to transport organic anions
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2.3 Organic Anion Transporter Proteins involved
in Renal Secretion of Organic Anions
2.3.1 Organic anion transporter 1 (OAT1)
Previously referred to as the PAH transporter (Lu et al., 1999), OAT1 is
the first of 5 members of the OAT family. OAT1 through OAT5 are all members
of the Slc22a (amphiphillic solute transporter) family, which is a subset of the
major facilitator superfamily (Koepsell and Endou, 2004). Sequencing of various
OAT1 clones reveals regions coding for 546 (mouse; Lopez-Nieto et al., 1997),
550 or 563 (hOAT1 short isoform; Hosoyamada et al., 1999; Race et al., 1999;
long isoforms; Hosoyamada et al., 1999;), or 551 (rat; Sekine et al., 1997; Sweet
et al., 1997; rabbit; Bahn et al., 2002) amino acids. Compared to hOAT1 (100%),
homologies decrease in order in comparison to hOAT1; rabbit (91.3%)>rat
(90.6%)>pig (89.6%)>mouse (87.9%)>>flounder (55.9%)>>C. elegans (28.1)
(Burckhardt and Burckhardt, 2003). In the human, OAT1 appears in four splice
variants; OAT1-1, OAT1-2, OAT1-3, and OAT1-4. Preliminary findings show no
difference between OAT1-1 and OAT1-2 with respect to transport whereas OAT
1-3 and OAT 1-4 appear to be nonfunctional (Buttler et al., 2001). Membrane
topology models of OAT1 predict 12 putative transmembrane domains. Four
consensus sequences for N-glycosylation are present in the large extracellular
loop between the first and second transmembrane domains and four protein
kinase C phosphorylation sites are predicted in a large intracellular loop between
the sixth and seventh transmembrane domains (Burckhardt and Burckhardt,
2003).

Studies using mouse OAT1 demonstrate that a large portion of the

protein remains in the intracellular compartment, suggesting that glycosylation of
OAT1 is involved in the sorting of the OAT1 protein to the plasma membrane.
Immunoblot analysis using polyclonal antibodies against hOAT1 shows a single
protein band with molecular mass of 80-90 kD in human kidney cortex extract.
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This size is decreased to 60 kD following deglycosylation (Cihlar et al., 1999). In
the rat kidney a single 77 kD protein band is detected with rOAT1 antiserum
(Nakajima et al., 2000). The predicted molecular weight of hOAT1 and rOAT1
from amino acid sequence is 60 kD. These heavier molecular weights suggest
that OAT1 is a glycosylated protein (Sekine et al., 2000).
Physiologically, OAT1 mediates the first step in the renal excretion of
many anionic drugs (e.g. antibiotics, anti-viral drugs, NSAIDs, diuretics,
angiotensin converting enzyme (ACE) inhibitors, angiotensin II antagonists, antineoplastic agents, anti-epileptic agents) and endogenous anions (e.g. cyclic
nucleotides, dicarboxylates, prostanoids, neurotransmitter metabolites) and acts
in parallel with other OA transporting proteins along the basolateral membrane in
the PT (Sekine et al, 2000). OAT1 is one of the primary transporters for OAs
along the basolateral membrane of the renal PT. The contribution of OAT1 in OA
secretion in numerous models has been thoroughly studied and characterized.
Molecular properties of OAT1 are summarized in Table 2.
2.3.1.1 Cloning and Tissue Distribution
Molecular cloning of organic anion transport proteins from a number of
species has greatly advanced the knowledge of organic anion transport. OAT1
(Slc22a6) was first identified by expression cloning from the kidneys of mouse
and initially identified as NKT (novel kidney transporter, Lopez-Nieto et al., 1997).
Later, OAT1 was identified in rat (OAT1, Sekine et al., 1997; ROAT, Sweet et al.,
1997), and flounder (fOAT1, Wolff et al., 1997). The human ortholog was cloned
in 1998 by Reid et al.

(hOAT1, 1998) and later by four other laboratories

(hOAT1, Hosoyamada et al.,1999; Race et al.,1999; Cihlar et al., 1999; PAHT,
Lu et al., 1999). Additional orthologs of OAT1 have also been identified in rabbit
(Bahn et al., 2002) and pig (Hagos et al., 2002). The term “OAT1” is used to
refer to all orthologs, and the species from which the ortholog was derived is
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Exchange of
organic anions
against αketoglutarate

Human: proximal
tubules, basolateral
membrane.
Rat: proximal
tubules, segments
S1~S2>S3;
basolateral
membrane

Human: basolateral
membrane of
proximal tubule
Rat: proximal
tubules, S1>S2=S3,
human:
basolateral
kidneys>>skeletal
membrane; thick
muscle, brain
rat: liver>>kidney> ascending limb of
Henle's loop,
brainb or
connecting tubule.
human, rat,
kidney>>liver>
colleting duct
mouse
lungs>braina

OAT 3

a. Buist et al. 2002
b. Kusuhara et al. 1999

Regulation

Down regulation
by protein kinase
C (PKC); upregulation by
PAH, FL, α-KG,
mitogen-activated
cAMP, cGMP,
NSAIDs, methotrexate, kinase (MEK)/
extracellular
β-lactam antibiotics,
ochratoxin A, uric acid, regulated kinase
(ERK)1/2
PGE2

Substrates

Exchange of
organic anions
against αketoglutarate

PAH, FL, cimetidine,
DHEA-S, estradiol
glucuronide, estrone
sulfate, methotrexate,
ochratoxin A, PGE2,
PGF2α, salicylate,
benzylpenicillin,
Down regulation
(E217βG)
by PKC

Human: Basolateral
membrane of
proximal tubule
Rat: luminal
membrane of
collecting ducts
cortical thick
assending limb of uniport of organic PAH, α-KG, salicylate,
Henle's loop
anions
acetylsalicylate, PGE2 not demonstrated

Transport

Localization

human, rat,
mouse

human:
liver>kidneys
male rat:
liver>kidneys
female rat:
kidneys>livera

Kidneys>>brain

Expression

OAT 2

OAT 1

human, pig,
rabbit, rat,
mouse,
flounder,
C.elgans

Transporter Cloned from

Table 1. Characteristics of basolateral OAT transporters in renal proximal tubules

generally indicated by a lower case letter designation preceding OAT1 (i.e.
rOAT1 for rat OAT1) (Burckhardt and Burckhardt, 2003).
Northern blot analysis has revealed that OAT1 is highly expressed in the
cortex of the kidney of the human (Cihlar et al., 1999; Hosoyamada et al., 1999;
Lu et al., 1999; Race et al., 1999), rat (Buist et al., 2002; Kobayashi et al., 2002a;
Sekine et al., 1997; Sweet et al., 1997), and mouse (Lopez-Nieto et al., 1997).
Besides kidney, OAT1 has also been detected to some degree in brain, liver,
skeletal muscle, and placenta and possibly retina (Burckhardt and Burckhardt,
2003). In SD rats, Buist et al. (2002) found that the amount of OAT1 mRNA in the
kidney steadily increased after birth, reaching a maximum around 30 days. After
30 days, mRNA levels decreased in females but remained constant in males.
This indicates that there is a gender difference in OAT1 expression in adult SD
rats. Kobayashi et al. (2002a) however, did not find a gender difference in the
expression of OAT1 in 35-day old Wistar rats. The potential for gender and
species difference in OAT1 expression must therefore be considered when
studying transport of organic anions and other compounds in various in vitro and
in vivo systems from different rat strains.
Immunohistochemical analysis of OAT1 protein has shown that OAT1 is
localized to the basolateral membrane of proximal tubular cells in humans
(Hosoyamada et al., 1999; Motohashi et al., 2002) and rat (Kojima et al., 2002;
Tojo et al., 1999). The proximal tubule, which is comprised of three sections (S1,
S2, S3) shows varying amounts of OAT1 expression in each section. It has been
demonstrated that, in rat, OAT1 is primarily expressed in the S2 portion of the
proximal tubule (Tojo et al., 1999) with the S1 and S3 segments showing only
weak expression of the OAT1 protein (Kojima et al., 2002). Protein labeling for
the OAT1 protein in the human PT has shown varying results, either showing
S1=S2=S3 (Motohashi et al., 2002) or labeling only in the S1 and S2 portions
(Hosoyamada et al., 1999). Cerrutti et al. (2002) demonstrated, using Western
blot studies, that OAT1 protein in basolateral membrane vesicles (BLMV) from
female Wistar rats at 110-130 days of age was present at only 40% of the level
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found in BLMV from male rats. Kobayashi et al. (2002a), however, did not find a
gender difference in expression of OAT1 in male and female Wistar rats at 7
weeks of age. Protein analysis has revealed that the amount of OAT1 protein can
potentially be different in male and female rats (possibly depending on age as
well), and this may contribute to gender differences in the pharmacokinetics of
anionic drugs.
2.3.1.2 OAT1 Substrates; Characterization and Specificity
Cloned OAT1 has been expressed in Xenopus laevis oocytes, COS7
cells, LLC-PK1 cells, HeLa cells, CHO cells, and in immortalized mouse PT cells.
More than 150 substrates have been tested with the cloned and heterologously
expressed OAT1 from human, rat, mouse, flounder and C. elegans,
demonstrating a wide range of compounds that are substrates for OAT1
(Burckhardt and Burckhardt 2003).
OAT1 demonstrates wide substrate selectivity including endogenous
substances such as cyclic nucleotides (cAMP, cGMP), prostaglandins (PGE2),
and uric acid, and numerous structurally unrelated drugs such as NSAIDs
(acetylsalicylate, indomethacin, salicylate), N-acetylcysteine conjugates, antiviral
drugs (acyclovir, cidofovir, zidovudine), diuretics (acetazolamide, bumetanide,
ethracrynic

acid,

tetracycline),

furosemide),

uricosuric

drugs,

antibiotics

(benzylpenicillin,

antineoplastic

drugs

cephaloridine,

(methotrexate)

and

ochratoxin A. The prototypical substrate for OAT1 is PAH (Miller and Pritchard
1997). Fluorescein (FL) also shows the same transport properties as PAH and is
thus used as a prototypical substrate for OAT1 as well (Dantzler, 2002).
Numerous studies have been conducted using PAH as a marker substrate for
OAT1 uptake.

Studies using various classes of substrates tested on PAH

transport have been used to establish the structural requirements for substrates
interacting with the PAH transporter (Burckhardt and Burckhardt 2003). It has
been determined that the structural requirements for OAT1 substrates include:
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1. Substrates must have a hydrophobic domain of 4-10 Å
2. An increase in the strength of the negative charge (decrease in pKa)
favors the interaction with the PAH transporter.
3. A full ionic charge is not necessary (uncharged polarized molecules
can interact with OAT provided they are hydrophobic enough)
4. Electron withdrawing side groups (Cl, Br, NO2) increase affinity for
OAT1 (Burckhardt and Burckhardt 2003)
Binding of substrates to the transporter most likely involves hydrophobic
interactions and the formation of hydrogen bonds.

The negatively charged

molecules may bind to oppositely charged amino acid residues of OAT1.
Because hydrogen bonds are relatively weak, release of substrates after
translocation into the cell is easier. The formation of hydrogen bonds enables a
transporter to interact with molecules from various chemical classes, indicating
that hydrogen bonds may play a key role in polyspecific transporters (Burckhardt
and Burckhardt, 2003). While OAT1 proteins from various species show similar
function, it has been demonstrated that there are species differences in substrate
specificity of the various isoforms. It has been shown that rOAT1 has the ability
to transport the compound methotrexate (Sekine et al., 1997; Uwai et al., 2000)
while hOAT1 does not (Lu et al., 1999). It is important to note also, that OAT1
transport is not strictly limited to OAs.

While the prototypical organic cation

tetraethylammonium (TEA) was not transported by rOAT1 (Uwai et al., 1998;
Sekine et al., 1997; Sweet et al., 1997) and did not inhibit other isoforms of OAT
(hOAT1: Cihlar et al., 1999; Islinger et al., 2001; fOAT1; Wolff et al., 1997), OAT1
has been shown to transport cimetidine, a weak base which forms a cation
(fOAT1: hOAT1: Burckhardt et al., 2003). Cimetidine has also been shown to
inhibit PAH accumulation in intact rat kidney (Ullrich et al., 1993).
OAT1 is thought to be the classic sodium-dependent organic anion
transporter along the PT. Characterization of OAT1 transport has been carried
out in various expression models using uptake experiments utilizing radiolabeled
PAH. Summary of transport and Km values for PAH transport are listed in Table
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3. Uptake of labeled PAH was found to be saturable, with Km values ranging
from 3.9 to 430 µM (Burckhardt and Burckhardt, 2003). In rOAT1 expressing
models, Km values for PAH uptake ranged from 11-85.1 µM where as in hOAT1
expressing models, Km for PAH uptake ranged from 3.9-22 µM (Table 3).
Transport by OAT1 involves transport against an electrochemical gradient
in exchange for α-ketoglutarate (or other dicarboxylates such as glutarate)
(Pritchard and Miller, 1996) (Fig. 2.5). OA exchange for dicarboxylate has been
demonstrated in several OAT1 clone models (Lu et al., 1999; Apiwattanakul et al,
1999; Cihlar and Ho, 2000). The α-ketoglutarate concentration is maintained by
metabolic production within the cell, and also by Na+ coupled uptake of αketoglutarate into PT cells via the Na+-dicarboxylate exchanger (NaDC3) (Fig.
2.5). This inside to outside concentration difference of Na+ provides the driving
force for the uptake of organic anions against negative membrane potential.
Preloading cells with glutarate has been shown to increase the uptake of PAH by
OAT 1 (human: Cihlar et al., 1999; Ho et al., 2000; Lu et al., 1999; Motojima et
al., 2002; rat: Cihlar et al., 1999; Pombrio et al., 2001; Sekine et al., 1997; Sweet
et al., 1997). Coexpression of OAT1 with the Na+-dicarboxylate exchanger also
demonstrated an increase in PAH uptake with dicarboxylate present outside of
the cell (thus available as substrate for the dicarboxylate exchanger; Sekine et
al., 1997; George et al., 1999).

Sodium that is transported into the cell by the

+

Na -dicarboxylate exchanger is removed by the membrane bound Na+/K+ATPase to maintain the sodium gradient across the basolateral membrane, thus
classifying OAT1 as a tertiary active transporter.
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Table 3 PAH substrate specificities for basolateral OAT transporters

Transporter
hOAT1

Species
Human

Expression
system

Transport (+/-)
or Km (µM)

Oocyte

+
3.9
4.0
9.3

rOAT1

Rat

References
Race et al. 1999
Islinger et al. 2001
Cihlar et al. 1999
Hosoyamada et al.
1999

CHO cells

15.4

Cihlar and Ho, 2000
Ho et al. 2000

HeLa cells

5.0

Lu et al. 1999

Mouse PTC

15.8
20.1

Takeda et al. 2000
Takeda et al. 2001

OK cells

22.0

Motojima et al. 2002

Oocyte

11.0
14.3
31.0
70.0

Pombrio et al. 2001
Sekine et al. 1997
Uwai et al. 2000
Sweet et al. 1997

LLC-PK1

47.0
59.5

Nagata et al. 2002
Hasegawa et al. 2002

Mouse PTC

43.2
85.1

Takeda et al. 1999
Sugiyama et al. 2001

hOAT2

Human

EcR293
LLC-PK1

+
+

Sun et al. 2001
Morita et al. 2001

rOAT2

Rat

Oocyte

+

Sekine et al. 1998

hOAT3

Human

Oocyte

87.2

Cha et al. 2001

rOAT3

Rat

Oocyte

64.7
278.0
+
-

Kusuhara et al. 1999
Feng et al. 2001
Hasegawa et al. 2002
Nagata et al. 2002

LLC-PK1
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2.3.1.3 Regulation
The mechanism responsible for the basolateral uptake of OAs is well
understood. However, the cellular regulation of OA transporters has only recently
begun to be studied. Physiological studies have established the regulation of
organic anion transport by hormones, kinases, growth factors and even
substrates (Terlouw et al., 2003).

OAT1 proteins possess several potential

phosphorylation sites for protein kinases, suggesting that phosphorylation of one
or more of these sites may play a role in OAT1 regulation (Sekine et al., 2000).
Studies carried out in various OAT expression models have all implicated that
protein kinase C (PKC) may play a role in the regulation of this transport system
(Shuprisha et al., 2000). Early studies on the activation of PKC by phorbol esters
in isolated PTs from rabbit revealed conflicting data.

Hohage et al. (1994)

demonstrated that activation of PKC revealed a stimulation of PAH uptake,
where Gekle et al. (1999) found that PKC activation by phorbol esters caused an
inhibition of PAH uptake.

Studies using stauorosporine, a PKC inhibitor,

reversed the stimulation or inhibition by phorbol esters, indicating that PKC has
the ability to regulate OAT activity. Stimulation of PKC by phorbol esters has
also been shown to inhibit the uptake of FL in killifish tubules (Miller, 1998) and
inhibit PAH transport across both the basolateral and luminal membranes in
opossum kidney (OK) cells (Sauvant et al., 2001; Takano et al., 1996). PKC
activation by parathyroid hormone has also been shown to cause an inhibition of
PAH transport in OK cells (Nagai et al., 1997). These studies in conjunction with
others indicate inhibition of OAT1 by activation of PKC (human: Lu et al., 1999;
rat: Uwai et al., 1998; mouse: You et al., 2000). Thus, while the definitive role of
PKC in activation or inactivation of OAT1 via phosphorylation remains to be fully
elucidated, it is evident that PKC plays an important role in the regulation of
OAT1 protein in the renal PT.
While studies have shown a relationship between PKC activation and
inhibition of OAT1 transport, it has not been determined whether PKC regulation
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involves a decrease in membrane expression by internalization of membrane
transporters or by inhibition of recruitment of transporters to the membrane. In
studies conducted on mouse OAT1, activation of PKC led to a decrease in Vmax
with no change in Km, indicating internalization of active transporters (You et al.,
2000). Interestingly, PKC was not shown to directly phosphorylate the mOAT1
protein, suggesting PKC may actually phosphorylate an OAT1 regulatory protein
that is responsible for internalization/inhibition of OAT1. Wolff et al. (2003) has
demonstrated that PKC-induced hOAT1 downregulation is achieved through
carrier retrieval from the cell membrane and does not involve phosphorylation of
the hOAT1 protein.
As described previously, OAT1 is a tertiary active transport carrier.
Therefore, inhibition of uptake via OAT1 can also be accomplished through
regulation of either the Na+/K+-ATPase or NaDC3. Treatment of flounder PTs
with phorbol esters is thought to inhibit OA uptake via OAT1 by inhibition of
Na+,K+-ATPase (Halpin and Renfro, 1996) because PKC activation has been
shown to partially deactivate renal Na+,K+-ATPase (Bertorello and Aperia, 1989).
Studies by Rover et al. (1998) indicate that PKC did not affect transport mediated
by the basolateral NaDC3 in rabbit.
Of additional interest is regulation via epidermal growth factor (EGF).
EGF is an endogenous compound that is important in normal tubulogenesis, and
has been shown to enhance the basolateral uptake of OAs in opossum kidney
(OK) cells (Sauvant et al., 2001).

This activation is believed to be via the

mitogen-activated protein kinase (MAPK) pathway because EGF stimulates both
OA uptake and phosphorylation of extracellular signal-regulated kinase 1 and 2
(ERK1/2).

Both OA uptake and ERK1/2 phosphorylation was prevented by

inhibition of mitogen activated extracellular signal-regulated kinase kinase (MEK)
(Sauvant et al., 2001) Sauvant et al. (2004) also showed in OK cells that EGF
stimulates basolateral OA transport.

They demonstrated that activation is

through ERK1/2, arachidonic acid, phospholipase A2, and generation of
prostaglandins. EGF activates adenylate cyclase and protein kinase A (PKA),
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stimulating OA uptake. Thus, this demonstrates another cellular mechanism for
regulation of OAT1 activity in the PT cell.
Triiodothyronine (T3) or dexamethasone (DEXA) pretreatment in rats has
been shown to increase renal PAH excretion (Bahn et al., 2003). Stimulation
was accompanied by increased protein synthesis in the renal cortex in both
cases. Increased OAT1 mRNA levels following T3 or DEXA treatment indicate
that OAT1 expression can also be regulated by T3 and DEXA.
There are indications that a number of physiological factors help regulate
basolateral organic anion transport in mammals. However, there are still many
details regarding the pathways involved in OAT regulation that remain to be
clarified, as well as questions about the actual physiological significance of
regulation that remain unanswered.
2.3.2 Organic Anion Transporter 2 (OAT2)
In humans, OAT2 (SLC22A7) appears to participate in the renal handling
of organic anions. OAT2 has been shown to share 42% amino acid sequence
identity to OAT1. OAT2 is quite possibly only a minor contributor to organic
anion secretion along the basolateral membrane of the PT, as it has only been
localized to that membrane in the human kidney. However, since information on
OAT2 is limited, its full contribution to OA handling has not been elucidated.
Molecular properties of OAT2 are summarized in Table 2.
2.3.2.1 Cloning and Tissue Distribution
OAT2 was the first member of the OAT family to be cloned. In 1994, a
gene product was cloned from rat liver and named novel liver transporter (NLT).
It has sequence motifs similar to a major facilitator superfamily and was cloned
but not characterized (Simonson et al., 1994).

Later, it was recloned and

identified as polyspecific organic anion transporter and renamed OAT2 (Sekine
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et al. (1998a). Two splice variants of hOAT2 have been reported (hOAT2A and
hOAT2B) but the sequences have not been determined (Sun et al., 2001).
Studies of the OAT2 proteins have shown that rOAT2 is a protein of 535 amino
acids (Simonson et al., 1994) and mOAT2 has 540 amino acids (Kobayashi et
al., 2002b). The two splice variants of hOAT2 (2A and 2B) have 546 and 538
amino acids respectively (Sun et al., 2001). The protein structure has been
predicted to contain 12 transmembrane spanning domains.

The large first

extracellular loop between the first and second transmembrane helix of rOAT2
and mOAT2 contains two potential sites for N-glycosylation. Two potential sites
for phosphorylation by protein kinase A (PKA) and protein kinase C (PKC) have
been reported for rOAT2 and six potential sites for PKC phosphorylation have
been reported for mouse OAT2 (Burckhardt and Burckhardt, 2003).
Expression of mRNA of hOAT2 has been detected in the liver and kidney
(liver>kidney) (Sekine et al., 1998a; Sun et al., 2001). Immunohistochemical
analysis revealed that hOAT2 is localized to the basolateral side of the PT in
kidney (Enomoto et al., 2002a; Khamdang et al., 2002). In male rats the OAT2
transcript was also found in the liver with little expression in the kidney (Sekine et
al, 1998b; Simonson et al, 1994; Sun et al., 2001). Immunofluorescence
localization by Kojima et al. (2002) demonstrated the presence of rOAT2 in the
renal cortex and medulla. The expression level of rOAT2 was much lower
compared to that of rOAT1 and rOAT3 (Kojima et al., 2002). rOAT2 has been
shown to be localized on the apical side of the medullary thick ascending limbs of
Henle’s loop, and cortical and medullary collecting ducts, whereas rOAT2 was
not detected in the proximal tubular cells (Kojima et al., 2002). Gender
differences in OAT2 expression have also been shown (Buist et al., 2002;
Kobayashi et al., 2002a). Female rats show a higher expression of OAT2 in the
kidneys compared to male rats. This gender difference appears at the onset of
estrogen production in female rats, suggesting that hormones may play a role in
regulation of renal OAT2, but not hepatic OAT2 (Kobayashi et al., 2002a).
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It is important to note that immunohistochemistry studies have yielded
results that differ for human and rat, as well as gender differences in expression.
Immunohistochemistry has shown that localization of OAT2 varies between
humans and rats, and this must be taken into consideration when studying and
comparing the effects of certain compounds that may be substrates for OAT2.
With varying levels of expression of OAT2, different organs from different species
may respond differently to therapeutic or toxic compounds. Gender differences
present the same problems when studying the effects of certain xenobiotics, as
males or females may be more or less susceptible to certain drug effects, thus
confounding any comparison that might be made between males and females.
Both of these points become additionally important in considering the contribution
of OAT2 in the secretion of OA along the basolateral membrane of the renal PT.
While studies in humans may show transport of a compound, studies in rats may
yield significantly different results, and results in male study models may yield
varying results from those found in females.
2.3.2.2 OAT2 Substrates; Characterization and Specificity
The substrate selectivity of OAT2 and OAT1 appear to be similar,
however, the transport efficacy for each substrate is different. The transport of
PAH by hOAT2 occurs at much lower levels than by hOAT1 (Sekine et al., 1997).
When expressed in Xenopus laevis oocytes, hOAT2 demonstrated uptake of
organic anions such as salicylate, acetylsalicylate, PGE2, methotrexate,
dicarboxylates and PAH (Sekine et al., 1998a).

hOAT2 has been shown to

transport PGF2α in a time- and concentration-dependent manner (Enomoto et al.,
2002a). Khamdang and colleagues (2002) have also documented transport of
cephaloridine by hOAT2 and its contribution to the renal excretion of this
antibiotic.

Studies conducted with rat OAT2 have shown that rOAT2 mediates

the transport of PGF2α with an affinity similar to that of hOAT2 (Takeda et al.,
2002).
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In the kidney (as well as liver) rOAT2 mediates saturable uptake of
salicylate from the blood in a sodium independent manner, like that of OAT1
(Sekine et al., 1998a). Salicylate uptake however, was not trans-stimulated by
intracellular glutarate (Sekine et al., 1998a). When OAT2 was expressed in LLCPK1 cells, transport of α-ketoglutarate was not found (Morita et al., 2001). This
indicates that OAT2 does not function as a dicarboxylate exchanger, exchanging
an extracellular OA against intracellular α-ketoglutarate. PAH transport was also
not inhibited by dicarboxylates further supporting this conclusion (Burckhardt and
Burckhardt, 2003). Summary of transport and Km values for PAH transport are
listed in Table 3. Wolff (unpublished results: Burckhardt and Burckhardt, 2003)
has indicated that OAT2 shows low affinity for PAH, concluding that if OAT2 is
present in the basolateral membrane of PT cells, it is unlikely to contribute much
to organic anion secretion.

Human OAT2 is also only weakly inhibited by

probenecid, the prototypical inhibitor of the OAT proteins. Enomoto et al. (2002)
have determined that the Ki value of probenecid for human-OAT2-mediated
organic anion uptake is 766 µM. Khamdang et al. (2003) demonstrated this point
by showing that cephaloridine induced nephrotoxicity was not reversible in
human OAT2-expressing S2 cells when treated with 1mM probenecid, but
nephrotoxicity could be reversed in S2 human-OAT1 and S2 human-OAT3 cells
by treatment with probenecid.
2.3.2.3 Regulation
Hormonal regulation of rOAT2 has been studied. Findings have shown
that there is an increase in OAT2 mRNA levels in male rat kidney following
castration, with subsequent decrease in levels following post castration treatment
with testosterone (Kudo et al., 2002; Kobayashi et al., 2002a). However, this
increase is minimal and does not approach the levels seen in female kidney.
Administration of estrogen to castrated males provided conflicting results in
mRNA levels of OAT2 (increase: Kudo et al., 2002; decrease: Kobayashi et al.,
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2002a). This indicates that sex steroids do not apper to be the primary mediator
of the gender difference in OAT2 expression in rats. Buist et al. (2003) and
Kobayashi et al. (2002a) were able to demonstrate in hypophysectomized (HX)
rats, a marked decrease in OAT2 mRNA in female rats, while the levels of OAT2
in HX male rats was not altered. Continuous infusion of growth hormone (GH)
(female pattern) significantly increased OAT2 mRNA in HX rats compared with
untreated rats (Buist et al., 2003). This demonstrated that the female pattern of
growth hormone secretion is at least partially responsible for the elevation of
OAT2 in the female rat kidney compared with male kidney. Other mechanisms of
regulation (e.g., PKC) have not been determined.
2.3.3 Organic Anion Transporter 3 (OAT3)
OAT3 (SLC22A8) has also been shown to participate in the renal
excretion and reabsorption of anionic drugs.

The OAT3 protein contains 536

amino acids for rOAT3, 537 for mOAT3, and either 543 or 568 for hOAT3. Rat
OAT3 is 49% and 39% identical to rOAT1 and rOAT2, respectively. Human
OAT3 is 51% and 36% identical to hOAT1 and hOAT2 respectively (Burckhardt
and Burckhardt, 2003). The expressed OAT3 protein is predicted to have 12
transmembrane domains with a large, putatively extracellular loop located
between the first and second transmembrane domain.
contains four potential sites for N-glycosylation.

The OAT3 protein

Rat OAT3 contains three

potential PKC phosphorylation sites, while hOAT3 contains eight potential
phosphorylation sites (Burckhardt and Burckhardt, 2003). There is no
experimental data available on the topological organization of OAT3 prevailing
within the membrane.
Due to OAT3 presence in the basolateral membrane of the PT, it can play
an important role in the renal excretion of organic anions. Physiologically, OAT3
also mediates the first step in the renal excretion of many anionic drugs and
endogenous anions, acting in parallel with other OA transporting proteins along
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the basolateral membrane in the PT.

Molecular properties of OAT3 are

summarized in Table 2.
2.3.3.1 Cloning and Tissue Distribution
OAT3 was first cloned from rat kidney (rOAT3: Kusuhara et al., 1999).
The human homolog, hOAT3 was later cloned by Race et al. (1999). Cha et al.
(2001) cloned the functional hOAT3 from human kidney based on sequences
derived from rOAT3.

OAT3 has also been cloned from rabbit (Dantzler and

Wright, 2003).
Northern blot analysis showed that rOAT3 is actually most abundantly
expressed in the liver, followed by the kidney, while hOAT3 transcripts are
expressed abundantly in the kidney and at lower levels in the brain and skeletal
muscle (Race et al., 1999; Kusuhara et al., 1999). Studies by Buist et al. (2002)
however, have shown rOAT3 to be most abundant in the kidney, rather than the
liver. Levels of renal OAT3 in rat have been shown to increase after birth and
reach maximum levels by 14 days. Similar levels were detected in male and
female animals (Buist et al., 2002). In human kidneys, it is important to note that
mRNA levels for OAT3 are nearly three times higher than that for OAT1
(Motohashi et al., 2002). In rat kidney, OAT1 has been found to be more highly
expressed in the kidney than OAT3, with OAT3 being expressed predominantly
in the liver (Dresser et al., 2000; Kusuhara et al., 1999). This indicates that
OAT3 may play a more significant role in OA transport in the human kidney than
OAT1.
OAT3 has been localized to the basolateral membrane of the renal PT in
both rat (Hasegawa et al., 2002) and human (Cha et al., 2001). Kojima et al.
(2002) have shown that rOAT3 is present at the basolateral membrane in all
sections of the PT (S1, S2, S3), as well as in the thick ascending limbs, the distal
tubules, and the collecting ducts. Interestingly, in the human kidney, OAT3
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appears to be confined to the basolateral membrane of the PTs where it is colocalized with OAT1 (Motohashi et al., 2002).
2.3.3.2 OAT3 Substrates; Characterization and Specificity
Characterization of OAT3 transport conducted in Xenopus laevis oocytes
showed PAH uptake by rOAT3 (Cha et al., 2001; Kusuhara et al., 1999).
Summary of transport and Km values for PAH transport for OAT3 are listed in
Table 3. Results from additional studies have indicated that rOAT3 does not
transport PAH, but rather suggest that the affinity of rOAT3 for PAH is lower than
that of rOAT1 (Sugiyama et al., 2001; Nagata et al., 2002). This is apparently
true for hOAT3 as well. Studies by Cha et al (2001) indicate a 4-10 fold higher
Km for PAH transport by hOAT3 compared to hOAT1 (87.2 µM and 9 µM
respectively). Rat OAT3 also demonstrated a higher Km for PAH transport than
rOAT1 (65 µM and 14 µM respectively (Cha et al., 2001), suggesting that OAT1
and OAT3 transporters would have different contributions in tubular secretion.
Rat OAT3 has been shown to transport several other OAT substrates,
including benzylpenicillin, cimetidine (cation), 17β-estradiol-D-17β-glucuronide
(E217βG), estrone sulfate, indoxyl sulfate, ochratoxin A and pravastatin.
hOAT3 has been shown to transport azidothymidine (AZT), cAMP, cimetidine,
dehydroepiandrosterone sulfate (DHEA-S), estradiol glucuronide, estrone sulfate,
methotrexate, ochratoxin A, PGE2, PGF2α, salicylate, taurocholate, urate, and
valacyclovir (Burckhardt and Burckhardt, 2003). OAT3 can be distinguished from
OAT1 by its ability to transport sulfate and glucuronide conjugates of steroid
hormones. For this reason an estrogen conjugate, estrone sulfate (ES), has
been used as the prototypical OAT3 substrate. OAT3 also shows interaction with
cimetidine (a cationic drug) whereas OAT1 does not (Cha et al., 2001, Feng et
al., 2001).

This indicates that OAT3 does not discriminate between organic

anions and cations as sharply as OAT1 (Burckhardt and Burckhardt, 2003).
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The mechanism of transport of OAT3 has recently been redefined. OAT3
was originally shown to function as a uniporter, and not as an anion exchanger in
the manner of OAT1 transport (exchange of an OA for a dicarboxylate).
Kusuhara et al. (1999) found that estrone sulfate (ES) transport by rOAT3 could
not be trans-stimulated by unlabeled ES, PAH, or ochratoxin A. Cha et al. (2001)
reported similar results for hOAT3. These findings lead to the conclusion that
OAT3 did not function as an anion exchanger like OAT1. However, up to this
point, no studies had been conducted to determine the contribution of internal αketoglutarate or glutarate to OAT3 transport.

It has been demonstrated that

hOAT3 has the ability to interact with glutarate (Cha et al., 2001), indicating the
potential for OAT3 to interact with dicarboxylates.

Recent findings however,

have shown that OAT3 does function as a dicarboxylate exchanger in the same
mechanism as OAT1. Sweet et al. (2003) demonstrated that ES transport by
rOAT3 expressed in Xenopus laevis oocytes was significantly trans-stimulated by
preloading cells with glutarate (a dicarboxylate). Additionally, it was shown that
when OAT3 was coexpressed with the Na+/dicarboxylate exchanger, ES
transport was significantly inhibited by the presence of Li+ or methylsuccinate,
and by the exclusion of Na+ from the preloading medium, all of which act to
inhibit the Na+/dicarboxylate exchanger. These results indicate that OAT3
functions as an OA/dicarboxylate exchanger that couples OA uptake indirectly to
the sodium gradient. Similar results were also found in rat renal cortical slices
(Sweet et al., 2003).

Bakhiya et al. (2003) have also shown that hOAT3

functions as an OA/dicarboxylate exchanger similar to OAT1.
2.3.3.3 Regulation
Treatment of rOAT3 expressing mouse proximal tubular cells with the
phorbol ester, phorbol 12-myristate 13-acetate(PMA), a PKC stimulator, inhibited
the uptake of ES in a dose and time-dependent manner (Takeda et al., 2000b).
Inhibition of PKC by chelerythrine chloride reversed the effects of PMA. These
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results indicated that PKC activation downregulates rOAT3 mediated organic
anion transport. Inhibition was determined to be due to the internalization of
transporters, or to an inhibition of translocation of preformed transporters to the
membrane.
Rat OAT3 also appears to undergo some regulation by testosterone. In
male rats, OAT3 is much more highly expressed in the liver, than in female rats
(renal expression is the same in males and females). Kobayashi et al. (2002a)
demonstrated that after castration, OAT3 levels in the liver of male rats decrease,
and testosterone treatment restored normal male levels.

Additionally, HX

increased OAT3 mRNA in female liver indicating a role for growth hormone in the
female pattern of OAT3 expression as well (Kobayashi et al., 2002a; Buist et al.,
2003).
2.3.4 Luminal Transport of Organic Anions
As mentioned previously, the secretion of OAs can be divided into two
processes (1) uptake of OA across the basolateral membrane into PT cells and
(2) efflux of the OA out of the cell into the tubule lumen across the luminal
membrane. Far less is known about the mechanisms involved in OA transport
into the tubular lumen than is known about basolateral transport of OAs.
Movement of OAs across the luminal membrane during the transepithelial
secretory process occurs down an electrochemical gradient. Since the luminal
membrane appears to be highly permeable to substances with low lipid
solubilities, this transport must be carrier-mediated. At the luminal membrane,
the efflux carriers differ among various species.
Currently, several OA transporters have been identified at the luminal
membrane of renal proximal tubular cells (Figure 2.6). The luminal membrane
may contain organic anion uniporters or “channels” (Burckhardt and Pritchard,
2000). These luminal uniporters have been identified in several animal species
including; flounder, rat, rabbit, and pig. A second type of transporter found at the
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luminal membrane includes organic anion/Cl- (OH-, HCO3-) antiporters, found in
dog and rat. A third type of transporter found in the luminal membrane is an
organic anion/α-ketoglutarate antiporter (human, cow).

A fourth type of OA

transporter localized to the luminal membrane is an ATP-driven organic anion
transporter (Burckhardt and Burckhardt, 2003). Several specific transporters
have been identified in the luminal membrane of the PT. Human type I sodiumdependent inorganic phosphate transporter, NPT1, a sodium phosphate
cotransporter, expressed in HEK293 cells by Uchino et al. (2000), was shown to
facilitate secretion of PAH and urate. OAT4 was cloned from human cDNA (Cha
et al., 2000) and shown to be localized at the luminal membrane (Babu et al.,
2002). However, the contribution of OAT4 to the efflux of OAs across the
basolateral membrane is uncertain, as it has not been show to transport PAH
(Cha et al., 2000).

URAT1 has also been cloned, based on its sequence

homology to OAT4 (Enomoto et al., 2002a) and has been shown to function as
an antiporter, exchanging urate against either chloride or certain monovalent
organic anions.

As with OAT4, PAH does not appear to be a substrate for

URAT1 and thus does not contribute to PAH secretion. Multidrug resistance
transporter 2 (MRP2) is mainly responsible for the ATP-dependent translocation
of sulfated or glucuronidated compounds such as glutathione S-conjugates,
bilirubin glucuronide, 17-β-glucuronosyl estradiol, and glutathione disulfide (Konig
et al., 1999; Keppler et al., 1997). In human and rat, MRP2 has been located in
the proximal tubular cell at the luminal membrane (Schaub et al., 1997, 1999),
and has been shown to transport PAH (Van Aubel et al., 2000b).

A kidney

specific transporter, termed rOAT-K1 was also cloned from rat kidney (Saito et
al., 1996) and has been shown to transport methotrexate, but not PAH. rOAT-K1
does not share any significant sequence identity with OAT isoforms and is
therefore thought to belong to a different gene family. A second kidney specific
transporter, rOAT-K2 was also identified from rat kidney (Masuda et al., 1999),
and has been shown to transport methotrexate, folate, taurocholate and PGE2.
PAH has been shown to interact only weakly with rOAT-K2. Rat OAT-K1 and
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OAT-K2 have been identified at the luminal membrane in the kidney (Masuda et
al., 1997, 1999; Tojo et al., 1999; Hasegawa et al., 2002). OATP1 transporters
have also been localized to the luminal membrane in the S3 segment of the renal
PT (Bergwerk et al., 1996) where it meditates uptake of OAs from the luminal
fluid into the proximal tubular cell. OATP3 is thought to be a multispecific anion
transporter that accepts many types of organic anions including taurocholate and
other bile acids as substrates (Echkardt et al., 1999; Burchkardt and Wolf, 2000).
The driving force for OATP3 is considered to be reduced glutathione (Li et al.,
1998). Isern et al. (2001) demonstrated that mouse OATP1 mediates sodiumindependent uptake of the anionic steroid conjugates dehydroepiandrosterone
sulfate (Km ~ 8 µM) and estradiol-17-glucuronide (Km ~ 5 µM). Rat OATP1 gene
expression was much higher in the kidneys of male rats than female rats (Kato et
al., 2002).
2.4 Renal Transport of Prototypical Organic Anions
2.4.1 Renal Transport of Para-aminohippuric Acid (PAH)
PAH is the prototypical substrate for OAT1 at the basolateral membrane of
the renal PT cell (Km values presented for various systems in Table. 2). OAT3
has also been shown to transport PAH (Table 3). At the basolateral membrane,
PAH uptake against its concentration gradient is coupled to dicarboxylate (most
often α-ketoglutarate) exchange (Pritchard, 1988; Burckhardt and Wolf, 2000;
Sekine et al, 2000) and is indirectly coupled to Na+ uptake (Shimada et al., 1987;
Pritchard 1988). PAH does not appear to interact with luminal transport proteins
in the kidney including hOAT4 (Cha et al, 2000), urate transporter (URAT1;
Enomoto et al., 2002a), rOATP1 or rOATP2 (Sugiyama et al., 2001). PAH shows
only limited affinity for NPT1 (Uchino et al., 2000) and MRP2 (Leier et al., 2000).
At the luminal membrane, PAH is transported by either an anion exchanger
which transports many organic and inorganic anions such as urate, lactate, OH-,
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and Cl- as substrates (Kahn et al., 1983; Kahn and Aronson, 1983; Guggio et al.,
1983; Steffens et al., 1989; Ohoka et al., 1993) or a membrane potential
sensitive system (Martinez et al., 1990; Werner et al., 1990; Ohoka et al., 1993).
In dog and rat renal brush-border membrane vesicles, an anion antiporter
exchanged PAH or urate against OH-, HCO3- CL-, lactate acetoacetate or
monovalent succinate (Burckhardt et al., 2001). Studies conducted by Ulrich and
Rumrich (1997) using PAH preloaded rat proximal tubular cells, demonstrated
that luminal PAH transport in the rat PT in situ is insensitive to electrical potential
and therefore may occur by anion exchange. The main driving force for luminal
PAH influx in rat nephrons in situ may be the intracellular PAH concentration, as
the electrical potential difference seems not to be important.
Currently, the molecular identity of the antiporters and/or uniporters
involved in PAH secretion across the luminal membrane is unknown. Of the
cloned OATP transporter proteins known to be located in the luminal membrane
of the kidney PTs, oatp1 and OAT-K1 do not transport PAH. This excludes these
transporters as candidates for PAH antiporters or uniporters. OAT-K2 was only
weakly inhibited by PAH, but transport of labeled PAH has not been
demonstrated. NPT1 had been shown to display low affinity uptake of labeled
PAH (Km of 2.7 mM). MRP2 has been shown to be a luminal transporter of
PAH; however there may be luminal PAH transporters that have not yet been
identified.
2.4.2 Renal transport of Estrone-3-Sulfate (ES)
ES is the prototypical substrate for OAT3 (see Table 4 for Km values in
various systems). Studies by Sweet et al. (2002) have indicated that OAT3 is not
the only basolateral transport protein responsible for ES uptake. ES transport by
OAT3 has not been shown to be trans-stimulated by unlabeled ES (Cha et al.,
2001) Interaction of ES with other basolateral transporters has also been
demonstrated.

ES has been suggested to interact with URAT1, as ES cis47

stimulated uptake of urate by URAT1 (Enomoto et al., 2002). There has been
conflicting results regarding the interaction of ES with MRP2.

Sasaki et al.

(2002) demonstrated that ES was not a substrate of MRP2, yet ES stimulated the
transport of other substrates of MPR2.

Of particular importance, Sweet et al.

(2002) determined that ES did not interfere with PAH transport by OAT1, thus
enabling the use of ES to determine the contribution of OAT3 in a system in
comparison to the contribution of OAT1 to a substrate’s transport by the OAT
system. At the luminal membrane, in humans, ES appears to be transported by
OAT4 (Cha et al., 2000), and stimulates efflux of substrates by the luminal
transporters URAT1 and MRP2.
2.4.3 Renal Transport of Fluorescein (FL)
FL has been used in several studies as a model OAT substrate. FL
accumulates in proximal tubular cells of the kidney (Terlouw et al., 2000). FL is
thought to be transported into the cytoplasm of PTs by a basolateral mechanism
similar to the classical organic anion system (Sullivan et al., 1990). In isolated
non-perfused proximal S2 segments from rabbit, Sullivan et al. (1990) found a
Km for FL transport of 10 µM. Masereeuw et al. (1994) determined that FL
uptake in isolated proximal tubular cells from rat was concentration dependent,
saturable and probenecid sensitive, with an apparent Km of 59 ± 15 µM. Dose
dependent inhibition of FL uptake by PAH indicated that FL uptake is regulated
by the PAH transport system, and therefore, FL is a suitable substrate for
studying this system. It has also been demonstrated that FL transport in isolated
S2 segments of rabbit PT is stimulated by increased intracellular α-ketoglutarate
levels, suggesting FL transport is carried out in the same manner as PAH
transport (Sullivan and Grantham, 1992; Nikiforov, 1995).
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Table 4. Substrate specificity of various compounds in selected OAT isoforms
Transport Inhibition
(+/-) or
(+/-) or
Km (µM) IC50 (µM)
Compound
Transporter Expression system
benzylpenicillin

hOAT1

Oocyte

+
+
+

HeLa cells
Mouse PTC
rOAT1

Oocyte

+

LLC-PK1

DHEA-S

Estrone Sulfate

1680.0
+
+
418
800.0

Jariyawat et al, 1999
Islinger et al. 2001;
Sekine et al. 1997
Hasegawa et al. 2002
Nagata et al. 2002

LLC-PK1

+

Morita et al. 2001

hOAT3

Oocyte
Mouse PTC

+
+

Cha et al. 2001
Jung et al. 2001

rOAT3

Oocyte

+
+
82.6
52.8

LLC-PK1

82.6

hOAT2

EcR293

-

hOAT3

Oocyte

+

hOAT3

Oocyte
Mouse

3.1
2.2
7.5

Oocyte

Mouse PTC
LLC-PK1
hOAT1

?
?

Oocytes
CHO cells
HeLa cells
rabbit S2 segments
rat isolated PT cells

rOAT1

Oocytes
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Deguchi et al. 2002
Kusuhara et al. 1999
Nagata et al. 2002
Hasegawa et al. 2002
Sun et al. 2001

+

Cha et al. 2001

+

Cha et al. 2001
Takeda et al. 2001
Takeda et al. 2000
Babu et al. 2002

2.34
33
+

Paracetamol

Hosoyamada et al. 1999
Islinger et al. 2001
Lu et al. 1999
Jung et al. 2001

rOAT2

rOAT3

Fluorescein

References

618
9.1
+
+
+
10
59
2099

Kusuhara et al. 1999
Feng et al. 2001
Feng et al. 2001
Deguchi et al. 2002
Takeda et al. 2002
Nagata et al. 2002
Islinger et al. 2001
Cihlar and Ho. 2000
Lu et al. 1999
Sullivan et al. 1990
Masereeuw et al. 1994
Apiwattanakul et al. 1999

FL transport in isolated S2 segments of rabbit PT is inhibited by probenecid and
PAH (IC50 6 µM and 141 µM respectively: Sullivan and Grantham, 1992). While
specific transport proteins have not been identified in the efflux of FL into the
luminal fluid, efflux at the luminal membrane of isolated perfused rabbit PTs has
been found to be a saturable process and, therefore, suggested to be a carriermediated process (Shuprisha et al., 2000).
2.4.4 Inhibition of Renal Organic Anion Transport by Probenecid
Probenecid is a highly lipid soluble benzoic acid derivative. Probenecid
has been used as the prototypical inhibitor of organic anion transport across
epithelial barriers. This becomes extremely important in the renal PT where it
inhibits the secretion of drugs and drug metabolites.

Probenecid was used

originally in medicine to prolong the action of penicillin and prevent its loss in the
urine (Insel, 1996). Probenecid has been shown to function as an inhibitor of
OAT1, OAT3, MRP, URAT1, NPT1, and OATP transporters (see Table 5 for
inhibitory values and references).

Probenecid inhibits renal secretion of the

glucuronide conjugates of NSAIDs such as naproxen, ketoprofen, indomethacin
and causes plasma concentrations of these compounds to increase (Insel, 1996).
Macdonald et al. (1995) also demonstrated in humans that co-administration of
probenecid with diflunisal greatly reduces the renal clearance of diflunisal
glucuronides (both acyl and ether). Dickinson (1993) also found a 70% reduction
in the renal clearance of both diflunisal glucuronide conjugates.

Vree et al.

(1993a) have suggested that probenecid may be glucuronidated in the kidney
and that it may inhibit renal glucuronidation of such drugs as nalidixic acid (Vree
et al., 1993b) and indomethacin (Vree et al., 1994). The role of probenecid,
particularly in vivo, can be complicated as it can inhibit the secretion and
formation of glucuronide conjugates, as well as the secretion of other organic
anions.
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2.4.5 Renal Secretion of Acetaminophen Glucuronide (AG)
Studies on renal tubular secretion of acetaminophen glucuronide have
offered confounding results.

The liver is the primary site of acetaminophen

glucuronidation, however, extrahepatic glucuronidation has also been found (Li et
al., 2004).

It has been shown that serum protein binding of acetaminophen

glucuronide in humans is less than 10% (Duggin and Mudge, 1975; Morris and
Levy, 1984), and therefore, AG is readily available for glomerular filtration. Renal
clearance of acetaminophen glucuronide in many instances was determined after
administration of acetaminophen (Morris and Levy, 1984; Galinsky and Levy,
1981; Duggin and Mudge, 1975) and conjugate clearance values must then be
considered as estimates of conjugate renal clearances. It has been
demonstrated that the kidney has the ability to glucuronidate acetaminophen
(Ross et al., 1980; Hart et al., 1980; Newton et al., 1982; Emslie et al., 1981; Li et
al., 2004).

When acetaminophen is administered, renal glucuronidation of

acetaminophen to AG with subsequent efflux into the tubular lumen cannot be
separated from secretion.
Several studies have been conducted to determine the renal secretion of
acetaminophen glucuronide. In 1975, Duggin and Mudge found in dog, that AG
at low plasma concentrations (~20 µg/ml), appears to undego tubular secretion
via an active transport process. At higher plasma concentrations of AG (~90
µg/ml), it was found that AG appeared to be reabsorbed. It was also found that
net tubular AG secretion was not probenecid sensitive, while secretion of the
sulfate conjugate of acetaminophen was probenecid sensitive (Duggin and
Mudge, 1975). Renal secretion of AG was also demonstrated in rat by Galinsky
and Levy (Sprague-Dawley rats: 1981) and Watari et al. (Wistar rats: 1983).
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Table 5. Substrate specificity of probenecid in selected OAT isoforms

Compound

Transporter

Expression system

Probenecid

hOAT1

Oocytes

Transport
(+/-) or Km
(µM)

Inhibition
(+/-) or IC50
(µM)

+

CHO cells

HeLa cells
Mouse PTC (S2)
OK cells

+
+
+
+
6.3
6.5
7.4
+

Cihlar et al. 1999
Hosoyamada et al.
1999
Islinger et al. 2001
Pombrio et al. 2001
Race et al. 1999
Cihlar et al. 1999
Ho et al. 2000
Mulato et al. 2000
Lu et al. 1999

4.29
12.1
+

Jung et al. 2001
Takeda et al. 2001
Motojima et al. 2002

+
+
+
+
+
+
+
+
+

Uwai et al. 1998
Cihlar et al. 1999
Mulato et al. 2000
Pombrio et al. 2001
Sekine et al. 1997
Sweet et al. 1997
Tsuda et al. 1999
Uwai et al. 2000
Wada et al. 2000

rOAT1

Oocyte

hOAT2

Mouse PTC (S2)

766

rOAT2

LLC-PK1

+

Morita et al. 2001

hOAT3

Oocyte

+

Cha et al. 2001

Mouse PTC (S2)

4.9
9

Oocyte

+

LLC-PK1

1.68
4.43
20

rOAT3
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-

References

Enomoto et al. 2002b

Jung et al. 2001
Takeda et al. 2001
Feng et al. 2001
Kusuhara et al. 1999
Deguchi et al. 2002
Nagata et al. 2002
Sugiyama et al. 2001

In contrast to these findings, Morris and Levy (1984) found that on
average, renal clearance of AG did not exceed creatinine clearance in human
subjects, suggesting that AG does not undergo appreciable tubular secretion.
This lack of secretion, however, may be due to a balance between secretion and
reabsorption. It has also been suggested in studies in dog, that AG is completely
filtered at the glomerulus and does not undergo secretion (Heckman et al., 1986).
There are many factors that determine renal secretion of AG. It has been
reported that the kidney has the potential to secrete AG, and this secretion is
most likely via the organic anion transport pathway. However, to date, all studies
have been conducted in whole animals, or whole organ systems. Currently there
is no information at the cellular level about the renal handling of AG, or other
glucuronide conjugates.
2.5 Summary
Glucuronidation is an important biotransformation process that can lead to
the formation of both inert and reactive metabolic metabolites.

Toxicity

associated with glucuronide conjugates has primarily been associated with the
glucuronide

metabolites

of

carboxylic

acid

containing

compounds.

Glucuronidation of carboxylic acids leads to the formation of acyl glucuronides
which have been shown to be reactive intermediates. Acyl glucuronides have
been shown to become covalently bound not only to serum proteins, but also
within various tissues of the body. This covalent binding can lead to toxicity and
hypersensitivity reactions.

Currently, there is little knowledge about how the

kidney handles glucuronide metabolites, and whether transport of reactive acyl
glucuronide metabolites has any implications for the nephrotoxicity of certain
compounds, particularly NSAIDs which have been shown to form acyl
glucuronide metabolites. Glucuronide conjugates are organic anions, carrying a
negative charge at physiological pH. The renal PT, which is the primary site of
xenobiotic secretion in the kidney, possesses several organic anion transport
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proteins along the basolateral membrane that facilitate uptake of organic anions
from the blood into the proximal tublular cells. Table 2 provides a brief summary
of the characteristics of these OAT transporters. The kidney has been shown to
demonstrate transport of several organic anions including PAH, fluorescein, and
estrone sulfate. Tables 4 and 5 provide a list of various OAT substrates with Km
values. These OAT proteins (principally OAT1 and OAT3) may be responsible
for the transport of glucuronide conjugates in the kidney. However, information
on renal handling of glucuronide conjugates by basolateral OAT proteins in the
kidney is currently lacking. Since information on renal glucuronide handling is
extremely limited, this project was designed to investigate the transport of a
prototypical glucuronide, acetamidophenyl glucuronide (AG).

To study the

transport of AG by the kidney, rat in vitro models were used to gain insight into
how the kidney may secrete glucuronide metabolites with emphasis on the
basolateral organic anion transport system.
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CHAPTER III
Methods
3.1 Animals
Male Fischer 344(F344; 175-200 g) and Sprague-Dawley rats (SD; 200250 g) were obtained from Hilltop Lab Animals, Inc. (Scottdale, PA) and were
placed in standard plastic cages prior to use. Animals were maintained under
controlled ambient temperature (21-23ºC), humidity (40-55%) and light cycle
(lights on 0600-1800 h) with free access to food (Purina Rat Chow) and water at
all times.

Animals were allowed a minimum of 5 days to acclimatize to the

animal facilities prior to tissue collection.
3.2 Materials
4-Acetamidophenyl-ring-UL14C β-D-glucuronide sodium salt (AG; specific
activity: 48.8 mCi/mmol ), was purchased from Sigma Chemical Co. (Saint Louis
MO) (Cat. no. A 1329). p-[Glycyl-14C]-aminohippuric acid (PAH; specific activity:
52.7 mCi/mmol) (Cat no. NEC 563), D-[1-3H(N)]-mannitol (MN; specific activity:17
Ci/mmol) and [6,7-3H(N)]-estrone sulfate, ammonium salt (ES; specific activity:
46 Ci/mmol) (Cat no. NET 1012 and NET 203, respectively) were purchased
from Perkin Elmer Life and Analytical Sciences (Boston, MA).

All other

chemicals not listed were purchased from Sigma Chemical Co (St. Louis, MO) or
Fisher Scientific (Agawam, MA) and were of highest purity available.
4-Acetamidophenol (acetaminophen, APAP): Aldrich: A7302
p-Acetamidophenyl β-D-glucuronide: Sigma: A4438
Adenosine 5’-triphosphate: Sigma: A2383
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Bovine Serum Albumin (BSA): Sigma: A4503
Brilliant Blue G250 (Coomassie blue): Fisher: BP100-25
Collagenase IV: Sigma: C9891
Dehydroepiandrosterone sulfate: Sigma: D5297
Deoxyribonuclease 1 (DNase 1): Sigma: DN 25
Diclofenac: Sigma: D6899
ECL™ Western Blotting Detection Reagents (Amersham Biosciences, RPN2106)†
Estrone-3-sulfate: Sigma: E 0251
Fluorescein: Sigma: F6377
Heparin: Sigma: H3393
HK-2 human kidney, PTCs, transformed (ATCC, CRL-2190)
Hyperfilm™ ECL high performance chemiluminescence film (Amersham Biosciences,
RPN2114K) †
Methylumbelliferyl glucuronide: Sigma: M9103
Nicotinamide adenine dinucleotide phosphate: Sigma: N0505
OAT1 antibodies, affinity pure (Alpha Diagnostic International, OAT11-A)
OAT3 antibodies, affinity pure (Alpha Diagnostic International, OAT31-A)
Ouabain: Sigma: O3125
p-aminohippuric acid: Sigma: A1422
Pentobarbital: Sigma: P3761
Penicillin G (Benzylpenicillin): Sigma: P3020
Percoll ®: Sigma: P1644
Probenecid: Sigma: P8761
D-Saccharic

acid 1,4-lactone: Sigma: S0375

Scintiverse II: Fisher: SX12-4
Soy bean trypsin inhibitor: Sigma: T9003
Testosterone glucuronide: Sigma: T8157
Triton X-100: Fisher: BP151
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Endo H (endoglycosidase H) (New England Biolabs, P0702S)
3.3 Equipment
Located in VA Research Building:
Masterflex peristaltic pump
Osmette S osmometer
Mettler analytical balance
Corning pH meter
Dubnoff metabolic shaking incubators
Sorvall® Microspin 12 Centrifuge
Common facilities VA Research Building:
Beckman J6 MI refrigerated centrifuge
Beckman Avanti J25 ultracentrifuge
Beckman Optimal XL-100K Ultracentrifuge, Rotor SW 60 Ti
Beckman Avanti centrifuge, rotor J14
Phase contrast microscope
Beckman UV/Vis spectrophotometer
Perkin Elmer HTS 7000 bioassay reader-fluorescent microplate reader
Wallac 1409 liquid scintillation counter
Forma Scientific BioFreezer (-80)
IEC Centra CL2 Centrifuge
Medical Education Building:
Sorvall® RC 5B Refrigerated Superspeed Centrifuge, SS-34 rotor
Sorvall® MC5B Centrifuge
Beckman 126 HPLC
Trans-Blot Electrophoretic Transfer Cell (BioRad)†
Micromax RF Centrifuge, International Equipment Company
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†

All reagents and equipment for Western blot analysis were kindly provided by Dr.

Kelley Kiningham.
3.4 Isolation of Renal Proximal Tubules (IRPT)
Male F344 rats were anestisized (pentobarbital sodium, 50mg/kg, i.p.) and
renal proximal tubule (IRPT) fragments were isolated following the procedure
described by Gesek et al. (1987) and modified by Aleo et al. (1991). Additional
modifications were made, initiating renal retrograde perfusion by the procedure of
Jones et al. (1979). The level of anesthesia was assessed using the toe pinch
and corneal reflex methods. The peritoneal cavity was opened by a midline
incision and 0.2 ml heparin (0.2% w/v in 0.9% saline) injected into the femoral
vein. Ligatures were placed under the lower abdominal aorta (below the renal
arteries), the coeliac and superior mesenteric arteries, and the upper abdominal
aorta (as high in the abdominal cavity as possible). The ligature was then tied
around the upper aorta, and the rat was sacrificed by bilateral pneumpthorax
exsanguination. The celiac, mesenteric and lower abdominal arteries were then
ligated.

A small incision was made in the lower abdominal aorta above the

ligature and a cannula (blunted 19 x 7/8 butterfly infusion set) inserted and tied in
place. Retrograde perfusion was then initiated with the kidneys in situ with 75 ml
of oxygenated (95% O2 /5% CO2) Perfusion buffer A (see appendix for buffer
composition) at 12 ml/min for 3 min at 37ºC. The kidneys were transferred to a
beaker containing continuously oxygenated Perfusion buffer A from which the
buffer was being withdrawn to provide a recirculating system.

After initial

perfusion, cannulated kidneys were transferred to Perfusion buffer B (see
appendix for buffer composition) for an additional 3 min (also continuously
oxygenated).

Following perfusion, kidneys were removed from the perfusion

apparatus, decapsulated, and cortical tissue dissected away from the medulla,
minced, and placed in a 50 ml plastic beaker with 25 ml of oxygenated
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collagenase containing Incubation buffer (see appendix for composition).
Digestion of cortical tissue was initiated at 37ºC in a shaking water bath (60 rpm)
with continuous oxygenation. After 15 min, solid kidney tissue was allowed to
settle in the beaker and freed PTs (PTs) remaining in suspension in the
incubation buffer were removed by transfer pipette and placed in a 50 ml
centrifuge tube. The suspension was centrifuged at 50 x g for 2 min at 4º C in a
Beckman J6MI centrifuge (JS 4.2 rotor). The supernatant was removed and
reserved for further cortical tissue digestion and the pellet was resuspended in
oxygenated ice cold 1x Krebs-Henseleit (KH) buffer (see appendix for
composition) and kept on ice.

The remaining tissue was digested with an

additional 25 ml of Incubation buffer for additional 5 min intervals until cortical
tissue was completely digested. Total incubation time was typically 25 min. PTs
were removed at the end of each 5 min interval, centrifuged as described and
combined. The total pellet was then rinsed three times by resuspension in 25 ml
ice cold 1x KH buffer and centrifugation at 50 x g for 2 min. The final PT pellet
was then resuspended in 10 ml 1x KH buffer. This suspension of PT tubules was
then divided in half and each 5 ml resuspended in polycarbonate round bottom
centrifuge tubes each containing 30 ml oxygenated 45% Percoll solution (see
appendix for compositon). A 5 ml 100% Percoll cushion was then injected into
the bottom of each tube using a transfer pipette (Fig. 3.1A). PTs were then
centrifuged at 17,000 x g for 10 min at 4º C in either a Beckman Avanti ™
Ultracentrifuge (JA 14 rotor) or a Sorvall® RC 5B superspeed centrifuge (SS 34
rotor) (allowed stopping without brake). Following centrifugation PTs formed a
uniform layer above the cushion layer (Fig. 3.1B). This layer was removed using
a transfer pipette, and rinsed three times in 1x KH buffer at 500 x g for 5 min at
4º C in a Beckman J6MI centrifuge (JS 4.2 rotor). PTs were then resuspended in
oxygenated Transport buffer #1 (see appendix for composition) at a
concentration of 1.0 mg protein/ml for all assays. Protein content was determined
by the Bradford (1976) method using BSA as the standard and expressed in mg
protein/ml.
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3.5 Characterization of proximal tubules
Following isolation of PTs, biochemical and visual characterization of the
isolated PTs was done to determine the purity of the isolated material. Analysis
was conducted immediately following tubule isolation from the renal cortical
tissue (pool sample), and again following Percoll density gradient enrichment (PT
sample). Tubules were analyzed for alkaline phosphatase (AP), a brush border
enzyme found only in the proximal tubular segment of the nephron and for
hexokinase (HK), a cytosolic enzyme present in highest concentrations in the
distal portion of the nephron. In addition to enzymatic characterization, lactate
dehydrogenase (LDH) release was analyzed to determine the viability of tubules
both before (pool sample) and after Percoll enrichment (PT sample). LDH is a
cytosolic enzyme that is released due to cell death or damage.
3.5.2 Biochemical characterization of proximal tubules
Alkaline

phosphatase

(AP):

AP

activity

was

measured

spectrophotometrically using Sigma Diagnostics Kit 104, based on the procedure
of Bessey et al (1946). This assay is a quantitative colorimetric determination of
AP and absorbance was measured on a Beckman DU® 530 Life Science UV/Vis
spectrophotometer at 410 nm (10 mm cuvet). This procedure depends on the
hydrolysis of p-nitrophenyl phosphate by the alkaline phosphatase enzyme
yielding p-nitrophenol and inorganic phosphate.

When made alkaline, p-

nitrophenol is converted to a yellow complex that is readily measured at 400-420
nm. The intensity of the color is proportional to the phosphatase activity.

For

comparison purposes, AP activity was expressed in nmol p-nitrophenol
liberated/min/mg protein.
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Glomeruli
Distal tubules
Proximal tubules
17,000 x g

Cells

100%

100%

A

B

Figure 3.1. Schematic diagram of renal cortical tissue before and after
Percoll density centrifugation. (A) Renal cortical tissue was resuspended in 30 ml of
45% Percoll solution with a 5 ml 100% Percoll cushion injected into the bottom of the tube.
Before separation, all digested cortical tissue was equally distributed in the 45% Percoll solution.
(B) Following centrifugation at 17,000 x g for 10 min. PTs formed a uniform layer above the 100%
Percoll cushion. This layer was then removed by transfer pipette and represents the purified PTs
used in uptake studies. Glomeruli, distal tubule (DT) fragments and individual cells were primarily
found at the top of the Percoll gradient. The PT layer has minimal contamination by short DT
fragments and individual cells as determined by enzymatic and visual characterization.

To determine AP content, 50 µl of sample or water (blank) was added to a
tube containing 0.5 ml 221 alkaline buffer solution and 0.5 ml stock substrate
solution (warmed to 37 º C) (see appendix for buffer and substrate composition),
mixed and incubated for 5 min at 37 º C. After 5 min, 10 ml 0.05 N NaOH was
added to each tube and mixed. Absorbance of the sample vs. blank was then
read at 410 nm and AP units determined from a calibration curve. Four drops of
concentrated HCl were then added to each tube (both sample and blank) and
absorbance of sample vs. blank read at 410 nm and AP activity determined from
the calibration curve. To determine the final value for AP activity, the AP activity
value following HCl treatment was subtracted from the original AP activity value
for each sample, yielding the corrected AP activity for each sample. This final
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value was then multiplied 3x to account for using only a 5 min incubation rather
than a 15 min incubation as directed by the assay protocol. This decreased
incubation time was used because tubules had such high concentrations of AP.
Calibration curve for alkaline phosphatase:
1

Tube
No.
1
2
3
4
5
6

2

3

Diluted pNitrophenol NaOH 0.02 N
solution (mL)
(mL)
1.0
10.0
2.0
9.0
4.0
7.0
6.0
5.0
8.0
3.0
10.0
1.0

4

Alkaline
Phosphatase
Activity Sigma
Units/mL
1.0
2.0
4.0
6.0
8.0
10.0

To create the calibration curve, the solutions indicated in columns 2 and 3
were pipetted into numbered tubes, and absorbance of each read immediately at
410 nm using 0.02 N NaOH as reference. The calibration curve was constructed
by plotting absorbance vs. units in column 4.
Hexokinase (HK): Hexokinase activity was measured by the method of
Joshi and Jagannathan (1966). This is a spectrophotometric kinetic assay
measured at 340 nm. To determine the HK activity in IRPT samples, 0.1 ml of a
1 mg protein/ml IRPT suspension was mixed with 0.01 ml 10 % (v/v) Triton-X
100, 0.5 ml substrate solution, 0.5 ml NADP+, 2.88 µl G6PDH (at 600 units/ml),
7.12 µl H2O, and 0.5 ml ATP in 10 mm pathlength 4.5 ml polystyrene disposable
cuvette (see appendix for composition of all substrates and chemicals). The total
reacting volume (1.62 ml) was then mixed and the change in absorbance was
measured immediately for 3 min. The hexokinase assay is based on the
following reactions:
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Glucose + ATP + H2O

Glucose-6-phosphate + ADP + Pi

Glucose 6-phosphate + NADP+

6-phosphoglucose + NADPH + H+

Hexokinase activity was calculated as follows:
HK activity = A340 min-1/ [6.22 x 103 mol-1L)(103 ml-1)]x 109 nmol mol-1 x 16.2)
= 2604.5 nmol x ∆ ABS/min
For comparison purposes activity was expressed in nmol NADP+
reduced/min/mg protein.
Visual characterization: Visual appearance of isolated material was
determined using a Nikon inverted Diaphot-TMD phase contrast microscope, with
100x magnification.

Using a transfer pipette, a small amount of PT suspension

was placed on a microscope slide and visualized for PT content following Percoll
separation.
3.5.2 Protein content analysis- Bradford method
Protein content was measured by the Bradford (1976) method using
bovine serum albumin (BSA) as the standard. To determine the amount of
protein in initial IRPT isolates from Percoll separation, a 100 µl aliquot was
removed and diluted in 400 µl H2O in a glass Wheaton Tissuemizer. The PT
suspension was homogenized and 25 µl of PT homogenate was analyzed for
total protein content and calculated from a standard curve. Each 25 µl aliquot
was placed in a 13x100 mm tube to which 25 µl of H2O was added for a total
reacting volume of 50 µl. Bradford reagent (2.5 ml) was then added to each
tube, mixed on a vortex and allowed to incubate at room temperature. The
remaining IRPT isolate from the Percoll separation was then diluted to a 1 mg
protein/ml concentration with the appropriate amount of transport buffer for
toxicity and uptake studies. The protein content in toxicity and uptake study
samples was determined by analyzing either a 10 or 25 µl aliquot of IRPT
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suspension from each flask and the amount of protein calculated from a standard
curve, following a freeze thaw cycle of each sample to rupture the cell
membranes. Each sample aliquot was brought to a final reacting volume of 50 µl
with the appropriate amount of H2O before the addition of Bradford reagent. The
concentration curve was made using 1 and 2 mg protein/ml stock solutions of
BSA. A 2 mg protein/ml solution of BSA was made by diluting 20 mg BSA/ 10 ml
distilled H2O and a 1 mg protein/ml solution was made by making a 1:1 dilution of
a portion of the 2 mg protein /ml solution. Protein standards for the assay were
prepared as described below (in duplicate) in 13x100 mm tubes:
Protein Stock
2 mg/ml
2 mg/ml
2 mg/ml
1 mg/ml
1 mg/ml
1 mg/ml
1 mg/ml

Volume stock
30 µl
25 µl
20 µl
30 µl
20 µl
10 µl
5 µl

Volume water
20 µl
25 µl
30 µl
20 µl
30 µl
40 µl
45 µl

Amount of Protein
60 µg
50 µg
40 µg
30 µg
20 µg
10 µg
5 µg

Bradford dye reagent (2.5 ml; see appendix for composition) was then added to
each tube, mixed on a vortex and absorbance read at 595 nm using a Stasar III
spectrophotometer (once mixed on a vortex, tubes were allowed to sit at room
temperature for a minimum of 2 min, maximum of 1 hour). The absorbance of
sample aliquots was measured in the same manner.
3.5.3 Lactate dehydrogenase (LDH) assay
LDH release was analyzed by a spectrophotometric kinetic assay (Sigma
Diagnostics® Lactate dehydrogenase (LD-L) kit (procedure No. 228-UV)
measured at 340 nm. This assay is based on the reaction:
Lactate + NAD+

LDH

Pyruvate +NADH + H+
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Formation of NADH results in an increase in absorbance at 340 nm. The
rate of increase in absorbance is directly proportional to LDH activity in the
sample.
LDH release was assayed upon completion of enzymatic isolation of renal
cortical tissue (pool sample), Percoll enrichment of cortical tissue (PT sample) or
following incubation of IRPTs with a test compound. At this time, a 0.5 ml PT
sample was taken and centrifuged to separate the “media” from “tissue” portion
of the sample.

The supernatant was decanted and reserved as the media

sample. The remaining pellet (tissue sample) was homogenized in 1.0 ml of 10%
Triton-X 100 to release intracellular LDH. The amount of LDH activity was then
determined for both the tissue and media portions of the sample and LDH
release into the media was expressed as percent of total.
3.6 Toxicity experiments in IRPTs
All toxicity experiments were conducted by placing 3-4 ml of tubule
suspension in 25 ml polycarbonate Erlenmeyer flasks. Flasks were then placed
in a shaking water bath incubator at 37ºC and sealed with a serum bottle stopper
with an inlet and outlet for gas flow (95% O2/5% CO2). The atmosphere was
equilibrated with shaking for 20 min in initial experiments but was shortened to 5
min in later experiments as shorter preincubations appeared to decrease
variability between treatments.

All assays were run in duplicate or triplicate

depending on yield of tubule material.
3.6.1 Toxicity studies with acetaminophen (APAP), acetamidophenyl-β-Dglucuronide (AG), and diclofenac (DC)
Assays were run in duplicate for each treatment and time point. Toxicity
was assessed by both increased lactate dehydrogenase (LDH) release and
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alterations nucleotide levels (ATP, ADP, AMP).

After preincubation, flasks

containing 3.0 ml of PT suspension were treated with 30.0 µL distilled H2O
(control), 20 or 50mM APAP, AG or DC for a final concentration of 200 or 500 µM
APAP, AG or DC.

After addition of compound, oxygenation stoppers were

replaced and shaking resumed at 100 rpm for 15, 30, or 60 min. At the end of
each time point, 1.0 ml was removed for nucleotide analysis, and 0.5 ml removed
and placed in a second 1.5 ml centrifuge tube for LDH analysis (as described in
section 3.5.3).
3.6.2 Nucleotide (ATP, ADP, AMP) isolation
Following incubation with control (H2O) or test compound 1.0 ml from each
flask was removed and placed in a labeled 1.5 ml centrifuge tube and centrifuged
for 10 min at maximum speed in a tabletop Sorvall Microspin centrifuge. The
supernatant was discarded, and 300 µl 0.9% saline added to each pellet. Each
pellet was mixed on a vortex to resuspend PTs and 50 µl removed for protein
analysis. Perchloric acid (3M, 125 µl) was added to the remaining 250 µl of PTs
in each sample tube and mixed on a vortex to precipitate proteins. Following
addition of perchloric acid, sample tubes were kept on ice for 5 min, mixed on a
vortex and centrifuged for 10 min at maximum speed. A 300 µl aliquot of
supernatant was then removed from each sample tube, placed on ice in a clean,
labeled 1.5 ml centrifuge tube, and the pH adjusted to approximately 7.0 with 6N
KOH (volume of KOH recorded).

All sample tubes were kept on ice for the

duration of nucleotide isolation. Following pH adjustment the tubes were
centrifuged for 10 min at 2000 x g in a Sorval MC12V centrifuge.

The

supernatant was prepared for HPLC analysis by filtration (Millipore HV .45 µm
syringe filter) of 200 µl of supernatant, 200 µl distilled H2O, and air pushed
through the filter into a clean labeled 1.5 ml centrifuge tube. Each filtered sample
was frozen at -80º C until analyzed.
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Levels of ATP, ADP and AMP were determined using an HPLC method
adapted from Lash et al. (1995). A 100 µl aliquot of extracted nucleotide sample
was injected into a Beckman 126 model HPLC with a 100 µl injection loop. The
mobile phase was a gradient of two solutions: Solvent A: 100 mM potassium
phosphate, pH 6.0, and Solvent B: methanol. The gradient was 7.5 min at 100%
A; 7.5 min linear gradient to 90% A; 15 min linear gradient to 75% A; 0.5 min
linear gradient to 100% A and a 10 min re-equilibration at initial conditions. The
flow rate of the mobile phase was 1.3 ml/min. The column was a Radial-Pak C18
cartridge (8 mm x 10 mm) (Waters Inc.; Milford, MA).

The wavelength for

detection was 254 nm. Adenine nucleotide concentrations were calculated from
standard curves of ATP, ADP and AMP (0.94 - 9.4 nM), and expressed as
nmol/mg protein.
Preparation of nucleotide standards:
Each standard sample for ATP, ADP and AMP was prepared in 1 ml of H2O.
2.07 mg ATP (3.75 mM)
1.60 mg ADP (3.75 mM)
1.30 mg AMP (3.75 mM)
Each standard was diluted 1:10 for a final concentration of 0.376 mM. A final 1.0
ml standard of each was made by adding 250 µl of 1:10 dilution to yield a final
standard concentration of 0.094 µmol/ml.
3.7 IRPT model characterization for organic anion transport (OAT)
Currently, there is limited quantitative information on the ability of the F344
rat kidney to transport classical organic anion transport (OAT) substrates. To
verify that this model carried out organic anion transport, tubules were treated
with various compounds that have been shown to be transported by the organic
anion transporting proteins in the proximal tubular basolateral membrane in the
kidney in other animal models. For these studies, the compounds selected to
characterize this model were fluorescein (FL) (OAT 1 and 3), p-aminohippuric
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acid (PAH) (OAT 1 and 3), and estrone sulfate (ES) (OAT 3). Both uptake and
inhibition studies were conducted to show the presence and function of OAT in
this system.
All uptake experiments were conducted by placing 3 ml (FL uptake
experiments) or 4 ml (radioisotope experiments) of tubule suspension in 25 ml
polycarbonate Erlenmeyer flasks. Flasks were then placed in a shaking water
bath incubator at 37ºC and sealed with a serum bottle stopper with an inlet and
outlet for gas flow (95% O2/5% CO2). The atmosphere was equilibrated with
shaking for 20 min in initial FL experiments but was shortened to 5 min in later FL
experiments as the longer time appeared to decrease variability between
treatments. Preincubation for all radioisotope studies was carried out for 5 min.
FL assays were conducted in duplicate or triplicate depending on tubule yield,
and all radioisotope experiments were conducted in duplicate.
3.7.1 Accumulation and quantification of FL in IRPTs
Uptake and accumulation of 4 µM fluorescein (FL) in IRPTs was used to
assess the presence and function of OAT transport in this model.

Each

experiment is described in detail following this section. This section primarily
describes the quantification of FL content from each PT suspension sample
following treatment.
In the experiments described in this section, to determine the amount of
FL accumulation in IRPTs, 1.0 ml of PT suspension was removed from each
flask at the end of the given time point and placed on ice in 5.0 ml ice cold
Transport buffer #1 in a 15 ml centrifuge tube to stop FL uptake. PT suspension
samples were immediately centrifuged at 2500 x g for 2 min. The supernatant
from each sample tube was discarded and PT pellets were then rinsed again in 5
ml ice cold buffer and pellets frozen in an inverted position to allow excess buffer
to drain from the PT material. PT pellets were ruptured either by freeze/thaw
(frozen at – 20 º C for approximately 12 hours with subsequent addition of 1.5 ml
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distilled water), or by homogenization with a Techmar Tissuemizer to release
intracellular (cytosolic) FL. After disruption, material was centrifuged at 2500 x g
for 5 min to pellet cellular debris. Cytosolic FL content in the supernatant was
determined using a Perkin Elmer HTS 7000 bioassay fluorescence microplate
reader (485 nm excitation, 538 nm emission). Triplicate 100 µl aliquots were
taken from each sample and placed in a 96 well plate. To determine the FL
content of each sample, samples were compared against standards of 4.0, 3.2,
2.4, 1.6, 0.8, 0.4, 0.2, and 0.0 µM FL and corrected for background untreated PT
fluorescence. FL values were then converted to nmol/mg protein. An additional
1.0 ml was removed from each flask for protein determination using the Bradford
(1976) method.
3.7.1.1 Time-dependent accumulation of FL in IRPTs
Time-dependent accumulation of FL was measured to assess the
temporal aspects of OAT transport function in this model, and also to determine
the best time points for subsequent assays.

Following preincubation as

previously described in section 3.6, 30 µl of 400 µM FL was added to each flask
containing 3 ml of PT suspension for a final concentration of 4 µM FL. Tubules
were then incubated at 37ºC in a shaking water bath (100 rpm) for 15, 30, 45, 60,
and 120 seconds.

At the end of each time point, samples were assayed for FL

content as described in section 3.7.1.
3.7.1.2 The effect of temperature on FL accumulation in IRPTs
Temperature dependent accumulation of FL by IRPTs was used as a
marker for active, carrier protein-mediated uptake along the tubular basolateral
membrane in this model. Cellular transport of molecules requires temperatures
closer to physiological levels (37ºC); accumulation of FL at cold temperatures
(4ºC) will allow the distinction between basolateral protein-mediated transport,
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and non-specific binding to tubular proteins or passive diffusion. Tubules were
preincubated at either 4ºC or 37ºC. Following preincubation, 4 µM FL was added
to each flask and incubated as previously described at 4ºC or 37ºC for 2 min. At
the end of the 2 min incubation period, samples were assayed for FL content as
described in section 3.7.1.
3.7.1.3 The effect of probenecid on FL accumulation in IPRTs and
determination of the IC50 for probenecid accumulation in IRPTs
Probenecid is used as the typical inhibitor of organic anion transport (both
OAT 1 and OAT 3) (Insel, 1996). To determine the effect of probenecid (and
thus the contribution of OAT) on FL accumulation in this model, 3 ml of IRPTs at
1 mg protein/ml were incubated for 2 min at 37ºC in a shaking water bath (100
rpm) with 4 µM FL alone or co-incubated with 4 µM FL and 1 mM probenecid. At
the end of the 2 min incubation period, samples were assayed for FL content as
described in section 3.7.1.
To determine the inhibitory concentration that provides half maximal
inhibition (IC50) for probenecid on FL accumulation in this model, 3 ml of IRPTs at
1 mg protein/ml were incubated for 2 min at 37ºC in a shaking water bath (100
rpm) in the presence of increasing concentrations of probenecid (5-250 µM). At
the end of the 2 min incubation period, samples were assayed for FL content as
described in section 3.7.1.
3.7.1.4 The effect of ouabain on FL accumulation in IRPTs
Ouabain is an inhibitor of the sodium/potassium ATPase, the energy
driving force for OAT 1 transport along the basolateral membrane in renal PTs.
To determine the effect of ouabain, and thus the contribution of OAT 1 to FL
accumulation in this model, 3 ml of IRPTs at 1 mg protein/ml were incubated for
2 min at 37ºC in a shaking water bath (100 rpm) with 4 µM FL alone or in the
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presence of 100 µM ouabain. Ouabain was added to tubules 10 min prior to the
addition of FL to insure adequate inactivation of sodium/potassium ATPase. Due
to the light sensitivity of ouabain, all incubations were conducted in the dark. At
the end of the 2 min incubation period, samples were assayed for FL content as
described in section 3.7.1.
3.7.1.5 The effect of benzylpenicillin (PG) on FL accumulation in IRPTs
PG has been shown to be a relatively selective inhibitor of rOAT3
(Hasegawa et al. 2002).

To determine the contribution of OAT 3 in the

accumulation of FL in this model, 3 ml of IRPTs at 1 mg protein/ml were
incubated for 2 min at 37ºC in a shaking water bath (100 rpm) with 4 µM FL
alone or in the presence of 1 mM PG. At the end of the 2 min incubation period,
samples were assayed for FL content as described in section 3.7.1.
3.7.1.6 The effect of dehydroepiandrosterone sulfate (DHEAs) on FL
accumulation in IRPTs
DHEAs has been demonstrated to be a substrate of OAT3 (Cha et al,
2001). To determine the contribution of OAT3 in the accumulation of FL in this
model, 3 ml of IRPTs at 1 mg protein/ml were incubated for 2 min at 37ºC in a
shaking water bath (100 rpm) with 4 µM FL alone or in the presence of 1 mM
DHEAs. At the end of the 2 min incubation period, samples were assayed for FL
content as described in section 3.7.1.
3.7.1.7 The effect of 4-acetamidophenyl-β-D-glucuronide (AG) on FL
accumulation in IPRTs
To determine the ability of AG to interact at the site of FL transport in this
model (presumably OAT1 and/or OAT3), 3 ml of IRPTs at 1 mg protein/ml were
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incubated for 2 min at 37ºC in a shaking water bath (100 rpm) with 4 µM FL
alone or in the presence of 500 µM AG. At the end of the 2 min incubation
period, samples were assayed for FL content as described in section 3.7.1.
3.7.2 Accumulation and quantification of radioisotopes (14C and 3H) in IRPTs
To further characterize the uptake of typical OAT substrates in IPRTs,
and

3

H radiolabeled substrates were used.

14

C

The general method of test

compound incubation and determination of isotope content of IRPTs following
treatment is discussed in this section. Specific details of each uptake experiment
are given in subsequent sections, but all analysis of radioisotope accumulation
follow the same method as described in this section. Briefly, 25 ml polycarbonate
flasks with 4 ml of 1 mg protein/ml PT suspension were preincubated for 5 min. A
1 ml aliquot was then removed for protein determination before addition of
isotope.

14

C-p-Aminohippuric acid (PAH), 3H-estrone-3-sulfate (ES), or

14

C-

acetamidophenyl-β-D-glucuronide (AG), (approximately 0.1 - 0.2 µCi/ml) was
added to each flask containing 3.0 ml of 1mg protein/ml IRPT suspension (see
appendix for composition of stock and working solutions of radioisotopes). In
each individual experiment, isotope concentrations vary slightly due to variation
in the mixing of new working isotope solutions. Each working solution was made
from stock isotope solutions and counted for radioactivity, and concentration
calculated before use in each experiment. Tubules were incubated at 37º C in a
shaking water

bath (180 rpm) (specific time points given in experiment

description). At the end of each time point, 5.0 ml ice cold transport buffer was
added to each flask to stop uptake. Flasks were decanted into 15 ml centrifuge
tubes and each flask was rinsed with an additional 5 ml cold buffer, and this rinse
was added to initial 8.0 ml before centrifugation. PT suspensions were then
centrifuged for 1 min at 7500 rpm in a IEC Centra CL2 Centrifuge. Tubule pellets
were rinsed 2x in 5 ml ice cold transport buffer, resuspended in 1.0 ml of distilled
H2O and homogenized with a Teckmar Tissuemizer. Radioactivity of the total 1
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ml IRPT homogenate (in two 0.5 ml aliquots) was then determined by liquid
scintillation counting on a Wallac 1409 Liquid Scintillation Counter (LSC). Each
0.5 ml aliquot was placed in a 5 ml plastic scintillation vial, to which 5 ml of
Scintiverse II were added. Each vial was labeled and mixed on a vortex before
being analyzed. Untreated tubules were used to correct for background activity.
Untreated tubules were prepared in the same manner as those treated with
radioisotopes.

Untreated tubules (1 ml) were homogenized and two 0.5 ml

aliquots were used for “blank” measurements on the LSC for each experiment.
3.7.2.1 The effect of probenecid on PAH accumulation and the
determination of the IC50 for probenecid on PAH accumulation in IRPTs
Accumulation of

14

C-PAH by IRPTs was used as a marker for basolateral

OAT1 and OAT3 uptake in this model. Three milliliters of tubule suspension
were incubated at 37ºC for 2 min with 73.8 µM
the presence of 1 mM probenecid.

14

C-PAH (0.2 µCi/ml) alone, or in

IRPT samples were then prepared and

analyzed for 14C-PAH content as described in section 3.7.2.
To determine the IC50 value for probenecid inhibition of PAH in this model,
3 ml of tubule suspension were incubated at 37ºC for 2 min with 4.5 µM

14

C-PAH

(0.24 µCi/ml) in the presence of increasing concentrations of probenecid; 25, 50,
100, 150, and 250 uM. IRPT samples were then prepared and analyzed for

14

C-

PAH content as described in section 3.7.2
3.7.2.2 The effect of AG on PAH accumulation in IRPTs
Inhibition of

14

C-PAH accumulation by AG was evaluated to assess the

interaction of AG at the site of basolateral PAH transport (OAT1 and OAT3) in
this model. Three milliliters of tubule suspension were incubated for 30 seconds
with 2.5 µM

14

C-PAH (0.13 µCi/ml) alone, or in the presence of 1 mM AG. The

concentration of PAH used in this experiment was minimized to maximize the
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potential for reaction at the transport site for PAH. Since PAH is such a good
substrate for OAT1 and OAT3, to determine whether AG could interfere with PAH
at the site of transport, the minimum amount of PAH was used so as to maximize
the effect of AG in competing for potential transport sites. IRPT samples were
then prepared and analyzed for 14C-PAH content as described in section 3.7.2.
3.7.2.3 The effect of testosterone glucuronide (TG) and methylumbelliferyl
glucuronide (MUG) and AG on PAH accumulation in IRPTs
Inhibition of

14

C-PAH accumulation in IRPTs by TG and MUG was

investigated to evaluate the interaction of additional glucuronide metabolites at
the site of basolateral PAH transport (OAT 1 and 3) in this model. The effect of
AG on14C-PAH accumulation was also determined in this experiment as an
additional control for the effects of TG and MUG (i.e. do all three glucuronides
appear to have the same or different effects on PAH accumulation). Tubule
suspensions (3 ml at 1 mg protein/ml) were incubated at 37ºC for 30 seconds
with 4.4 µM 14C-PAH (0.23 µCi/ml) alone, or in the presence of 500 µM TC, MUG
or AG. A higher concentration of PAH was used in this experiment to assure
consistant counting results on the LSC. Lower concenterations used in previous
experiments often resulted in less consistant LSC results. IRPT samples were
prepared and analyzed for 14C-PAH content as described in section 3.7.2.
3.7.2.4 The effect of temperature on ES accumulation in IRPTs
Temperature dependent accumulation of 3H-ES by IRPTs was used as a
marker for active, protein-mediated OAT3 uptake in this model (Sweet et al.,
2003).

Cellular transport of molecules requires temperatures closer to

physiological levels (37ºC); accumulation of ES at cold temperatures (4ºC) will
allow distinction between basolateral protein-mediated transport, and non
specific binding to tubular proteins or passive diffusion. Three milliliters of tubule
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suspension were incubated at 4ºC or 37ºC for 60 seconds with 4 pM 3H-ES (0.2
µCi/ml). IRPT samples were then prepared and analyzed for 3H-ES content as
described in section 3.7.2.
3.7.2.5 The effect of probenecid on ES accumulation in IRPTs
Accumulation of 3H-ES by IRPTs was used as a marker for OAT 3 uptake
along the basolateral membrane in this model.

Three milliliters of tubule

suspension were incubated at 37ºC for 30 seconds with 4 pM 3H-ES (0.18
µCi/ml) alone or in the presence of 1mM probenecid. IRPT samples were then
prepared and analyzed for 3H-ES content as described in section 3.7.2
3.7.2.6 The effect of self-inhibition on ES accumulation in IRPTs
Inhibition of 3H-ES accumulation by unlabeled (cold) ES was examined to
assess whether basolateral uptake was a carrier protein-mediated transport
process in this model, versus passive diffusion or other means of cellular
accumulation. Ability of a compound to “self inhibit” accumulation indicates that
the compound is taken into the tubules by carrier-mediated transport
mechanisms.

Three milliliters tubule suspension were incubated at 37ºC for 60

seconds with 4 pM 3H-ES (0.2 µCi/ml) alone, or in the presence of 500 µM ES.
IRPT samples were then prepared and analyzed for 3H-ES content as described
in section 3.7.2
3.7.2.7 The effect of AG on ES accumulation in IRPTs
Inhibition of 3H-ES accumulation by AG was explored to assess the
interaction of AG at the site of ES transport (OAT3) in this model.

Three

milliliters of tubule suspension were incubated at 37ºC for 60 seconds with 4 pM
3

H-ES (0.18 µCi/ml) alone or in the presence of 1 mM AG. The concentration of
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ES used in this experiment was minimized to maximize the potential for reacting
at the transport site for ES. IRPT samples were then prepared and analyzed for
3

H-ES content as described in section 3.7.2.
3.8 14C-Acetamidophenyl-β-d-glucuronide (AG)
accumulation studies in IRPTs
AG was selected as a model glucuronide to determine whether IRPTs

demonstrated accumulation of glucuronide metabolites. Due to its commercial
availability, and because it was available in a radiolabeled form, AG was selected
as a model glucuronide.

To determine whether IRPTs facilitate glucuronide

accumulation, various experiments, as described in subsequent sections, were
conducted to determine the role of the basolateral membrane in the renal
secretion of AG.

Experiments were designed to determine whether the

basolateral membrane demonstrated carrier protein-mediated transport of AG,
and more importantly, whether AG interacts with OAT proteins along the
basolateral membrane.

3.8.1 Time-dependent accumulation of AG in IRPTs
To determine if there was a temporal factor for the accumulation of 14C-AG
in this model, 3 ml of tubule suspension were incubated at 37ºC for 15, 30, 45,
60, 120 or 300 seconds with 4.5 µM
then prepared and analyzed for

14

14

C-AG (0.22 µCi/ml). IRPT samples were

C-AG content as described in section 3.7.2.

Temporal studies also allowed for the determination of the best time points for
further uptake and inhibition studies to be conducted using 14C-AG.
3.8.2 The effect of temperature on AG accumulation in IRPTs
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Temperature dependent accumulation of

14

C-AG was used as a marker

for active, carrier protein-mediated uptake of AG along the tubular basolateral
membrane in this model. Accumulation of

14

C-AG at cold temperatures (4ºC) will

allow distinction between basolateral carrier protein-mediated transport, and nonspecific binding to tubular proteins or passive diffusion. Three milliliters of tubule
suspension were incubated at 4ºC or 37ºC for 30 seconds with 2 µM 14C-AG (0.1
µCi/ml). IRPT samples were then prepared and analyzed for

14

C-AG content as

described in section 3.7.2.
3.8.3 The effect of probenecid on AG accumulation on IRPTs
To determine whether basolateral OAT proteins played a role in AG
accumulation in this model, probenecid, the classical OAT inhibitor, was used to
determine whether accumulation of AG could be inhibited. Three milliliters of
tubule suspension were incubated for 30 seconds with 2 µM
(30 µl of

14

14

C-AG (0.1 µCi/ml)

C-AG at 10 µCi/ml) alone or in the presence of 1mM probenecid.

Probenecid was added at the same time as AG, or added 5 min prior to the
addition of AG. IRPT samples were then prepared and analyzed for

14

C-AG

content as described in section 3.7.2.
3.8.4 The effect of self-inhibition on AG accumulation in IRPTs
To determine whether basolateral carrier-mediated transport mechanisms
played a role in

14

C-AG accumulation in this model, self-inhibition studies were

conducted to determine whether unlabeled (cold) AG could inhibit the uptake of
14

C-AG by IRPTs. Three milliliters of tubule suspension were incubated for 30

seconds with 4.5 µM 14C-AG (0.22 µCi/ml) alone, or in the presence of 5 mM AG.
IRPT samples were then prepared and analyzed for 14C-AG content as described
in section 3.7.2
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3.8.5 The effect of ES on AG accumulation in IRPTs
Inhibition of

14

C-AG accumulation by ES in this model was examined to

determine whether a known substrate of OAT3 could effectively act as an
inhibitor of AG accumulation in this model. This study was used to elucidate the
role of OAT3 in AG uptake in this model. Three milliliters of tubule suspension
were incubated for 30 seconds with 4.5 µM

14

C-AG (0.22 µCi/ml) alone, or in the

presence of 100 µM ES. IRPT samples were then prepared and analyzed for
14

C-AG content as described in section 3.7.2.
3.8.6 The effect of D-saccharic acid 1,4-lactone on AG accumulation
in IRPTs
Since IRPTs still have metabolic capabilities, including the deconjugation

of glucuronide metabolites by β-glucuronidase, it was important to determine
whether accumulation of

14

C-AG was being affected by the presence of β-

glucuronidase in the tubule preparation. To assure that accumulation of AG was
due to the conjugate, D-saccharic acid 1,4-lactone (SL) was used as an inhibitor
of β-glucuronidase activity. Three milliliters of tubule suspension were incubated
for 2 min with 4.5 µM

14

C-AG (0.21 µCi/ml) alone, or in the presence of 10 or 20

mM SL. Tubules were pre-incubated with SL for 5 min prior to the addition of
14

C-AG. IRPT samples were then prepared and analyzed for

14

C-AG content as

described in section 3.7.2.
3.9 Western blot analysis for OAT1 and OAT3 in IRPTs and HK2 cells
3.9.1 Cell Fractionation
Plasma membrane fractions of immortalized human kidney (HK-2) cells were
prepared from 7 day old monolayers scraped from T75 flasks or from Transwell
membranes, pelleted at 270 x g and frozen. Cell pellets (HK-2 and F344 rat PTC)
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were resuspended in homogenization buffer (HB; see appendix for composition),
homogenized (15 slow strokes) and centrifuged (100 x g, 2 min) to remove intact
cells. To separate membrane from cytosolic fractions, three different methods were
used. The supernatants (whole cell lystes) were centrifuged at 100,000 x g for 1
hour at 4oC (procedure provided by Dr. Mary Vore) to isolate crude membrane
fractions or at 15,000 x g for 30 minute at 4oC (Kikuchi et al., 2003) to isolate
plasma membrane fractions. Proteins from the membrane pellets were extracted
in HB containing 1% Triton-X 100 by frequent mixing on a vortex for 1 hour then
tumbling overnight at 4oC. The extracts were centrifuged for 30 minutes at 14,000
x g at 4oC and the supernatants (membrane proteins) were assayed for protein
content.
3.9.2 SDS-PAGE and Western Blot Procedure
Each sample was solubilized in loading buffer (4% sodium dodecyl sulfate,
62.6 mM Tris, 10% glycerol) with or without 5% 2-mercaptoethanol, loaded at 200250 µg HK-2 protein/lane and 100 µg F344 rat or human protein/lane and
separated by polyacrylamide gel electrophoresis on a 12.5% or 8% gel overnight
at 4oC (12.5% gel for 15 hours at 70 V; 8% gel for 15 hours at 74V). Proteins were
transferred onto a nitrocellulose membrane, blocked with 5% nonfat dry milk in
Tris-buffered saline containing 0.3% Tween 20 for 1 hour at 25oC and incubated
overnight at 4oC with anti-ratOAT1 or OAT3 antibodies reported by the
manufacturer to be specific for respective OATs and cross-reactive with the
respective human orthologues (1:333, Alpha Diagnostics International).

The

bound antibody was detected on x-ray film by enhanced chemiluminescence with
horseradish peroxidase-conjugated anti-rabbit IgG antibody.
formulations are recorded in the appendix.
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Buffer and gel

3.10 Accumulation studies with OAT substrates in
renal cortical slices (RCS)
Since IRPT isolation involves enzymatic digestion to release the tubules
from the cortical tissue, there is the potential that this digestion could also
damage the transport proteins along the basolateral membrane of the tubules.
To determine whether enzymatic digestion had any consequence in the ability of
IRPTs to demonstrate transport of both known OAT substrates and AG, renal
cortical slices were used to study the accumulation of PAH, ES, and AG.
Transport of these compounds was then compared to the findings in IRPTs to
determine whether accumulation results were altered by enzymatic digestion of
the basolateral membrane of the IRPTs.
3.10.1 Preparation of RCSs.
Rats were anesthetized with diethyl ether and tested for surgical
anesthesia with toe pinch and corneal reflex. The abdomen was opened with a
midline incision and the animal exsanguinated by rupturing the diaphragm and
cutting the vena cava. The kidneys were removed, decapsulated and cut into
quarters. Each quartered kidney was then placed in a 30 ml beaker containing
10 ml ice cold oxygenated Transport buffer #2 (see appendix for composition).
The kidneys were kept on ice for the remainder of the slice preparation. Renal
cortical slices were prepared free hand as previously described (Valentovic et. al.
1992) and placed in a clean 30 ml beaker containing 10 ml ice cold Transport
buffer #2. To conduct uptake studies, slices were transferred with forceps into a
12 well cell culture plate in a shaking water bath incubator. Each well contained
3-4 slices (30-60 mg) in 1.0 ml of oxygenated Transport buffer #2 at 37ºC. Slices
were allowed 5 min to equilibrate at 37º C at 100 rpm before the addition of test
compound. Assays were conducted in duplicate at each concentration and time
point.
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3.10.2 Accumulation and quantification of radioisotopes (14C and 3H) in RCSs
This section describes the general method for analyzing uptake of
radiolabeled substrates in RCSs. Details of specific experiments (time points
and isotope concentrations) are provided in subsequent sections. This section
also describes the method used in all experiments to determine the isotope
content of treated slices.
At the end of each incubation period with a selected radioisotope, slices
were removed from each assay well with forceps and placed in 2.0 ml of ice cold
Transport buffer #2 in the corresponding well of a clean 12 well cell culture plate.
This was done to both stop uptake of the radioisotope and to rinse excess
radioisotope from the slices. After all slices were removed from the assay wells
and transferred to rinse wells, the slices from each rinse well were removed and
placed on a disk of heavy filter paper. Excess buffer was then removed from the
slices by pressing slices between several discs of filter paper. The slices were
removed from the filter paper and then weighed. Following weight determination
the slices were transferred to labeled 13 x 100 mm glass tubes containing 1 ml
H2O and homogenized using a Teckmar Tissuemizer.

Homogenates were

divided into two 0.5 ml aliquots in 5 ml scintillation vials to count the total slice
sample for each assay. Five milliliters of scintillation fluid (Scintiverse II) were
added to each vial, mixed and analyzed for radioisotope content using a Wallac
1409 Liquid Scintillation Counter.

3.10.2.1 Time-dependent 3H-Mannitol accumulation in RCS
Mannitol (MN) is not actively transported by any portion of the renal
cortical slice. Thus, MN accumulation can be used to assess the amount of
diffusion into interstitial spaces in the RCSs. Slices (30-60 mg) were incubated
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at 37ºC for 10, 15, 30 or 60 min in the presence of 176 pM MN (0.3 µCi/ml).
Slices were then prepared and analyzed for 3H-MN content as described in
section 3.10.2.
3.10.2.2 The effect of probenecid on PAH accumulation in RCSs
Inhibition of PAH accumulation by probenecid was studied to characterize
the ability of this model to transport a classical OAT substrate, with inhibition by a
the classical OAT transport inhibitor. Slices (30-60 mg) were incubated at 37ºC
for 30 min with 4.7 µM
probenecid.

14

C-PAH (0.25 µCi/ml) alone or in the presence of 1 mM

Slices were then prepared and analyzed for

14

C-PAH content as

described in section 3.10.2.
3.10.2.3 The effect of testosterone glucuronide (TG), methylumbelliferyl
glucuronide (MUG) and acetaminophen glucuronide (AG) on PAH
accumulation in RCSs
The ability of TG, MUG and AG to inhibit the accumulation of

14

C-PAH in

renal cortical slices was evaluated to explore the interaction of glucuronide
metabolites at the site of basolateral PAH transport (OAT1 and 3) in this model.
Slices (30-60 mg in 1 ml Transport buffer #2) were incubated for 30 min with 4.7
µM

14

C-PAH (0.25 µCi/ml) alone or in the presence of 500 µM TG, MUG or AG.

Slices were then prepared and analyzed for

14

C-PAH content as described in

section 3.10.2.
3.10.2.4 Time-dependent accumulation of ES in RCSs
To determine the presence and function of OAT3 along the basolateral
membrane of PTs in RCS, ES was chosen as the substrate for transport (Sweet
et al, 2003). Time-dependent accumulation also allowed for assessment of OAT
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transport function over time to determine the best time points for subsequent
assays. Slices (30-60 mg) were incubated at 37ºC for 5, 10, 15, 30 and 60 min in
the presence of 4 pM 3H-ES (0.2 µCi/ml).

Slices were then prepared and

3

analyzed for H-ES content as described in section 3.10.2.
3.10.2.5 The effect of temperature on ES accumulation in RCSs
To demonstrate that accumulation of ES in RCSs is via a carrier proteinmediated mechanism, temperature-dependent accumulation of

3

H-ES was

assessed. Slices (30-60 mg) were incubated at 4ºC or 37ºC for 10 min with 4 pM
3

H-ES (0.2 µCi/ml). Slices were then prepared and analyzed for 3H-ES content

as described in section 3.10.2.
3.10.2.6 The effect of probenecid on ES accumulation in RCSs
Inhibition of 3H-ES accumulation in RCS by probenecid was used to
evaluate further the function of basolateral OAT3 transport in this model. Slices
(30-60 mg) were incubated at 37ºC for 10 min with 4 pM 3H-ES (0.2 µCi/ml)
alone or in the presence of 1 mM probenecid. Slices were then prepared and
analyzed for 3H-ES content as described in section 3.10.2.
3.11 14C-acetamidophenyl-β-D-glucuronide (AG)
accumulation studies in RCS
3.11.1 Time-dependent accumulation of AG in RCSs
To determine if there was a temporal factor for the accumulation of 14C-AG
in this model, slices (30-60 mg) were incubated at 37ºC for 2.5, 5, 15, 30, 45 or
60 min with 4.7 µM

14

C-AG (0.23 µCi/ml). Slices were then prepared and

analyzed for 14C-AG content as described in section 3.10.2.
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3.11.2 The effect of temperature on AG accumulation in RCSs
Temperature-dependent accumulation of 14C-AG was used as an indicator
for active, protein-mediated uptake of AG along the tubular basolateral
membrane in this model. Accumulation of

14

C-AG at cold temperatures (4ºC) will

allow distinction between basolateral protein-mediated transport, and nonspecific binding to tissue or passive diffusion. Slices (30-60 mg) were incubated
at 4ºC or 37ºC for 30 min with 4.7 µM
prepared and analyzed for

14

14

C-AG (0.23 µCi/ml). Slices were then

C-AG content as described in section 3.10.2.

3.11.3 The effect of probenecid on AG accumulation in RCSs
To determine whether OAT proteins along the basolateral membrane of
RCS played a role in AG accumulation in this model, probenecid was used to
determine whether accumulation of AG could be inhibited by a classical OAT
inhibitor. Slices (30-60 mg) were incubated at 37ºC for 30 min with 4.7 µM

14

C-

AG (0.23 µCi/ml) alone or in the presence of 1 mM probenecid. Slices were then
prepared and analyzed for 14C-AG content as described in section 3.10.2.
3.11.4 The effect of self-inhibition on AG accumulation in RCSs
To determine whether basolateral transport mechanisms played a role in
14

C-AG accumulation in this model, self-inhibition studies were conducted to

determine whether unlabeled (cold) AG could inhibit the uptake of
Slices (30-60 mg) were incubated at 37ºC for 30 min with 4.7 µM

14

14

C-AG.

C-AG (0.23

µCi/ml) alone or in the presence of 500 µM AG. Slices were then prepared and
analyzed for 14C-AG content as described in section 3.10.2.
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3.11.5 The effect of PAH and ES on AG accumulation in RCSs
To explore further whether OAT plays a role in the accumulation of AG
along the basolateral membrane of the PT in this model, known organic anion
substrates of OAT1 and OAT3 were used as potential inhibitors of AG
accumulation. Slices (30-60 mg) were incubated at 37ºC for 30 min with 4.7 µM
14

C-AG (0.23 µCi/ml) alone or in the presence of 1mM PAH or 500 µM ES. Slices

were then prepared and analyzed for

14

C-AG content as described in section

3.10.2.
3.12 14C-AG accumulation studies in RCSs from male Sprague-Dawley rat
Several studies have reported contradicting results regarding the ability of
the kidney to secrete glucuronide conjugates, namely AG (Duggin and Mudge,
1975, Galinsky and Levy, 1981, Watari et al, 1983, Morris and Levy, 1984
Heckman et al. 1986). Since these studies have been conducted in different
animal models and strains, it was important to determine whether genetic strain
had any influence in the ability to show basolateral transport of AG by the renal
PT. The renal cortical slice model was chosen to assess renal transport of AG in
the male SD rat. SD rats were chosen as an alternate rat strain because it was
demonstrated by Galinsky and Levy (1981) that the SD strain appears to renally
secrete AG.
The following studies were conducted and carried out as previously
described for the corresponding studies conducted in RCSs from F344 rat at 4.3
µM 14C-AG (0.21 µCi/ml):
3.12.1 The effect of temperature on AG accumulation in RCSs from SD rat
(see section 3.11.2 for details on assay methods)
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3.12.2 The effect of probenecid on AG accumulation in RCSs from SD rat
(see section 3.11.3 for details on assay methods)
3.12.3 The effect of self-inhibition on AG accumulation in RCSs from S-D
rat (see section 3.11.4 for details on assay methods)
3.12.4 The effect of PAH on AG accumulation in RCSs from S-D rat (see
section 3.11.5 for details on assay methods)

3.13 Statistics
Values are expressed as the mean ± SE for 3-4 experiments. Values from
each rat represent n=1.

Data were analyzed using Non-linear Regression

Analysis, Student t-test or One-Way Repeated Measures Analysis of Variance
(ANOVA) followed by a Dunnett or Student-Newman-Keuls analysis.

All

statistical tests were run at 95% confidence interval, significance at P<0.05.
Statistics were analyzed using Sigma Stat ® 2.03 statistical software (SPSS Inc.,
1992-1997).
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CHAPTER IV
Results
4.1 Studies Using Isolated Renal Proximal Tubules (IRPTs)
4.1.1 Characterization of Isolated Proximal Tubules
Since the renal PT is the primary site of drug transport and metabolism in
the kidney, the first step of this study was to isolate renal PT segments from male
F344 rats.

Before the initiation of any toxicity or transport studies, it was

necessary to characterize the isolated renal material to ensure that the tissue
population

that

was

isolated

consisted

primarily

of

PT

fragments.

Characterization of the PT fraction was carried out through enzymatic analysis
and visual assessment.

HK activity, AP activity, protein content and LDH

release assays were conducted on the initial sample of digested cortical tissue
containing tubules (pool sample) and on the enriched sample of tubules collected
after Percoll separation (PT sample). HK and AP enzyme assays were used to
assess the enrichment of the tubule sample.

AP, which is a brush-border

enzyme, was used as a marker for PT content. HK, a cytosolic enzyme with
greatest activity in distal tubular cells was used as a marker for distal tubule
contamination. Lash and Tokarz (1989) have reported PT fractions to have AP
and HK activities of 403 ± 113 and 111 ± 48 nmol/min/mg protein respectively.
Based on this information and assay results it was determined that the enriched
proximal tubule (PT) samples isolated in these studies are of proximal tubular
origin (Table 6). Viability was evaluated by measuring lactate dehydrogenase
(LDH) release into the media and reported as a percent of total.

LDH is a

cytosolic enzyme and leakage from cells into the media can be correlated to
sample viability (as percent LDH release increases, percent viability decreases).
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Tubule viability for samples following Percoll separation was found to be
approximately 89%, reported by percent LDH release in the range of 11.73 ±
0.91 (Table 6). These results indicated that the Percoll isolation procedure did
not cause excessive damage to the tubule segments and they are adequate for
toxicity and uptake studies.

While it did not appear that the enzyme values

changed significantly, the Percoll separation did effectively separate out any
glomeruli and blood vessel tissue present in the pooled sample. Percoll density
centrifugation provided a final PT sample that consisted primarily of proximal
tubules with minimal distal tubule contamination. PT content was also observed
microscopically as PTs were identified by their large diameter and unbranched
morphology (Fig. 4.1). Based on morphological examination, there were a few
distal tubules or collecting ducts (thin, straighter tubule segments) present in the
sample and the major portion of the sample appeared to consist of PTs. Tubules
appeared largely undamaged, although segments were shorter following Percoll
separation and rinsing.

No glomerular contamination was present in the PT

sample based on microscopic examination.
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Table 6. Biochemical characteristics of IRPTs from male F344 rata.
Parameter
Protein content (mg protein/ml)

Pool Sample

PT Sample

7.80 ± 0.23

7.62 ± 0.39

4.84 ± 0.63

11.7 ± 0.91

521 ± 30.9

542 ± 26.9

24.8 ± 1.94

22.6 ± 1.91

Cell viability
LDH release (%)
Enzymesb
Alkaline Phosphatase
Hexokinase

Note: a. All values are means ± SE of measurements from 8 rat preparations.
b. Enzyme results are total activity in nmol product per min, per mg protein.

Figure 4.1. Freshly isolated renal proximal tubules from Fischer 344 rat.
Tubules were isolated by collagenase digestion and enriched through Percoll density gradient
centrifugation. The resulting isolated material consisted primarily of PT fragments as noted by
their large diameter and unbranched morphology. Distal tubular contamination was minimal and
no glomerular contamination was noted. Magnification 100x, Nikon inverted Diaphot-TMD phase
contrast microscope.
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4.1.2 Toxicity studies
Prior to conducting uptake studies it was necessary to ensure that the
model compound (AG) was not toxic in this study system (IRPTs).
Acetaminophen (APAP), the parent compound of AG, and diclofenac (DC) were
also studied for toxicity since both of these compounds have been associated
with nephrotoxicity. Additionally, DC is known to form an acyl-glucuronide
metabolite. Toxicity was measured by LDH release from tubules incubated with
200 or 500 µM AG (Fig. 4.2), APAP (Fig 4.3) or DC (Fig 4.4). Incubations were
carried out for 30 and 60 min for AG and APAP. DC studies were carried out for
15 and 30 min, as toxicity was already noted (by LDH release) by 30 min. These
studies indicate that AG and APAP are not toxic at these concentrations or time
points, and are therefore suitable for use in uptake studies in IRPTs. Since DC
was found to be slightly toxic by 30 min it was not used in any future studies.
In addition to LDH release, nucleotide levels were also used to assess
toxicity of AG, APAP and DC. Nucleotide levels were measured to determine
whether tubules were not showing signs of toxicity at an earlier stage than could
be detected by LDH release.

Treatment with some chemicals may not trigger

LDH release, but they may have a profound effect on the ability of a cell to
produce energy in the form of ATP. To determine whether AG, APAP or DC had
any intracellular toxic effects, following incubation of 3 ml of tubule suspension
with 200 or 500 µM AG (Fig 4.5), and APAP (Fig. 4.6) for 30 or 60 min, or DC
(Fig. 4.7) for 15 or 30 min, 1 ml of the tubule suspension was assayed for ATP,
ADP, and AMP content. These studies indicate that AG and APAP do not show
any early, toxic events at these concentrations or time points (i.e., no depressed
production of nucleotides), and are therefore suitable for using in uptake studies
in IRPTs. DC, however, was again found to be slightly toxic by 30 min as seen
by depressed nucleotide levels. Toxicity studies at 15 min were also conducted
with DC to determine whether depression of nucleotide levels might occur on an
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earlier time frame than LDH release. Studies at 15 min demonstrate that while
LDH release is not at significantly different levels than control, by this time point,
ATP levels are already significantly decreased below control.

This finding

indicates that DC toxicity includes early cellular effects that occur before
significant LDH release.
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Figure 4.2. Percent LDH release from IRPTs treated with AG. To determine the
toxicity of AG in IRPTs, 3 ml of tubule suspension (at 1 mg protein/ml) were incubated in the
absence or presence of either 200 or 500 µM AG for 30 or 60 min. Separate flasks were used for
each time point, and each concentration/time point was determined in duplicate. At the end of
each time point, 1 ml of PT suspension was removed and assayed for LDH content. Each bar
represents LDH release from the tubules into the incubation medium, and expressed as percent
of total LDH ± SE for n=4. Percent LDH release by tubules treated with 200 or 500 µM AG was
not significantly different from water treated tubules at either time point. LDH release was also
not significantly different between time points for each concentration. Data were analyzed by
Repeated Measures ANOVA.
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Figure 4.3. Percent LDH release from IRPTs treated with APAP. To determine
the toxicity of APAP in IRPTs, 3 ml of tubule suspension (at 1 mg protein/ml) were incubated in
the absence or presence of either 200 or 500 µM APAP for 30 or 60 min. Separate flasks were
used for each time point, and each concentration/time point was determined in duplicate. At the
end of each time point, 1 ml of PT suspension was removed and assayed for LDH content. Each
bar represents LDH release from the tubules into the incubation medium, and expressed as
percent of total LDH ± SE for n=4. Percent LDH release by tubules treated with 200 or 500 µM
AG was not significantly different from water treated tubules at either time point. LDH release
was also not significantly different between time points for each concentration.
analyzed by Repeated Measures ANOVA.
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Figure 4.4. Percent LDH release from IRPTs treated with DC. To determine the
toxicity of DC in IRPTs, 3 ml of tubule suspension (at 1 mg protein/ml) were incubated in the
absence or presence of either 200 or 500 µM DC for 15 and 30 min. Separate flasks were used
for each time point, and each concentration/time point was determined in duplicate. At the end of
each time point, 1 ml of PT suspension was removed and assayed for LDH content. Each bar
represents LDH release from the tubules into the incubation medium, and is expressed as
percent of total LDH release ± SE for n=4 or 5. (* Percent LDH release significantly different from
the appropriate control value (P<0.05)). Percent LDH release was significantly higher following
DC treatment at 30 min. There was not a significant difference in LDH release between 200 and
500 µM DC at either time point. Data were analyzed by Repeated Measures ANOVA followed by
Dunnett’s analysis with a 95% confidence interval.
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Figure 4.5. Effect of AG on nucleotide levels in IRPTs.

To determine whether

there may be earlier toxic events than LDH release associated with treatment of IRPTs with AG,
nucleotide levels were determined after 30 and 60 min and used as a marker for tubular
sensitivity to AG. Tubules (3 ml at 1 mg protein/ml) were treated in the absence or presence of
200 or 500 µM AG for 30 or 60 min.

Separate flasks were use for each time point and each

concentration/time point was measured in duplicate. At the end of each time point, each flask
was sampled and ATP, ADP and AMP levels determined by HPLC for each sample. Each bar
represents the mean nucleotide level (nmol/mg protein) ± SE for n=10 (30 min H2O treatment),
n=4 (60 min H2O treatment) and n=4 (30 and 60 min AG treatments). No significant difference
in nucleotide levels was determined for any AG concentration or time point for ATP, ADP or AMP
as compared to control values. Data were analyzed by Repeated Measures ANOVA.
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Figure 4.6. Effect of APAP on nucleotide levels in IRPTs. To determine whether
there may be earlier toxic events than LDH release associated with treatment of IRPTs with
APAP, nucleotide levels were determined after 30 and 60 min and used as a marker for tubular
sensitivity to AG. Tubules (3 ml at 1 mg protein/ml) were treated in the absence or presence of
200 or 500 µM APAP for 30 or 60 min.

Separate flasks were use for each time point and each

concentration/time point was determined in duplicate. At the end of each time point, each flask
was sampled and ATP, ADP and AMP levels determined by HPLC for each sample. Each bar
represents the mean nucleotide level (nmol/mg protein) ± SE for n=10 (30 min H2O treatment),
n=4 (60 min H2O treatment) and n=4 (30 and 60 min APAP treatments).

No significant

difference in nucleotide levels was determined for any APAP concentration or time point for ATP,
ADP or AMP as compared to control values. Data were analyzed by Repeated Measures
ANOVA.
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Figure 4.7. Effect of DC on nucleotide levels in IRPTs. To determine whether
there may be earlier toxic events than LDH release associated with treatment of IRPTs with DC,
nucleotide levels were determined after 15 and 30 min and used as a marker for tubular
sensitivity to DC. Tubules (3 ml at 1 mg protein/ml) were treated in the absence or presence of
200 or 500 µM DC for 15 or 30 min.

Separate flasks were use for each time point and each

concentration/time point was determined in duplicate. At the end of each time point, each flask
was sampled and ATP, ADP and AMP levels determined by HPLC analysis. Each bar represents
the mean nucleotide level (nmol/mg protein) ± SE for n=4 (all 15 min treatments) n=10 (30 min
H2O treatment), and n=3 or 4 (30 min DC treatment). (* Significantly different from 15 min control
(H2O) levels P< 0.05)). ATP levels following DC treatment for 15 min were significantly lower
than control ATP levels. ADP and AMP levels did not show a significant difference between
control and DC treatment at 15 min. (# Signifncantly different from 30 min control (H2O) levels
(P<0.05)). ADP and ATP levels were both significantly lower than control levels following 30 min
treatment with DC.

AMP levels are not significantly different between control and DC treated.

Data were analyzed by Repeated Measures ANOVA, followed by Dunnett’s analysis with a 95%
confidence interval.
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4.1.3 Uptake studies
4.1.3.1 Fluorescein accumulation in IRPTs
Transport of organic anions by renal PTs of F344 rats has not been
previously characterized. FL, a typical OAT1 and OAT3 substrate, has been
used in numerous studies to assess the function of OAT transporters in various
models.

Thus, FL was used to study OAT function along the basolateral

membrane of freshly isolated renal PTs from F344 rats. Based on studies
conducted by Groves and Morales (1999) in suspensions of rabbit renal PTs, 4
µM was selected as the concentration of FL for uptake studies in this rat IRPT
model. Temporal studies using IRPTs in the presence of 4µM FL revealed that
FL is accumulated in IRPTs in a time-dependent manner (Fig. 4.8).
Accumulation of FL appears steady up to 120 seconds. Time-dependent uptake,
however, does not solely indicate uptake of FL by OAT proteins along the
basolateral membrane.

To characterize further OAT function in this model,

various inhibition studies were conducted to determine whether accumulation of
FL was a protein carrier-mediated process, and to further elucidate the
contribution of OAT1 and OAT3 to FL accumulation.
To determine whether accumulation of FL along the basolateral
membrane was via a protein carrier-mediated process, temperature dependent
transport of FL was assessed. IRPTs were incubated with 4 µM FL at either
37ºC to allow protein-mediated transport, or at 4ºC to minimize protein-mediated
transport.

Tubules incubated with FL for 2 min revealed that at 4ºC,

accumulation of FL was significantly lower than at 37ºC by approximately 93 %
(Fig. 4.9). This reduction in basolateral uptake at 4ºC is consistent with transport
mediated by a protein such as an organic anion transporter.
To characterize further the contribution of OAT along the basolateral
membrane in IRPTs, inhibition of FL accumulation by probenecid was assessed.
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Probenecid is the prototypical inhibitor of renal OAT (Insel, 1996), and should
therefore inhibit FL uptake into IRPTs. To study the effect of probenecid on FL
accumulation, tubules were incubated with 4µM FL in the presence or absence of
1 mM probenecid for 2 min (Fig. 4.10). Probenecid significantly inhibited FL
accumulation along the basolateral membrane of IPRTs by approximately 86%.
This reduction in basolateral uptake in the presence of probenecid is consistent
with transport mediated by OAT proteins.

To determine the IC50 value of

probenecid for FL transport in the IRPT model, tubules were incubated with 4 µM
FL for 2 min in the presence of increasing concentrations of probenecid (Fig.
4.11). The IC50 value was calculated from the non-linear regression equation to
be approximately 67 µM in this model, with 250 µM probenecid yielding nearly
maximal inhibition of FL accumulation (approximately 80%) in IRPTs.
Additional studies were conducted to further characterize FL accumulation
in the F344 IRPT model. To help elucidate the role of OAT1 vs. OAT3 in FL
accumulation along the basolateral membrane, various inhibitors were used that
were selective for either OAT1 or OAT3. The first inhibitor used was the cardiac
glycoside, ouabain. Ouabain directly inhibits the Na+/K+ ATPase which is known
to drive OAT1 transport (Kelly and Smith, 1996). Tubules were incubated with 4
µM FL alone, or preincubated in the dark for 10 min with 100 µM ouabain, and
then coincubated for 2 min with 4 µM FL, (Fig. 4.12).

Ouabain significantly

inhibited the basolateral accumulation of FL in IRPTs by approximately 51%
suggesting a role for OAT1 in FL accumulation.
The effect of benzylpenicillin (penicillin G, PG) on FL accumulation along
the basolateral membrane was assessed to elucidate the role of OAT3 in FL
accumulation. PG is an OAT3-selective substrate for rOAT3 (Hasegawa et al.,
2002). Tubules were incubated for 2 min with 4 µM FL in the presence or
absence of 1mM PG (Fig. 4.13).

PG significantly inhibited basolateral FL
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accumulation in IRPTs by approximately 40%.

The effect of PG on FL

accumulation indicates that OAT3 also plays a role in FL transport in this model.
The

effect

of

dehydroepiandrosterone

sulfate

(DHEAs)

on

FL

accumulation along the basolateral membrane was also used to assess the
potential role of OAT3 in FL accumulation. DHEAs is a substrate of OAT3 (Cha
et al., 2000) and has been used in many models to study the function of OAT3
transport. To assess its value as a potential OAT3 inhibitor in this model, tubules
were incubated with 4 µM FL in the presence or absence of 1 mM DHEAs (Fig.
4.14). DHEAs significantly inhibited basolateral FL accumulation in IRPTs by
approximately 82%.

The effect of DHEAs at this concentration indicates

interaction with OAT1 and OAT3 as inhibition is comparable to that found for
probenecid (86%).
To determine whether glucuronide metabolites interact with OAT
transporters along the basolateral membrane of IRPTs, acetamidophenyl
glucuronide (AG) was selected as a model glucuronide metabolite to assess
whether it interacted with OAT proteins in this model. To determine whether AG
interacted with OAT1 and OAT3, AG was used as a potential inhibitor of FL
accumulation. If AG interacts with OAT proteins, it would cause inhibition of FL
uptake by competition for the site of transport. Tubules were incubated for 2 min
with 4 µM FL in the presence or absence of 1 mM AG (Fig. 4.15). AG did not
cause significant inhibition (< 7%) of basolateral FL accumulation. This result
indicates that AG does not appear to undergo transport via the same
mechanisms (OAT1 and OAT3) as FL in this model. It may also indicate that AG
is such a weak substrate for OAT that it does not have the ability to displace FL
from the transporter protein (competitively inhibit FL binding).
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Figure 4.8. Time-dependent accumulation of FL in IRPTs. IRPTs were incubated
at 1mg protein/ml in the presence of 4µM FL for 15, 30, 45, 60 and 120 sec. FL was added to
each flask containing 3ml of tubule suspension (at 1 mg protein/ml) and incubated at 37ºC in a
shaking water bath (100 rpm) under 95% O2/5% CO2. At the end of each assay, 1 ml of tubule
suspension was removed from each flask and analyzed for tubular FL accumulation. Each point
represents mean FL accumulation in nmol FL/mg protein ± SE for n=4. Data were analyzed by
Nonlinear Regression analysis [(f=a*x/(b*x) ; a= 4.44, b= 436.73; r2=0.96].
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Figure 4.9. The effect of temperature on FL accumulation in IRPTs. To
determine the effect of temperature on FL uptake in IPRTs, 3 ml of tubules (at 1 mg protein/ml)
were incubated at 37ºC and 4ºC in the presence of 4 µM FL. FL was added to each flask of IRPT
suspension and incubated for 2 min in a shaking water bath (100 rpm) under 95% O2/5% CO2.
At the end of the assay, 1 ml of tubular suspension was removed from each flask and tubular FL
accumulation determined. Each assay was run in triplicate. Bars represent mean FL content
(nmol/mg protein) ± SE for n=4.

(* Significantly different from control (37ºC) value). FL

accumulation was significantly inhibited by incubation at 4ºC (P<0.001). Data were analyzed by
Student’s t-test, with a 95% confidence interval.
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Figure 4.10. The effect of probenecid on FL accumulation in IRPTs. To
determine the effect of probenecid on FL uptake in IPRTs, 3 ml of tubules (at 1 mg protein/ml)
were incubated at 37ºC with 4 µM FL in the presence or absence of 1mM probenecid. Each flask
containing IRPT suspension was incubated for 2 min in a shaking water bath (100 rpm) under
95% O2/5% CO2. At the end of the assay, 1 ml of tubular suspension was removed from each
flask and tubular FL accumulation determined. Each assay was run in triplicate. Bars represent
mean FL content (nmol/mg protein) ± SE for n=4.

(* Significantly different from control (FL

alone) treatment). FL accumulation in IRPTs was significantly inhibited by probenecid (P<0.001).
Data were analyzed by Student’s t-test, with a 95% confidence interval
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Figure 4.11. IC50 determination of probenecid for FL uptake in IRPTs. To
determine the IC50 value of probenecid for FL uptake in IRPTs, 3 ml tubules (at 1 mg protein/ml)
were incubated with 4 µM FL in the presence of increasing concentrations of probenecid. Each
flask was incubated at

37 º C for 2 min in a shaking water bath (100 rpm). All assays were run

in duplicate. At the end of each assay, 1 ml of tubular suspension was removed from each flask,
and tubular FL accumulation determined.

Probenecid concentrations used were 5, 25, 50, 100

or 250 µM. Each point represents mean FL content (nmol/mg protein) ± SE for n=3. Data were
analyzed by Nonlinear Regression analysis. The IC50 value of probenecid for FL uptake in IPRTs
was calculated from the nonlinear regression equation [(f=a*x/(b*x); r2=0.94] to be 67.4 µM.
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Figure 4.12. The effect of ouabain on FL accumulation in IRPTs. To determine
the effect of ouabain on FL uptake in IPRTs, 3 ml of tubules (at 1 mg protein/ml) were incubated
at 37ºC with 4 µM FL in the presence or absence of 100 µM ouabain. Each flask containing
IRPT suspension was incubated for 2 min in a shaking water bath (100 rpm) under 95% O2/5%
CO2. At the end of the assay, 1 ml of tubule suspension was removed from each flask and
tubular FL accumulation determined. Each assay was run in triplicate. Bars represent mean FL
content (nmol/mg protein) ± SE for n=4.

(* Significantly different from control (FL alone) value).

FL accumulation in IPRTs was significantly inhibited by ouabain (P<0.05). Data were analyzed by
Student’s t-test, with a 95% confidence interval.
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Figure 4.13. The effect of benzylpenicilin on FL accumulation in IRPTs. To
determine the effect of benzylpenicillin on FL uptake in IPRTs, 3 ml of tubules (at 1 mg protein/ml)
were incubated at 37ºC with 4 µM FL in the presence or absence of 1 mM benzylpenicillin. Each
flask containing IRPT suspension was incubated for 2 min in a shaking water bath (100 rpm). At
the end of the assay, 1 ml of tubule suspension was removed from each flask and tubular FL
accumulation determined.

Each assay was run in triplicate. Bars represent mean FL content

(nmol/mg protein) ± SE. n=4. (* Significantly different form control (FL alone) values).
accumulation in IPRTs was significantly inhibited by benzylpenicillin (P<0.05).
analyzed by Student’s t-test, with a 95% confidence interval.

105

FL

Data were

Fluorescein (nmole/mg protein)

1.4
1.2
1.0
0.8
0.6
0.4

*

0.2
0.0
FL

FL + DHEAs

Treatment

Figure 4.14. The effect of dehydroepiandrosterone sulfate on FL
accumulation in IRPTs. To determine the effect of DHEAs on FL uptake in IPRTs, 3 ml of
tubules (at 1 mg protein/ml) were incubated at 37ºC with 4 µM FL in the presence or absence of 1
mM DHEAs. Each flask containing IRPT suspension was incubated for 2 min in a shaking water
bath (100 rpm) under 95% O2/5% CO2. At the end of the assay, 1 ml of tubule suspension was
removed from each flask and tubular FL accumulation determined.

Each assay was run in

triplicate. Bars represent mean FL content (nmol/mg protein) ± SE for n=4.

(* Significantly

different from control (FL alone) values). FL accumulation in IPRTs was significantly inhibited by
DHEAs (P<0.05). Data were analyzed by Student’s t-test, with a 95% confidence interval.
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Figure 4.15. The effect of acetamidophenyl glucuronide on FL accumulation
in IRPTs. To determine the effect of AG on FL uptake in IPRTs, 3 ml of tubules (at 1 mg
protein/ml) were incubated at 37ºC with 4 µM FL in the presence or absence of 1 mM AG. Each
flask containing IRPT suspension was incubated for 2 min in a shaking water bath (100 rpm)
under 95% O2/5% CO2. At the end of the assay, 1 ml of tubule suspension was removed from
each flask and tubular FL accumulation determined.

All assays were run in triplicate. Bars

represent mean FL content (nmol/mg protein) ± SE for n=4.

FL accumulation was not

significantly inhibited by incubation with AG. Data were analyzed by Student’s t-test, with a 95%
confidence interval.
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4.1.3.2 PAH accumulation in IRPTs
PAH, a typical substrate of OAT1 and OAT3 proteins, has been used
widely to study OAT uptake in various renal models.

14

C-PAH was used to

further study and characterize the presence of OAT transporters along the
basolateral membrane of the PT of F344 rats. Since PAH is readily available
radiolabeled, and there is great deal of information available about this OAT
substrate, PAH is useful for assessing OAT function in this model. Since PAH is
a substrate for both OAT1 and OAT3, it provides an indication of OAT function in
this model.
To determine first whether PAH uptake in this model was due to OAT
transport across the basolateral membrane, the effect of probenecid on PAH
uptake was assessed. Since probenecid is the typical inhibitor of OAT transport,
and PAH is the typical OAT substrate, treatment with probenecid should block
PAH uptake in this system if PAH uptake is OAT-mediated. To study the effects
of probenecid on PAH accumulation, IRPTs (1mg protein/ml) were incubated with
73.8 µM PAH in the absence or presence of 1mM probenecid for 2 min (Fig.
4.16).

This concentration of PAH was originally selected as the value that

provided the Km concentration of PAH at 0.2 µCi/ml (Sweet et al., 1997; Kushara
et al., 1999)

Probenecid significantly inhibited PAH uptake in IPRTs by

approximately 87%. This reduction in basolateral uptake in the presence of
probenecid is consistent with transport mediated by OAT proteins. To determine
the IC50 value of probenecid for PAH transport in the IRPT model, tubules were
incubated with 4.5 µM PAH for 2 min in the presence of increasing
concentrations of probenecid (Fig. 4.17). The IC50 value was calculated from the
nonlinear regression equation to be approximately 106 µM in this model, with 250
µM probenecid yielding approximately 73% inhibition of PAH accumulation in
IRPTs.
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To assess further the contribution of OAT in glucuronide metabolite
transport, AG was again used as a potential inhibitor of uptake of a known
substrate of OATs. To determine the effect of AG on OAT protein transport, PAH
was used as the known substrate, since PAH was shown to interact with OAT
proteins in this IRPT model.

In this study, IRPTs (1mg protein/ml) were

incubated with 2.5 µM PAH in the absence or presence of 1 mM AG for 30
seconds (Fig. 4.18). This concentration of PAH is equivalent to .13 uCi/ml, and
was used to try to minimize the amount of PAH in the incubation, thus
maximizing the potential for interaction of AG with OAT. Incubation with AG did
not significantly inhibit PAH uptake (approximately 9%), indicating either that AG
does not interact with the same transporters responsible for PAH accumulation in
this model or that AG is such a weak substrate for OAT (very low affinity for OAT)
that it does not have the ability to displace PAH from the transport (OAT)
proteins.
To determine whether other glucuronide metabolites may interact with
PAH

transport

in

this

model,

testosterone

glucuronide

(TG)

and

methylumbelliferyl glucuronide (MUG) were used as alternate potential inhibitors
of PAH accumulation in IRPTs.

AG inhibition was also studied again as a

second control for TG and MUG inhibition.

If inhibition with TG and MUG

produced different results than inhibition with AG, it would indicate that various
glucuronides may have different substrate specificities for basolateral OAT
transporters. To study the effects of TG and MUG on renal OAT, IPRTs were
incubated with 4.4 µM PAH in the absence or presence of 500 µM TG, MUG, or
AG for 30 seconds (Fig. 4.19). Due to increased variability in the results obtained
in the previous experiment, the concentration of PAH was increased to 0.25
µCi/ml to minimize the variability in

14

C-PAH counting. Significant inhibition of

PAH accumulation was not seen in the presence of TG, MUG or AG. These
results suggest that these glucuronide metabolites do not interact strongly with
PAH transporters (OATs) along the basolateral membrane of IRPTs or again, TG
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and MUG also have such weak affinity for the PAH transporter that they cannot
displace PAH and thus inhibit PAH transport.
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Figure 4.16. The effect of probenecid on PAH accumulation in IRPTs.
To determine the effect of probenecid on PAH accumulation in IRPTs, 3 ml of tubules (at 1 mg
protein/ml) were incubated for 2 min with 73.8 µM

14

C-PAH in the absence or presence of 1 mM

probenecid. Each flask was incubated at 37ºC in a shaking water bath (180rpm) under 95%
O2/5% CO2. At the end of two min the total IRPT sample in each flask was analyzed for tubular
PAH accumulation.

All assays were run in duplicate.

(pmol/mg protein) ± SE for n=3.

Bars represent mean PAH content

(*Significantly different from control (PAH alone) values).

Probenecid significantly inhibited PAH accumulation in IRPTs from Fischer 344 rat (P<0.05).
Data were analyzed by Student’s t-test, with a 95% confidence interval.
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Figure 4.17. IC50 determination of probenecid for PAH uptake in IRPTs.
To determine the IC50 value of probenecid for 14C-PAH uptake in IRPTs, 3 ml tubules (at 1 mg
protein/ml) were incubated with 4.5 µM PAH in the presence of increasing concentrations of
probenecid. Each flask was incubated at 37 º C for 2 min in a shaking water bath (180 rpm)
under 95% O2/5% CO2. Assays were run in duplicate at each concentration. At the end of each
assay the total IRPT sample in each flask was analyzed for tubular PAH accumulation.
Probenecid concentrations used were 25, 50, 100, 150 or 250 µM. Each point represents mean
PAH content (pmol/mg protein) ± SE for n=8 (PAH) or n=4 (+probenecid). Data were analyzed by
Nonlinear Regression analysis. The IC50 value of probenecid for PAH uptake in IPRTs was
calculated from the nonlinear equation (f=a*x/(b+x); r2=0.97) to be 106.5 µM.

111

PAH (pmol/mg protein)

20

15

10

5

0

PAH

PAH + AG

Treatment
Figure 4.18. Effect of acetamidophenyl glucuronide on PAH accumulation
in IRPTs.

To determine the effect of AG on PAH accumulation along the basolateral

membrane in IRPTs, 3 ml of tubules (at 1 mg protein/ml) were incubated at 37ºC with 2.5 µM 14CPAH in the presence or absence of 1 mM AG. Each flask containing IRPT suspension was
incubated for 30 seconds in a shaking water bath (180 rpm) under 95% O2/5% CO2. At the end
of the assay, the total IRPT sample in each flask was analyzed for tubular PAH accumulation. All
assays were run in duplicate. Bars represent mean PAH content (pmol/mg protein) ± SE for n=4.
PAH accumulation was not significantly inhibited by incubation with AG. Data were analyzed by
Student’s t-test, with a 95% confidence interval.
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Figure 4.19. Effect of testosterone glucuronide (TG), methylumbelliferyl
glucuronide (MUG), and acetamidophenyl glucuronide (AG) on PAH
accumulation in IRPTs. To determine the effect of TG, MUG, and AG on PAH
accumulation in IRPTs, 3 ml of tubule suspension (1mg protein/ml) were incubated with 4.4µM
14

C-PAH in the absence or presence of 500 µM TG, MUG, or AG. Tubules were incubated at

37ºC for 30 seconds in a shaking water bath (180 rpm) under 95% O2/5% CO2. At the end of
each assay, the total IRPT sample in each flask was analyzed for tubular PAH accumulation. All
assays were run in duplicate. Bars represent mean PAH content (pmol/mg protein) ± SE for n=4
(PAH + TG) or n=5 (PAH + MUG, AG). Incubation with PAH in the presence of TG, MUG or AG
did not cause significant inhibition of PAH accumulation in IRPTs. Data were analyzed by
Repeated Measures ANOVA.
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4.1.3.3 Estrone sulfate accumulation in IRPTs.
Estrone sulfate (ES) has been used as the typical substrate of OAT3 in
numerous OAT transport studies. Since ES is selective for OAT3 rather than
OAT1, it allows for direct study of the interaction of compounds with the OAT3
protein. Therefore, ES was used to characterize the contribution of OAT3 in
transport along the basolateral membrane of IRPTs from F344 rat, and to
determine also the potential role of OAT3 in glucuronide metabolite uptake.
To characterize OAT3 transport in this IRPT model, it was first necessary
to determine whether accumulation of ES in this model was a carrier proteinmediated process. To determine this, temperature dependent uptake of ES was
studied. Tubules (1 mg protein/ml) were incubated with 3H-ES in a shaking water
bath (180 rpm) at 37 or 4ºC (Fig. 4.20). Incubation at 4ºC significantly inhibited
ES uptake in IRPTs by approximately 38%.

This temperature dependent

inhibition is consistent with the presence of carrier protein-mediated transport.
To further characterize ES transport in this model, probenecid was used
as the classical OAT inhibitor to determine whether ES transport in this model
was probenecid sensitive.

Probenecid sensitivity would give additional

supporting evidence for the presence and function of OAT3 in this model. For
this study, tubules (1 mg protein/ml) were incubated with 4 pM 3H-ES in the
absence or presence of 1 mM probenecid (Fig. 4.21). Incubation with ES in the
presence of probenecid caused significant inhibition of ES uptake in IRPTs by
approximately 41%. This indicates that OAT transport (as demonstrated by ES
accumulation) is in part carried out by OAT3 in this model.

These results

combined with those found for temperature sensitivity of ES uptake, also suggest
that there may be other transporters involved in ES transport in this model, or
potentially another transporter involved in the transport of OAT3 substrates.
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Self-inhibition of ES accumulation in IRPTs was also used to characterize
ES transport and OAT3 function in this model. Self-inhibition, or the inhibition of
radiolabeled substrate uptake by addition of excess amounts of unlabeled
substrate, is commonly used as an indicator of true carrier-mediated “transport”
of a compound vs. other forms of entry into a cell (i.e. diffusion). To determine
whether ES is subject to self-inhibition, IRPTs (1 mg protein/ml) were incubated
with 4 pM 3H-ES, in the absence or presence of 500 µM unlabeled ES (Fig 4.22).
Incubation of IRPTs with 3H-ES in the presence of excess unlabeled ES showed
significant

inhibition

of

ES

accumulation

by

approximately

63%.

This

demonstrates that ES transport in IRPTs from Fischer 344 rat is a carriermediated transport process, and also demonstrates the presence and function of
OAT3 along the tubular basolateral membrane.
To assess the potential interaction between AG and OAT3, AG was used
as a potential inhibitor of uptake of ES, a known OAT3 substrate. In this study
IRPTs (1 mg protein/ml) were incubated with 4 pM 3H-ES in the absence or
presence of 1 mM AG for 60 seconds (Fig. 4.23). Incubation of IRPTs with ES in
the presence of AG did not demonstrate significant inhibition of ES accumulation.
This indicates that AG does not interfere with ES transport, further demonstrating
that AG either does not interact with OAT3 transporters along the basolateral
membrane of the PT, or is such a weak substrate that it can not displace ES (a
high-affinity OAT3 substrate) from the protein.
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Figure 4.20. The effect of temperature on estrone sulfate accumulation in
IRPTs. To determine the effect of temperature on ES uptake in IPRTs, 3 ml of tubules (at 1 mg
protein/ml) were incubated at 37ºC or 4ºC in the presence of 4 pM 3H-ES. ES was added to each
flask of IRPT suspension and incubated for 60 seconds in a shaking water bath (180 rpm) under
95% O2/5% CO2. At the end of each assay, the total IRPT sample in each flask was analyzed for
tubular ES accumulation. All assays were run in duplicate. Bars represent mean ES content
(fmol/mg protein) ± SE for n=5, * Significantly different from control (37) values (P<0.05). Data
were analyzed by Student’s t-test, with a 95% confidence interval.
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Figure 4.21. The effect of probenecid on ES accumulation in IRPTs.
To determine the effect of probenecid on ES accumulation in IRPTs, 3 ml of tubules (at 1mg
protein/ml) were incubated for 30 seconds with 4 pM 3H-ES in the absence or presence of 1 mM
probenecid. Each flask was incubated at 37ºC in a shaking water bath (180rpm) under 95%
O2/5% CO2. At the end of each assay the total IRPT sample in each flask was analyzed for
tubular ES accumulation.

All assays were run in duplicate. Bars represent mean ES content

(fmol/mg protein) ± SE, n=3.

* Significantly different from control (ES) values (P<0.05). Data

were analyzed by Student’s t-test, with a 95% confidence interval.
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Figure 4.22. The effect of self-inhibition on estrone sulfate accumulation in
IRPTs. To determine the effect of self-inhibition on ES uptake in IRPTs, 3 ml tubules (at 1 mg
protein/ml) were incubated for 60 seconds with 4 pM 3H-ES in the absence or presence of 500
µM unlabeled ES. Each flask was incubated at 37ºC in a shaking water bath (180rpm) under
95% O2/5% CO2. At the end of each assay the total IRPT sample in each flask was analyzed for
tubular ES accumulation. All assays were run in duplicate. Bars represent mean ES content
(fmol/mg protein) ± SE for n=4. * Significantly different from control (3H-ES) values (P<0.05).
Data were analyzed by Student’s t-test, with a 95% confidence interval.
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Figure 4.23. The effect of acetamidophenyl glucuronide on estrone sulfate
accumulation in IRPTs.

To determine the effect of AG on ES accumulation along the

basolateral membrane in IRPTs, 3 ml of tubules (at 1 mg protein/ml) were incubated for 60
seconds with 4 pM 3H-ES in the presence or absence of 1 mM AG. Each flask containing IRPT
suspension was incubated for 37 ºC in a shaking water bath (180 rpm) under 95% O2/5% CO2.
At the end of the assay, the total IRPT sample in each flask was analyzed for tubular ES
accumulation. All assays were run in duplicate. Bars represent mean ES content (fmol/mg
protein) ± SE for n=3. ES accumulation was not significantly inhibited by incubation with AG.
Data were analyzed by Student’s t-test, with a 95% confidence interval.
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4.1.3.4 Acetamidophenyl glucuronide (AG) accumulation in IRPTs
AG was selected as a model glucuronide for the study of glucuronide
transport along the basolateral membrane of the renal PT. This compound was
available radiolabeled, and previous studies suggest that AG has the ability to be
secreted by the kidney (Duggin and Mudge, 1975; Galinsky and Levy, 1981;
Watari et al., 1983).

To elucidate whether OAT proteins contribute to AG

secretion (and possibly glucuronide metabolites in general) across the
basolateral membrane of the PT, various aspects of AG accumulation by IRPTs
were studied.

Temporal studies revealed that when IRPTs are incubated with

4.5 µM AG, AG appears to demonstrate time-dependent accumulation within the
tubule fragments (Fig. 4.24). Accumulation appeared gradual over time with AG
tubular content doubling between 15 and 300 seconds.
To elucidate further the mechanism of uptake of AG in IRPTs, temperature
dependent studies were used to determine whether accumulation of AG
appeared to be via a carrier protein-mediated process (such as OAT). IRPTs
incubated with 2 µM

14

C-AG at either 37ºC or 4ºC did not reveal significant

decrease in AG accumulation across the basolateral membrane of IRPTs (Fig.
4.25).

Decreased temperature generated only approximately 18% inhibition.

These results indicate that AG entry into IRPTs across the basolateral membrane
may, in large part, be due to mechanisms other than a carrier protein-mediated
pathway.
To determine whether AG interacts with OAT transporters, probenecid
was used as the typical OAT transport inhibitor. Since probenecid has been
demonstrated to inhibit the uptake of organic anions in this model, if AG
accumulation is due in any part to transport by OAT proteins, treatment with
probenecid should yield inhibition of AG accumulation. IRPTs pretreated with
probenecid or coincubated with probenecid in the presence of 2 µM
120

14

C-AG did

not demonstrate inhibition of AG accumulation (Fig. 4.26). Lack of inhibition of
AG accumulation in IRPTs by probenecid demonstrates that AG accumulation
may by via a different mechanism than OAT transport.
Since the previous experiments raise question as to whether transport of
AG across the basolateral membrane is due to a protein-mediated transport
process, self-inhibition studies were used to characterize further the mechanism
of AG transport into IRPTs. IRPTs incubated with

14

C-AG in the presence of

excess unlabeled AG did not demonstrate inhibition of labeled AG accumulation
(Fig. 4.27). This provides further evidence that AG entry across the basolateral
membrane in this IRPT model may be due to other mechanisms than carriermediated transport.
To characterize further whether AG interacts with OAT transporters along
the basolateral membrane, potential transport by OAT3 was specifically
examined.

Since AG is a bulky, charged molecule (as are glucuronides in

general), AG is more likely to interact with OAT3 than other OATs should AG
have any interaction with OAT proteins along the basolateral membrane of renal
PTs. IRPTs incubated with 4.5 µM AG in the presence of 100 µM ES did not
demonstrate inhibition of AG accumulation (Fig. 4.28). Since the presence of ES
(a high affinity substrate for OAT3) did not interfere with AG accumulation in this
model, this finding further supports that AG accumulation into IRPTs is not due to
OAT proteins along the basolateral membrane, and more specifically, AG does
not appear to interact with OAT3 proteins.
In the previous studies, the mechanism of AG uptake across the
basolateral membrane of IRPTs does not appear to be due to a carrier proteinmediated process such as OAT. With concern that these results may have been
affected by metabolism of the AG metabolite by β-glucuronidase during
incubation, AG accumulation studies were conducted in the presence of D121

saccharic acid 1,4-lactone (SL), a β-glucuronidase inhibitor (Soars et al., 2001).
Since deconjugation of AG would have yielded a glucuronic acid moiety, and a
labeled acetaminophen (APAP) molecule, it was necessary to determine whether
what was documented as AG uptake was due to AG or APAP, since APAP does
have the ability to diffuse through the cell membrane. If uptake was due to
diffusion of APAP into the IRPTs rather than AG, treatment with SL should
completely inhibit accumulation of labeled substrate (AG). IRPTs treated with 4.5
µM AG in the presence of SL demonstrated no inhibition of AG accumulation
(Fig. 4.29). This indicates that the demonstrated accumulation of AG in previous
studies is in fact due to the AG molecule, and not deconjugation to APAP with
subsequent entry of APAP into the tubules.
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Figure

4.24.

Time-dependent

accumulation

of

acetamidophenyl

glucuronide in IRPTs. To determine the time-dependent accumulation of AG in IRPTs, 3 ml
tubules (at 1 mg protein/ml) were incubated with 4.5 µM

14

C-AG for 15, 30, 45, 60,120 or 300

seconds. Tubules were incubated at 37 ºC in a shaking water bath (180 rpm) under 95% O2/5%
CO2. All assay was run in duplicate. At the end of each time point, the total tubule suspension
from each flask was analyzed for tubular AG accumulation. Each point represent mean tubular
AG content (pmol/mg protein) ± SE for n=3.
2

analysis [(f=a*x/(b+x)+c*x); r =0.994].
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Data were analyzed by Nonlinear Regression
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Figure 4.25. The effect of temperature on acetamidophenyl glucuronide
accumulation in IRPTs. To determine the effect of temperature on AG uptake in IPRTs, 3
ml of tubules (at 1 mg protein/ml) were incubated at 37ºC or 4ºC in the presence of 2 µM 14C-AG.
AG was added to each flask of IRPT suspension and incubated for 30 seconds in a shaking water
bath (180 rpm) under 95% O2/5% CO2. At the end of each assay, the total IRPT sample in each
flask was analyzed for tubular AG accumulation.

All assays were run in duplicate.

represent mean AG content (pmol/mg protein) ± SE for n=4,
significantly inhibited by incubation at 4ºC.

Bars

AG accumulation was not

Data were analyzed by Student’s t-test, with a 95%

confidence interval.
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Figure 4.26. The effect of probenecid on acetamidophenyl glucuronide
accumulation in IRPTs. To determine the effect of probenecid on AG accumulation in
IRPTs, 3 ml of tubules (at 1mg protein/ml) were either incubated for 30 seconds with 2 µM 14CAG in the absence or presence of 1 mM probenecid or preincubated with 1mM probenecid before
the addition of 2 µM 14C-AG. Each flask was incubated at 37ºC in a shaking water bath (180rpm)
under 95% O2/5% CO2. At the end of each assay the total IRPT sample in each flask was
analyzed for tubular AG accumulation. All assays were run in duplicate. Bars represent mean
AG content (pmol/mg protein) ± SE for n=4. Probenecid did not significantly inhibited AG
accumulation in IRPTs from Fischer 344 rat. Data were analyzed by Student’s t-test, with a 95%
confidence interval.
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Figure 4.27. The effect of self-inhibition on acetamidophenyl glucuronide
accumulation in IRPTs. To determine the effect of self-inhibition on AG uptake in IRPTs, 3
ml tubules (at 1 mg protein/ml) were incubated for 30 seconds with 4.5 µM 14C-AG in the absence
or presence of 5 mM unlabeled AG. Each flask was incubated at 37ºC in a shaking water bath
(180rpm) under 95% O2/5% CO2. At the end of each assay the total IRPT sample in each flask
was analyzed for tubular AG accumulation.

All assays were run in duplicate. Bars represent

mean AG content (pmol/mg protein) ± SE for n=3.
significantly inhibit the accumulation of

14

The presence of unlabeled AG did not

C-AG in IRPTs. Data were analyzed by Student’s t-test,

with a 95% confidence interval
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Figure 4.28. The effect of estrone sulfate on acetamidophenyl glucuronide
accumulation in IRPTs. To determine the effect of ES on AG accumulation in IRPTs, 3 ml
of tubules (at 1mg protein/ml) were incubated for 30 seconds with 4.5 µM

14

C-AG in the absence

or presence of 100 µM ES. Each flask was incubated at 37ºC in a shaking water bath (180rpm)
under 95% O2/5% CO2. At the end of each assay the total IRPT sample in each flask was
analyzed for tubular AG accumulation.

All assays were run in duplicate. Bars represent mean

AG content (pMole/mg protein) ± SE for n=3.

Incubation with ES did not significantly inhibited

AG accumulation in IRPTs. Data were analyzed by Student’s t-test, with a 95% confidence
interval.
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Figure 4.29. The effect of D-saccharic acid 1,4-lactone on acetamidophenyl
glucuronide accumulation in IRPTs.

To determine the effect of SL on AG

accumulation in IRPTs, 3 ml of tubules (at 1mg protein/ml) were incubated for two min with 4.5
µM

14

C-AG in the absence or presence of either 10mM or 20 mM SL following 5 min

preincubation with SL.

Each flask was incubated at 37ºC in a shaking water bath (180rpm)

under 95% O2/5% CO2. At the end of each assay the total IRPT sample in each flask was
analyzed for tubular AG accumulation.

All assays were run in duplicate. Bars represent mean

AG content (pMole/mg protein) ± SE for n=3. Incubation with SL at either concentration did not
significantly inhibited AG accumulation in IRPTs. Data were analyzed by Repeated Measures
ANOVA, with a 95% confidence interval.
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4.1.3.5 Western Blot Analysis of OAT1 and OAT3 in Fischer 344 IRPTs
Western blot analysis of the organic anion transporters, OAT1 and OAT3,
was performed using crude membrane fractions isolated from Fischer 344 rat
IRPTs (Fig. 4.30). IRPTs were isolated as described in the Methods chapter and
western blot analysis was carried out by Eliza Robertson. Molecular weight is
given for protein bands larger than 50 kD, as smaller bands are thought to be
due to either incompletely formed proteins or breakdown products. Antibodies
synthesized against peptides homologus to the amino-terminus were used and
would therefore bind whole and partial proteins. The OAT1 band demonstrated
for Fisher 344 IRPTs at 75 kD is comparable to the 77 kD band reported by Ji et
al (2002) for OAT1, where the 61.3 kD band is likely the nonglycosylated protein
form. Faint bands for OAT3 were detected at 54 and 63 kD which is comparable
to the 54 and 65 kD, bands reported by Hasegawa et al. (2002) for rOAT3. Heavier
darker bands may potential represent breakdown products. While western blot
analysis can not show whether OAT1 and OAT3 are functional, it demonstrates
that OAT1 appears to be present while raising question as to the presence of
OAT3 in F344 IRPTs.
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Figure 4.30. Western Blot Analysis for OAT1 and OAT3. Crude membrane fractions
(250 µg/lane) isolated from HK-2 cells, passage 29, scraped from T75 flasks and from Fisher 344
(F344) rat IRPTs were separated on a 12% polyacrylamide gel, blotted onto nitrocellulose then
exposed to antibodies against OAT1 or OAT3.

In freshly isolated F344 IRPTs, bands were

detected at 61.3 and 75 kD for OAT1, and faint bands for OAT3 were detected at 54 and 63 kD.
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4.2 Studies in Renal Cortical Slices (RCS)
4.2.1 Uptake studies in renal cortical slices (RCSs)

The isolation of renal PTs used in the previously described studies
involved the use of collagenase digestion.

Collagenase digestion, while

providing healthy tubule fragments for uptake studies, may potentially cause
partial digestion of some transporters along the basolateral membrane.

To

determine whether the results for AG uptake in IRPTs are due to partial digestion
of

the

transport

mechanisms

for

the

AG

molecule

(partial digestion of OAT transporters at a critical AG binding site) has occured,
additional studies were conducted in renal cortical slices. It is important to note
that the IRPT model was able to demonstrate transport of known organic anions
such as FL, PAH, and to a certain extent ES. These compounds may have
multiple recognition sites within the OAT proteins and transport of these OAs
would be less sensitive to partial digestion by collagenase. AG however, if it has
extremely low substrate specificity for OAT, may be more susceptible to the
effects of partial digestion of the OAT proteins by collagenase digestion. RCSs
have the same transport properties as IRPTs, but their isolation does not involve
the use of collagenase. Therefore, in the RCS model, OAT proteins along the
proximal tubular basolateral membrane should remain fully intact. If digestion of
OAT proteins in the IRPT model caused decreased affinity of AG for the
transporter proteins, this affinity should be unchanged in the RCS model.
4.2.1.1 Mannitol accumulation in RCSs
Accumulation of 3H-mannitol was used to assess interstitial accumulation
in the RCS model.
RCS.

Mannitol does not undergo transport by any portion of the

Therefore, mannitol does not accumulate in RCSs by transport

mechanisms but accumulation is due to movement (leak) of MN into interstitial
131

spaces between cells within the slices.

Thus, MN accumulation gives an

indication as to the amount of interstitial space where compounds may collect by
mechanisms other than cellular transport. RCSs incubated over time in the
presence of 176 pM 3H-mannitol demonstrated accumulation of less than 7
fmol/mg protein of mannitol over a 60 min incubation time (Fig. 4.31).
Accumulation of mannitol was minimal over the entire time period (10-60 min),
indicating that the slices were of good quality (no large interstitial spaces or gaps
created during slicing) and could be used for uptake studies.
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Figure 4.31. Mannitol accumulation in RCSs. To assess the quality of the RCS
technique, RCSs (30-60 mg) were incubated for 10, 15, 30, and 60 min in the presence of 176
pM 3H-mannitol. Slices were incubated at 37ºC in a shaking water bath (100 rpm). At the end of
each time point, the total slice content of each well was analyzed for mannitol accumulation.
Each assay was run in duplicate. Each point represents mean mannitol content (fmol/mg protein)
± SE for n=4. Mannitol accumulation appeared to reach a maximum of less than 7 fmol/mg
protein. Data were analyzed by Nonlinear Regression analysis [f=a*x/(b+x); r2=0.99].
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4.2.1.2 PAH accumulation in RCSs
Accumulation of PAH, the typical OAT1/OAT3 substrate, was used to
assess the activity of OAT transporters along the basolateral membrane of PTs
in the RCS model. Since the tubular lumens collapse in the slice model, the only
entry for PAH into the PT cells in RCSs is via tubular OAT transporters along the
basolateral membrane.
To characterize best that PAH uptake in the RCS model is mediated by
OAT proteins, probenecid, the typical OAT transport inhibitor, was used to
demonstrate inhibition of PAH uptake. RCSs incubated with 4.7 µM

14

C-PAH in

the presence of probenecid showed accumulation of PAH with significant
inhibition of PAH accumulation in the presence of 1 mM probenecid (Fig. 4.32).
Inhibition of PAH accumulation by probenecid was approximately 80%.

This

result is similar to that found in IRPTs (86%; Fig. 4.16), indicating that OAT
proteins are functional in this model and transport is probenecid sensitive.
To characterize the potential interaction of OAT transport with glucuronide
metabolites in the RCS model, TG, MUG, and AG were used to assess their
interaction with PAH transport.

RCSs incubated with 4.7 µM

14

C-PAH in the

presence of 500 µM TG, MUG, or AG demonstrated no inhibition of PAH
transport (Fig. 4.33). TG, MUG, and AG all failed to inhibit PAH accumulation in
RCSs, indicating that these compounds do not interact with the same transport
mechanisms as PAH in the RCS model. This finding is also in agreement with
that found in the IRPT model (Fig. 4.19).
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Figure 4.32. The effect of probenecid on PAH accumulation in RCSs. To
determine the effect of probenecid on PAH transport in RCS, RCSs (30-60 mg) were incubated
for 30 min with 4.7 µM

14

C-PAH in the absence or presence of 1mM probenecid. RCSs were

incubated at 37ºC in a shaking water bath (100 rpm). At the end of each assay, total slice
content of each well was analyzed for PAH accumulation. Each assay was run in duplicate. Bars
represent mean PAH content (pmol/mg protein) ± SE for n=4. * Significantly different from control
(PAH) values (P<0.05). Data were analyzed by Student’s t-test with a 95% confidence interval.
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Figure 4.33. The effect of testosterone glucuronide (TG), methylumbelliferyl
glucuronide (MUG), and acetamidophenyl glucuronide (AG) on PAH
accumulation in RCSs.

To determine the effect of TG, MUG and AG on PAH

accumulation in RCSs., RCSs (30-60 mg) were incubated for 30 min with 4.7 µM PAH in the
absence or presence of 500 µM TG, MUG or AG. Slices were incubated at 37ºC in a shaking
water bath (100 rpm). At the end of each assay, total slice content from each well was analyzed
for PAH accumulation. Each assay was run in duplicate.

Each bar represents mean PAH

content (pmol/mg protein) ± SE for n=4. Data were analyzed by One Way Repeated Measures
ANOVA.
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4.2.1.3 Estrone sulfate accumulation in RCSs.
To evaluate the activity and contribution of OAT3 to organic anion
transport in RCSs, estrone sulfate was used as the typical substrate for OAT3.
Since OAT3 is most likely responsible for the transport of bulky organic anions
(and thus glucuronide conjugates), it was important to determine the presence of
active OAT3 function in this model, and determine whether AG appeared to have
any interaction at this transporter. Temporal uptake studies in RCSs, show that
when treated with 4 pM 3H-ES, RCSs accumulate ES in a time-dependent
manner (Fig. 4.34). Accumulation of ES increases steadily until 30 min, and by
60 min uptake appears to be reaching equilibrium.
To characterize further ES transport, and thus OAT3, in the RCS model,
the effects of probenecid and temperature on ES accumulation were assessed.
Probenecid inhibition would indicate that ES is transported by an OAT protein in
this model, and temperature sensitivity would indicate that transport is via a
carrier protein-mediated process.

RCSs incubated with 4 pM 3H-ES in the

presence of 1mM probenecid or at 4ºC demonstrated significantly decreased ES
accumulation (Fig. 4.35). Probenecid treatment caused a 33% reduction in ES
accumulation, while incubation at 4ºC caused an 80% decrease in ES
accumulation.

Since low temperature demonstrated a significantly greater

decrease in ES accumulation than treatment with probenecid, this indicates that
there may be another transport mechanism involved in ES accumulation.
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Figure 4.34.

Time-dependent accumulation of estrone sulfate in RCSs.

RCSs (30-60mg) were incubated for 10, 15, 20, 30 or 60 min in the presence of 4 pM 3H-ES.
Slices were incubated at 37ºC in a shaking water bath (100 rpm). At the end of each time point,
total slice content of each well was analyzed for ES accumulation. Each assay was run in
duplicate. Each point represents mean ES content (fmol/mg protein) ± SE for n=4. Data were
analyzed by Nonlinear Regression analysis [f=a*x/(b+x); r2=0.99].
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Figure 4.35. Effect of probenecid and temperature on ES accumulation in
RCSs. To determine the effect of probenecid and temperature on ES accumulation, RCSs (3060 mg) were incubated for 10 min with 4 pM 3H-ES in the absence or presence of 1mM
probenecid at 37ºC, or with 4 pM 3H-ES alone at 4ºC. At the end of each assay, total slice
content from each well was analyzed for ES accumulation. Assays were run in duplicate. Each
bar represents mean ES content (fmol/mg protein) ± SE, n=4. * Significanlty different from
control (ES) value (P<0.001). # Significantly different from treatment with probenecid (P<0.001).
Data were analyzed by One Way Repeated Measures ANOVA, followed by Student-NewmanKeuls analysis with a 95% confidence interval.
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4.2.1.4 Acetamidophenyl glucuronide accumulation in RCSs
Accumulation of AG in RCSs was studied in various experiments to
determine whether the affinity of AG for OAT transporters may have been
affected by the collagenase digestion treatment in the IRPT isolation procedure.
If OAT proteins along the basolateral membrane had become partially digested,
the tubule fragments may no longer be able to recognize AG as a potential
substrate.

Accumulation studies in RCS allow for the study of glucuronide

transport in a model that does not have enzymatically digested proteins, such as
OAT.

If enzymatic digestion has destroyed a critical recognition site for

glucuronide substrates in IRPTs, this may be a reason why the IRPT model
appears to lack the ability to demonstrate AG accumulation via carrier proteinmediated mechanisms.

If a critical binding site has been digested in the IRPT

model, this site should be functional in the RCS model. Therefore, the RCS
model should demonstrate a protein carrier-mediated accumulation mechanism
for AG, if AG or other glucuronide metabolites are transported across the
basolateral membrane by carrier proteins such as OAT1 or OAT3. To assess
whether accumulation of AG in RCS differed from that seen in IRPTs, temporal
studies were conducted. RCSs incubated over time in the presence of 4.7 µM
14

C-AG demonstrates a slightly biphasic accumulation pattern (Fig. 4.36). AG

accumulation in RCS occurs rapidly during the first 5 min, and reaches an
apparent equilibrium by 20 min. At 45 min, accumulation appears to begin to
increase, however this increase may be due to loss of slice integrity with
increased accumulation within interstitial spaces, or increased binding to
exposed intracellular proteins.
To determine whether AG accumulation in slices is due to carrier proteinmediated process temperature sensitive studies were conducted. At the same
time studies were conducted to determine the effects of probenecid on AG
accumulation.

Inhibition of AG accumulation by probenecid would give an

indication of the role of OAT in AG accumulation in this model. RCS incubated
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with 4.7 µM 14C-AG at 4ºC demonstrated a significantly lower accumulation of AG
than RCSs incubated at 37ºC (Fig. 4.37). AG accumulation was inhibited at 4ºC
by approximately 30%. While this is not a large degree of inhibition, it indicates
that there may be some protein-mediated process for AG accumulation in RCS.
No inhibition was seen in the IRPT model. When RCSs were incubated with 4.7
µM

14

C-AG in the absence or presence of 1mM probenecid, AG accumulation

was significantly inihibited (Fig. 4.37).

Accumulation of AG was inhibited

approximately 22%. This probenecid sensitivity of AG accumulation in RCSs
indicates that OAT may play a small role in AG accumulation in this model. It is
important to note, however, that there is a large amount of AG accumulation that
is not accounted for by either a temperature-dependent, carrier protein-mediated
mechanism, or by a probenecid-sensitive (OAT) mechanism (70% and 78%,
respectively).
To study further whether AG interacts with OAT proteins along the tubular
basolateral membrane in RCS, PAH and ES were used as potential competitive
inhibitors of AG accumulation. PAH was used to assess both OAT1 and OAT3,
and ES used to assess primarily the OAT3 contribution. RCSs incubated with
4.7 µM

14

C-AG in the absence or presence of either 1mM PAH or 500 µM ES did

not demonstrate inhibition of AG accumulation in RCSs (Fig 4.38). This finding is
similar to that found in IRPTs for ES, and further indicates that OAT1 and OAT3
may not be responsible for AG accumulation in this model.
Since AG accumulation did not appear to be due to OAT transport along
the basolateral membrane, self-inhibition studies were conducted to further
characterize the presence of a protein carrier-mediated uptake mechanism, as
demonstrated by the temperature dependent studies. While uptake does not
appear to be via OAT proteins, there may be other protein carriers responsible
for AG accumulation in the RCS model. However, RCSs incubated with 4.7 µM
14

C-AG in the absence or presence of 500 µM unlabeled AG did not show
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inhibition of AG accumulation (Fig. 4.39). This indicates that AG accumulation in
the RCS model is not due to a carrier protein-mediated process, supporting the
results found in the IRPT model. Accumulation of AG must, therefore, be due to
other mechanisms such as non-specific binding.
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Figure 4.36 Time-dependent accumulation of acetamidophenyl glucuronide
in RCSs. RCS (30-60 mg) were incubated for 2.5, 5, 15, 30, 45 or 60 min in the presence of
4.7 µM 14C-AG. Slices were incubated at 37ºC in a shaking water bath (100 rpm). At the end of
each time point total slice content of each well was analyzed for AG accumulation. Each assay
was run in duplicate. Each point represents mean AG content (pmol/mg protein) ± SE for n=3.
Data were analyzed by Nonlinear Regression analysis [(f=a*x/(b+x)+c*x); r2=0.96].
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Figure 4.37. The effect of temperature and probenecid on AG accumulation
in RCSs. To determine the effects of temperature on AG accumulation, RCSs (30-60 mg)
were incubated for 30 min with 4.7 µM 14C-AG at either 37ºC or at 4ºC. To determine the effect of
probenecid on AG accumulation, RCSs were incubated for 30 min with 4.7 µM

14

C-AG at 37ºC in

the absence or presence of 1 mM probenecid. Slices were incubated in a shaking water bath
(100 rpm). At the end of each assay, total slice content from each well was analyzed for AG
accumulation.

Each assay was run in duplicate.

(pmol/mg protein) ± SE for n=4.

Each bar represents mean AG content

* Significantly different from control (AG) values (P<0.05).

Temperature and probenecid treatments were not significantly different from each other. Data
were analyzed by One Way Repeated Measures ANOVA, followed by Student Newman-Keuls
analysis at a 95% confidence interval.
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Figure 4.38. The effect of p-aminohippuric acid and estrone sulfate on AG
accumulation in RCSs. To determine the effects of PAH and ES on AG accumulation,
RCSs (30-60 mg) were incubated for 30 min with 4.7 µM

14

C-AG in the absence or presence of

either 1 mM PAH or 500 µM ES. Slices were incubated at 37ºC in a shaking water bath (100
rpm).

At the end of each assay, total slice content from each well was analyzed for AG

accumulation.

Each assay was run in duplicate.

Each bar represents mean AG content

(pmol/mg protein) ± SE for n=5. Incubation with PAH or ES did not significantly inhibit AG
accumulation in RCSs. Data were analyzed by One Way Repeated Measures ANOVA.
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Figure 4.39. The effect of self-inhibition on AG accumulation in RCSs. To
determine the effect of self-inhibition on AG accumulation, RCSs (30-60 mg) were incubated for
30 min with 4.7 µM

14

C-AG in the absence or presence 500 µM unlabeled AG. Slices were

incubated at 37ºC in a shaking water bath (100 rpm). At the end of each assay, total slice
content from each well was analyzed for AG accumulation. Each assay was run in duplicate.
Each bar represents mean AG content (pmol/mg protein) ± SE for n=5 (14C-AG) or n=4 (14CAG+AG). Incubation with excess AG did not significantly inhibit AG accumulation in RCSs. Data
were analyzed by Student’s t-test with a 95% confidence interval.
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4.2.1.5 Acetamidophenyl glucuronide accumulation in RCSs from SpragueDawley (SD) rat
Studies conducted in IRPTs and RCSs from male F344 rat provided
evidence that these models are able to accumulate organic anions such as FL,
PAH and ES.

Uptake of these molecules was carrier protein-mediated, and

determined to be via OAT transport proteins. However, these models did not
demonstrate that accumulation of AG was due to a protein-mediated process,
and more importantly, accumulation does not appear to be via OAT mechanisms
along the basolateral membrane of the PT. Because studies that have indicated
renal secretion of AG were conducted in other rat strains (SD; Galinsky and
Levy, 1981) (Wistar; Watari et al. 1983), it was necessary to investigate whether
studies in a different rat strain would produce different results. Possibly the F344
rat does not have the same renal OAT substrate specificities as other rat strains.
To investigate whether AG accumulation can be documented in another rat
strain, male SD rats were chosen for this study, and RCS selected as the model
(to eliminate collagenase digestion issues).
To determine whether AG accumulation appeared to be via a carrier
protein-mediated process, temperature-dependent studies were conducted.
Probenecid sensitivity was used to determine whether AG accumulation across
the basolateral membrane is an OAT-mediated process.
rats incubated with 4.3 µM

14

RCSs from male SD

C-AG at 4ºC demonstrated significantly reduced AG

accumulation (Fig. 4.40). Incubation at 4ºC decreased AG accumulation
approximately 29%. This finding is similar to that found in RCS from F344 rats
(30%).

However, when RCSs were incubated with 4.3 µM

14

C-AG in the

presence of 1 mM probenecid, no reduction of AG accumulation was found (Fig
4.40). This finding differs from that found in F344 RCSs. Most importantly, this
indicates that AG accumulation, while it may have a small protein-mediated
component, does not appear to be via OAT in SD RCSs.
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To document further any potential interaction of AG with OAT proteins
along the basolateral membrane, PAH was selected as a competitive inhibitor of
AG accumulation. RCSs incubated with 4.3 µM

14

C-AG in the presence of 1 mM

PAH showed no inhibition of AG accumulation (Fig. 4.41). This again indicates
that AG uptake does not appear to be via OAT proteins along the basolateral
membrane of the renal PT.
To verify whether apparent AG accumulation is truly via a carrier proteinmediated process, self-inhibition studies were conducted in RCSs from male
Sprague-Dawley rats as had been conducted in Fischer 344 models.
incubated with 4.3 µM

14

RCSs

C-AG in the presence of 500 µM unlabeled AG

demonstrated no inhibition of AG accumulation in this model (Fig. 4.42). This
result again demonstrates that AG accumulation is via a mechanism(s) other
than carrier protein-mediated process.
Together, these findings demonstrate that AG accumulation in SD rat is
comparable to that found in models from F344 rat. AG accumulation does not
appear to be mediated by a carrier protein mechanism, and cannot be
demonstrated to be due to OAT proteins at the basolateral membrane of the PT
in either F344 or SD rat strains. Accumulation of AG must, therefore, be due to
other mechanisms.
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Figure 4.40. The effect of temperature and probenecid on AG accumulation
in RCSs from Sprague-Dawley rat. To determine the effects of temperature on AG
accumulation, SD RCSs (30-60 mg) were incubated for 30 min with 4.3 µM 14C-AG at either 37ºC
or at 4ºC. To determine the effect of probenecid on AG accumulation, RCSs were incubated for
30 min with 4.3 µM 14C-AG at 37ºC in the absence or presence of 1 mM probenecid. Slices were
incubated in a shaking water bath (100 rpm). At the end of each assay, total slice content from
each well was analyzed for AG accumulation. Each assay was run in duplicate.

Each bar

represents mean AG content (pmol/mg protein) ± SE for n=4. *Significanlty different from control
(AG at 37ºC) values (P<0.05). Data were analyzed by One Way Repeated Measures ANOVA,
followed by Dunnett’s analysis with a 95% confidence interval.
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Figure 4.41. The effect of p-aminohippuric acid on AG accumulation in
RCSs from Sprague-Dawley rat. To determine the effects of PAH on AG accumulation,
SD RCSs (30-60 mg) were incubated for 30 min with 4.3 µM

14

C-AG in the absence or presence

of 1 mM PAH. Slices were incubated at 37ºC in a shaking water bath (100 rpm). At the end of
each assay, total slice content from each well was analyzed for AG accumulation. Each assay
was run in duplicate.

Each bar represents mean AG content (pmol/mg protein) ± SE for n=4.

Incubation with PAH did not significantly inhibit AG accumulation in RCSs. Data were analyzed
by Student’s t-test with a 95% confidence interval.
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Figure 4.42. The effect of self-inhibition on AG accumulation in RCSs from
Sprague-Dawley rat. To determine the effect of self-inhibition on AG accumulation, SD
RCSs (30-60 mg) were incubated for 30 min with 4.3 µM

14

C-AG in the absence or presence 500

µM unlabeled AG. Slices were incubated at 37ºC in a shaking water bath (100 rpm). At the end
of each assay, total slice content from each well was analyzed for AG accumulation. Each assay
was run in duplicate.

Each bar represents mean AG content (pmol/mg protein) ± SE for n=4.

Incubation with excess AG did not significantly inhibit AG accumulation in S-D RCSs. Data were
analyzed by Student’s t-test with a 95% confidence interval.

150

CHAPTER V
Discussion
5.1 Characterization of IRPTs
Characterization of IRPTs utilized for organic anion uptake in these
studies involved enzymatic analysis and visual assessment.

Because the

isolation technique for IRPTs from rat has been established previously, only
minor

characterization

was

necessary.

The

main

objective

of

this

characterization was to establish that the population of renal tissue isolated from
the male F344 kidney was enriched in proximal tubular segments. Hexokinase
(HK) and alkaline phosphatase (AP) enzyme assays demonstrated that the
tubular samples isolated are of PT origin. Microscopic examination also revealed
that the population of tubules isolated was primarily of proximal tubular origin,
and there was no glomerular contamination. Viability for IRPTs was found to be
approximately 89%, indicating that the tubule fragments were not damaged in the
isolation process.

Western blot analysis also demonstrated the presence of

OAT1 and OAT3 proteins in IRPTs. Enzymatic, microscopic and Western blot
analysis demonstrated that IRPTs isolated from male F344 rat are greatly
purified, intact, and contain both OAT1 and OAT3 proteins, demonstrating that
the IRPTs isolated can be used to study OA transport.
5.2 Toxicity Studies
Toxicity studies utilizing APAP and AG both demonstrated that these
compounds are non-toxic in the IRPT model. Both LDH release and nucleotide
levels remained at control levels indicating that these compounds do not cause
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any type of toxic reactions within the proximal tubular cells at the concentrations
and time points studied. This allowed for the study of transport of AG knowing
that AG did not interfere with any cellular mechanisms (e.g., ATP production) that
may be directly connected to the ability of the cells to transport the compound.
Studies with DC provided important new information on the toxicity of this
compound in the IRPT model. Diclofenac had been associated with nephrotic
syndrome and acute interstitial nephritis, however, the exact mechanism of DC
toxicity in the kidney is not fully understood. Initial studies conducted at 30 min
demonstrated that DC was mildly toxic at both concentrations. LDH release was
significantly increased over control LDH release values, and ATP and ADP levels
were significantly depressed compared to control nucleotide values.

To

determine whether this toxicity originated with an early toxicity event (e.g.,
depression of mitochondrial function and thus altered ATP production) or whether
toxicity appeared to be a whole cell event, as demonstrated by cellular LDH
release, studies were reduced to a 15 min time frame. At 15 min, LDH release
was not elevated compared to control values, however, ATP levels showed
significant depression over control values. This finding demonstrates that the
early events in DC toxicity appear to result in the alteration of mitochondrial
production of ATP, or, due to a toxic cellular reaction, the cellular needs for ATP
exceed the ability of the cells to produce ATP. This finding is in agreement with
those of Bort et al. (1998), demonstrating that acute diclofenac-induced toxicity in
hepatocytes was preceded by a decrease in ATP levels. Bort et al. (1998)
concluded that the toxic effect of diclofenac on hepatocytes may have been
caused by drug-induced mitochondrial impairment. These results appear to be
similar to those found in this study in the kidney. Whether this toxic event is due
to the diclofenac molecule or another metabolite (such as DC-acyl glucuronide)
remains to be clarified.
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5.3 OAT1 and OAT3 studies in IRPTs
Because the transport of organic anions across the basolateral membrane
of renal PTs from F344 rats has not been studied previously, it was important to
demonstrate the transport of known organic anions (FL, PAH, ES) by the IRPT
model. In studying transport of organic anions, inhibition of OA uptake by various
mechanisms (low temperature, inhibitors, and self-inhibition) helped characterize
the function of the transport proteins (primarily demonstrating the presence of
OAT1 and OAT3) along the basolateral membrane of the IRPT model. Time and
temperature-dependent accumulation of FL demonstrated that FL accumulation
is a protein-mediated process. Further studies using competitive inhibition of FL,
PAH and ES accumulation also demonstrated that accumulation of these OAs
supported a protein-mediated process. Since FL and PAH are the prototypical
substrates for OAT1 and OAT3, this indicates that OAT1 and/or OAT3
transporters are present and functional along the basolateral membrane in
IRPTs.
Additional evidence of the role of OAT1 and OAT3 in FL transport is the
sensitivity of FL accumulation to probenecid, the prototypical OAT inhibitor.
Accumulation of PAH and FL has been demonstrated in isolated proximal tubular
cells from Wistar rat and additional studies concluded that in isolated cells,
accumulation of FL and PAH was mediated by a carrier at the basolateral
membrane (Masereeuw et al., 1994).

Findings of the present study are in

agreement with these findings as accumulation of both FL and PAH appear to be
carrier-mediated. Additionally, FL and PAH appear to undergo accumulation via
similar or the same transport mechanisms along the basolateral membrane
(OAT1 and OAT3).

Sensitivity of FL accumulation to ouabain additionally

supports uptake of this compound by OAT1. Treatment of IRPTs with ouabain
resulted in approximately 51% inhibition of FL accumulation, providing indirect,
supportive evidence that OAT1 is partially responsible for FL accumulation in
IRPTs. These findings are in agreement with those found in isolated PTs from
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rabbit by Sullivan et al. (1990), thus indicating the role for the classical organic
anion system in FL accumulation in the IRPT model.

FL transport was also

sensitive to inhibition by the OAT3 substrates benzylpenicillin (40%) and DHEA
sulfate (82%), indicating a role for OAT3 in FL accumulation as well. The degree
of inhibition of DHEAs appears to indicate that at high concentrations (1 mM),
DHEAs loses its specificity for OAT3 and appears to inhibit OAT1 transport as
well. This is supported by the fact that Hasegawa et al. (2003) demonstrated
DHEAs inhibition of rOAT1 PAH uptake.

Hasegawa et al. (2003) also

demonstrated inhibition of PAH accumulation by rOAT1 with benzylpenicillin,
however, the concentrations of benzylpenicillin needed to inhibit FL transport
appear to be higher to produce comparable inhibition of FL transport by DHEAs.
Because there is overlap with FL and PAH for transport by OAT1 and
OAT3, it is difficult to determine the exact contribution of each transporter in total
accumulation of FL and PAH. The potential role of other transporters besides
OAT1 and OAT3 can also not be ruled out. Accumulation of ES, the prototypical
OAT3 substrate, suggests that OAT3 transporters are also present and functional
in the IRPT model, and provides a useful substrate to probe the contribution of
OAT3 along the basolateral membrane. Probenecid sensitivity for FL, PAH and
ES also provided supporting evidence that accumulation of these compounds is
via organic anion transport proteins along the basolateral membrane, as
probenecid is the prototypical inhibitor of OAT transport.
While the use of ES helped to identify the function of OAT3 in this model,
it does not appear to demonstrate the expected inhibition by probenecid and
temperature as would be expected with OAT3 transport. Very weak inhibition by
probenecid (41%) and treatment at 4ºC (38%) indicates that there may be other
mechanisms for ES accumulation in this model, be it via other non-OAT
transporters, or nonspecific binding. Sweet et al. (2003) demonstrated nearly
complete inhibition of ES via rOAT3 (~88%) in rOAT3 transfected oocytes. Selfinhibition studies of ES accumulation further support that there may be other
mechanisms than OAT transport for ES in this model as self-inhibition provided a
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greater level of inhibition of ES than either probenecid treatment or reduction in
temperature.
It is important to note that recent studies have shown that OAT1 and
OAT3 share similar mechanisms of action as dicarboxylate exchangers indirectly
coupled to the sodium gradient (Sweet et al., 2003). Since there is a great deal
of overlap in substrate specificity with FL and PAH for OAT1 and OAT3, it cannot
be definitively stated that both of these transporters are functional in this model
based on data obtained for FL, PAH and ES accumulation by IRPTs. Since both
OAT1 and OAT3 may function via a similar mechanism (dicarboxylate exchange
coupled to the sodium gradient), OAT1 and OAT3 may be sensitive not only to
probenecid but also to ouabain as ouabain would affect the ability of the cells to
maintain the sodium gradient necessary for transport via.

Whether ouabain

interferes with OAT3 transport remains to be clarified in this model. Cha et al.
(2001) and Kusuhara et al. (1999) demonstrated that hOAT3 and rOAT3
expressed in oocytes were not inhibited by ouabain. This raises the question as
to the driving force of OAT3 transport, whether OAT3 is also dependent on the
Na+/K+ ATPase to maintain the sodium gradient for α-ketoglutarte, thus
maintaining the α-ketoglutarte gradient to drive OAT3 transport.
5.4 Acetamidophenyl glucuronide accumulation in IRPTs
OAT proteins, specifically OAT3, have been demonstrated to transport the
glucuronide conjugate 17β-estradiol-d-17β-glucuronide.

In the IRPT model,

OAT1 and OAT3 appear to be functional, transporting the known organic anions
PAH (OAT1 and OAT3) and ES (OAT3).

Since glucuronide metabolites are

organic anions at physiological pH, AG may be a substrate for the OAT
transporters along the basolateral membrane of the renal PT. This is the first
time that IRPTs have been used to study the renal handling (secretory process)
of a non-steroid glucuronide conjugate across the basolateral membrane of the
renal PT. While rOAT3 has been shown to transport estradiol glucuronide, it has
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not been determined whether transport of estradiol glucuronide relies on the
glucuronide moiety, or the steroid structure.

Previous studies that have

assessed renal secretion of AG have used whole animal studies where the exact
nature of the interaction of AG with renal OAT transporters cannot be
determined.

Use of the IRPT model to study renal AG secretion allows for the

assessment of the interaction of the AG molecule directly with the basolateral
membrane, and thus, the transport proteins (OAT1 and OAT3 primarily) that are
active along that membrane.
The accumulation of AG in IRPTs does not support protein-mediated
uptake across the basolateral membrane. While AG accumulation appears to
have a time-dependent factor for accumulation, uptake can not be deminished by
reduction of temperature to 4ºC. Since uptake is not temperature dependent, it
indicates that accumulation is not by a protein-mediated mechanism, and is more
likely due to non-specific binding of the AG molecule to proteins along the tubule,
or gradual accumulation into interstitial spaces between the proximal tubular
cells, as rat PTs in general are noted to be significantly leaky. In addition to not
being temperature sensitive, self-inhibition studies using 1000-fold excess
unlabeled AG did not show inhibition of AG accumulation as well. This again
demonstrates that apparent accumulation of AG is not due to a protein-mediated
process.
As it has been shown that AG accumulation does not appear to be a
protein-mediated process, more specifically, it does not appear to be mediated
by OAT proteins along the basolateral membrane of the IRPTs. Cotreatment
with AG was not able to inhibit the accumulation of the known OAs, FL, PAH or
ES. In addition, the accumulation of AG was not inhibited by the presence of ES.
This demonstrates that AG does not appear to interact with the organic anion
transporters OAT1 or OAT3 along the basolateral membrane in this model. In
addition, AG accumulation was also not found to be probenecid sensitive, again
showing that AG does not appear to interact with OAT proteins in this model.
This finding supports the finding by Duggin and Mudge (1975) that AG secretion
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did not appear to be probenecid sensitive, while the secretion of the sulfate
conjugate was. Additionally, AG accumulation was not found to be influenced by
metabolism (deconjugation) during incubation with IRPTs, as inhibition of βglucuronidase activity had no effect of AG accumulation. The fact that inhibition
of glucuronide deconjugation did not affect the results of AG accumulation in
IRPTs shows that results obtained in these experiments are due directly to
movement of the AG molecule and not deconjugation to the parent compound
APAP.
5.5 OAT1 and OAT3 studies in RCSs
To assure that these studies were not compromised by inadequate activity
of OAT proteins due to partial enzymatic digestion, a number of studies were
also carried out in renal cortical slices. Since AG appears to have extremely
limited affinity for OAT transporters, it was necessary to demonstrate that
collagenase digestion during the IRPT preparation did not have a detrimental
effect on the activity of OAT transporters. If the OAT transporters had become
partially digested during the PT isolation procedure, their ability to interact with
AG may have been greatly weakened, or collagenase digestion may have left
fewer functional OAT transporters along the basolateral membrane of the
tubules. Partial digestion of membrane OAT proteins could potentially account
for the apparent lack of AG transport by basolateral OAT proteins.
Initial OAT transporting capabilities were tested with PAH and ES. RCS
demonstrated probenecid sensitive uptake of both PAH and ES, as well as time
and temperature dependent accumulation of ES. Time-dependent accumulation
of ES by RCS follows a similar pattern as that determined by Sweet et al. (2003)
and Hasegawa et al. (2003), with nearly linear uptake for the first 15 min and
approaching steady state during the subsequent 45 min. Additionally, uptake of
ES was concentrative. These PAH and ES accumulation studies indicate that the
OAT transporters are functional in this model and this model could be used to
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study the interactions between OAT transporters and AG. Probenecid inhibition
of PAH uptake was approximately 80% which was very similar to inhibition in
IRPTs (86%). ES accumulation also appeared to show similar results as those
found in IRPTs. Inhibition of ES with probenecid demonstrated a 33% inhibition
in RCSs, which is similar to the 41% inhibition found in IRPTs, indicating that the
same mechanisms for ES accumulation are in place in both models.
Interestingly, Sweet et al. (2003) demonstrated nearly twice the amount of
inhibition of ES accumulation by probenecid (66%) in their rat renal cortical slice
model.

This indicates that in the F344 rat, there may be a lower level of

expression of OAT3 compared to other rat strains. This was further supported by
Western blot analysis, demonstrating only weak labeling for OAT3 in the F344
kidney.
Temperature-sensitive uptake of ES in RCSs however, appeared quite
different than in IRPTs. In RCSs, reduction of temperature to 4ºC caused an
80% reduction in ES accumulation, whereas in IRPTs, it only inhibited ES uptake
by 38%.

This seems to indicate that there are also mechanisms of ES

accumulation other than OAT3 in the RCS model, as in the IRPT model, that may
be more sensitive to the effects of collagenase digestion. While non-specific
binding appears to be less in the RCS than in the IRPT model, the amount of ES
accumulation accounted for by OAT3 (probenecid sensitive) appears to be
similar.

Since these results in general appear similar to those found in IRPTs,

the similarity of results in both RCS and IRPT models indicates that in the IRPT
model, the digestion of proteins did not appear to affect OAT transporting
capabilities. Additionally, both the RCS and IRPT models appear to show similar
capabilities for OAT transport and both are useful models for studying the effects
of OAT transport on AG accumulation in the renal PT.
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5.6 Acetamidophenyl glucuronide accumulation in RCSs
In renal cortical slices, AG accumulation appears to demonstrate possible
protein-mediated transport. Temperature-dependent uptake showed only a 30%
decrease in AG accumulation, indicating that while it appears there may be some
type of protein-mediated transport, there is still a large amount of AG
accumulation that cannot be accounted for by a protein-mediated transport
mechanism (e.g., non-specific binding).

However, while temperature and

probenecid sensitivity can indicate a carrier-mediated OAT mechanism lack of
self-inhibiton of AG accumulation is a more accurate determination of whether a
carrier-mediated mechanism exists for AG accumulation. Self-inhibition studies
did not demonstrate any inhibition of AG accumulation. Lack of self-inhibition in
AG accumulation provides a conflicting result to the temperature-dependent
study. Since self-inhibition failed to demonstrate inhibition of AG accumulation,
this suggests that AG accumulation is actually not a protein-mediated process in
this model and provides additional new in vitro data that may help to clarify in
vivo results found by other investigators.
OAT proteins in RCSs do not appear to play a major role in AG
accumulation at the basolateral membrane. AG accumulation in RCSs was only
weakly inhibited (22%) by treatment with probenecid, indicating a very weak
interaction at OAT proteins.

More importantly, however, is the finding that

cotreatment of AG with PAH or ES was not able to inhibit the accumulation of AG
in RCSs. This strongly suggests that AG does not interact with OAT1 and OAT3
along the basolateral membrane.

These findings are similar to those found in

IRPTs.
To assure that the results found in male F344 rats were not a straindependent phenomenon (i.e., this strain may show a lower expression of OAT
transporters than another strain), AG accumulation was also studied in RCSs
from male SD rats. AG has been suggested to undergo renal secretion in SD
rats (Galinsky and Levy, 1981) as well as Wistar rats (Watari et al. 1983).
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Findings in SD rats, however, did not support the findings of Galinsky and Levy
(1981), and rather supported those found in this lab in F344 rats. Decreasing the
incubation temperature inhibited AG accumulation by only 29%, similar to that
found in RCSs from F344 rats. Self-inhibition studies however, did not
demonstrate any inhibition of AG accumulation. This finding is also the same as
the findings in F344 rat and reconfirms that AG accumulation is not via a proteinmediated process.

AG accumulation in RCSs from SD rats was also not

probenecid sensitive, indicating that AG accumulation is not via OAT proteins.
The finding that AG is not transported by OATs was further verified by the fact
that AG accumulation was not inhibited by the presence of PAH, a known OAT
substrate.

These findings demonstrate that the results found in F344 rats are

not a rat strain-dependent phenomenon, and AG accumulation does not appear
to undergo protein-mediated transport, and more specifically does not interact
with OAT transporters along the basolateral membrane of the renal PT in rat
models.
While AG does not appear to undergo transport in this model, it does
appear to accumulate via some mechanism. It is possible that this accumulation
is actually by non-specific binding. The studies that examined mannitol uptake
actually further suggest that AG accumulation may be due to protein binding, as
AG accumulation is much greater than mannitol accumulation, as can be seen by
the time-dependent accumulation of each compound. Mannitol uptake, which
measures the amount of substrate accumulation into water filled spaces is much
smaller than that of AG, indicating that while AG may also accumulate in spaces
between the cells in both IRPTs and RCSs, there appers to be another factor to
AG accumulation that is not accounted for by transport or accumulation into
spaces. This mechanism is quite possibly via protein binding within the tissue, or
intercalation of the APAP portion of the AG molecule into the surface of the IRPT
or RCS, since APAP is lipid soluble and can undergo diffusion through
membranes.
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5.7 Interaction of glucuronide metabolites with OAT1 and OAT3
in IRPTs and RCSs
While studies using AG have indicated that this glucuronide metabolite
does not interact with OAT1 or OAT3 transporters along the basolateral
membrane, it was important to determine whether other glucuronide metabolites
may interact with transporters along the PT basolateral membrane. To study the
potential interaction of other glucuronide metabolites with OAT, PAH was used
as the prototypical substrate to determine whether testosterone glucuronide (TG)
or methylumbelliferyl glucuronide (MUG) demonstrated any interaction with the
transport of PAH (OAT1 and OAT3). Since TG is a steroid, studies with TG may
potentially help to elucidate the role of the steroid portion of the molecule in
transport across the basolateral membrane vs. the glucuronide portion of the
moiety, helping determine whether there is a difference in transport of steroid
glucuronides and non-steroid glucuronides. MUG is a non-steroid glucuronide
metabolite of a similar molecular weight as AG (352.3 and 349.3, respectively).
Studies conducted in both IRPTs and RCSs from F344 rats showed that these
glucuronide metabolites do not appear to inhibit the accumulation of PAH along
the basolateral membrane. In these studies AG was also used as a secondary
control for the effects of TG and MUG. Treatment with TG and MUG were not
statistically different from AG treatment, suggesting that TG and MUG may
possibly interact along the basolateral membrane in a similar manner as AG.
The fact that TG and MUG do not interfere with PAH accumulation suggests that
these glucuronide metabolites do not interact with OAT proteins along the
basolateral membrane of rat PTs, and may be transported or enter the proximal
tubular cells by other mechanisms.
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5.8 Conclusion
The present study provides some of the first characterization of organic
anion transport in the F344 rat. Several studies have been conducted in SD and
Wistar rats, but to date, information in the F344 model is lacking. With the vast
amounts of toxicity data for various compounds available in the F344 rat, it is
important to more fully understand the function of transport mechanisms for
potentially toxic compounds in the F344 rat model. With the information gained
in this study, it can help to better understand the mechanisms of cellular entry of
potentially toxic compounds. Uptake of organic anions appears to follow similar
patterns in both IRPT and RCS from Fisher 344 rats.

In the IRPT model,

collagenase digestion does not appear to have a negative impact on the ability of
this model to demonstrate OA transport, as compared to the RCS model. In
general, the RCS model has some benefits over the IRPT model, mainly in
technical simplicity. While the isolation procedure for IRPTs is time consuming,
the IRPT model offers a highly purified population of PT fragments that are useful
for studying the impact of OAT transport in the proximal tubules handling of
xenobiotics without the interference of other cell populations.
In terms of glucuronide transport, studies in IRPTs and RCSs from both
F344 and SD rats suggest that glucuronide metabolites are not transported by
the OAT proteins along the basolateral membrane of rat PTs.

While

glucuronides are organic anions at physiological pH, it appears that the
specificity of these compounds for OAT is extremely low, and if they have the
ability to cross the basolateral membrane, it is via another mechanism. It is also
important to note that the findings presented in these studies do not support the
findings found in the literature. The findings of Duggin and Mudge (dog; 1975),
Galinsky and Levy (SD rat; 1981), and Watari et al. (Wistar rat; 1983) have all
suggested that the kidneys possess the ability to secrete glucuronide
metabolites, and demonstrate renal secretion with AG. The conflicting findings
with those of Duggin and Mudge (1975) may be accounted for by species
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differences in transporters along the basolateral membrane of the renal PT (rat
vs. dog). However, similar results were expected in these studies as those found
by Galinsky and Levy (1981) and Watari et al. (1983), who suggested renal
secretion of AG in rat models.
Upon thorough study of the findings in these papers, there were a number
of mechanistic discrepancies that may account for the conflicting results between
their studies and those found in this present study. During studies on the renal
clearance of AG in SD rats conducted by Galinsky and Levy (1981), control rats
for renal CLCR were not the same rats used for studying AG clearance. Since AG
clearance values and CLCR values were not conducted in the same rats at the
same time, the actual CLCR values determined do not reflect any potential effects
that AG itself may have on renal clearance, and therefore CLCR values.
Therefore, the clearance of AG may have appeared to be higher than control
renal creatinine clearance, thus indicating secretion. To accurately determine the
true AG clearance in the model, AG treatment and clearance should have been
conducted on the same rats at the same time, and control values should not
have been determined in a separate group of rats. A similar discrepancy also
occurs with the study conducted in Wistar rats by Watari et al. (1983). In the
study conducted by Watari et al. (1983) control CLCR values used for comparison
with AG clearance values were those determined by Galinsky and Levy (1981) in
SD rats. Thus, the same control issues exist. CLCR values and AG clearance
values in the study by Watari et al. (1983) were not only measured in separate
rats at a separate time, but data was collected in a different rat strain as well.
Making the comparison between CLCR in SD rats from one experiment to AG
clearance in Wistar rats in a separate experiment, under likely different laboratory
conditions, compromises the validity of the results. Therefore, what Watari et
al.(1983) demonstrate as secretion of AG, based on AG clearance values in
Wistar rats being higher than CLCR in SD rats, cannot be accurate.
The current findings in the literature on the renal secretion of glucuronide
metabolites remain limited. AG has been used in a number of studies as it is a
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common, renally excreted metabolite of acetaminophen.

While the studies

mentioned above suggest that the kidney can secrete AG, other conflicting
studies suggest that it is not secreted but rather is excreted in the urine solely via
glomerular filtration (Heckman et al. 1986). The findings in the present study
support the role for glomerular filtration rather than secretion of this glucuronide
metabolite (AG) along the basolateral membrane of the PT. Specifically, AG
does not appear to be a substrate for renal basolateral membrane OAT proteins
in the F344 model. The overall contribution of OAT in the basolateral membrane
transport of AG (and potentially other glucuronide metabolites, as suggested by
OAT inhibition studies with TG and MUG), is also minimal in the F344 rat.
Furthermore, while there appears to be tubular accumulation of AG, the
accumulation of AG does not appear to be due to a non-OAT, protein carriermediated mechanism along the basolateral membrane.

Thus, rat renal

basolateral proximal tubular cells do not appear to facilitate the transport of
glucuronide conjugates, and thus do not appear to contribute to the renal
secretion of glucuronide conjugates by transport mechanisms along the
basolateral membrane. If uptake with subsequent secretion is occurring across
the basolateral membrane, it is by a mechanism other than a protein-mediated or
OAT transport and other mechanisms of flux of AG across the basolateral
membrane need to be evaluated.
5.9 Future Directions
To gain a more complete picture of the renal secretion of AG, and
potentially other glucuronide metabolites, the other type of information that needs
to be gathered is an accurate measurement of the renal secretion of AG in a rat
model. Because the papers mentioned in this discussion failed to accurately
establish the values of AG clearance, it is difficult to determine whether the data
truly reflect AG secretion.

Based on the findings of this current study, it is

believed that their results do not reflect true AG secretion.
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Accurate

determination of AG secretion by the rat kidney could be accomplished by
repeating data collection for AG clearance in the whole animal with inulin
clearance values being measured in the same animals at the same time as
APAP or AG clearance.

These data would help to clarify the discrepancy

between the studies discussed and this one.
As far as determining further the potential role for OAT transporters in the
uptake of glucuronide conjugates, particularly AG, the simplest way to
accomplish this would be to use rOAT1 and/or rOAT3 transfected cells (i.e.,
oocytes or LLC-PK1 cells).

Transfected cell models, used frequently in OA

uptake studies, would allow for direct contact between the selected transporter
without interference from other transport proteins that are present in the
basolateral membrane of IRPT and RCS models.

By directly treating a cell

expressing rOAT1 or rOAT3 with AG, the uptake of AG could be determined,
assessing the contribution of each transporter in the renal handling (secretion) of
AG.
Another potential for studying further glucuronide transport would be the
use of cultured cells.

The use of primary cell culture could provide crucial

evidence for the renal handling of these conjugates as cells grown on permeable
membranes would allow for a dynamic system from which data could be obtained
from both the basolateral and luminal membranes of the renal PT. Where this
study in IRPT and RCS demonstrated that there did not appear to be a secretory
mechanism for AG, it does not address the potential for luminal uptake of the AG
compound and potentially other glucuronide conjugates.

Primary cultures of

renal PTs from F344 rat was the original aim of this study. However, a number of
contamination conditions led to the use of IRPTs and RCSs to study the
basolateral uptake of AG. Initial characterization of PT cells grown in culture
demonstrated that they were of PT origin (based on enzymatic analysis as in the
IRPT model) and should, therefore, have been capable of demonstrating OATmediated transport. In the right setting, primary cultures would have provided a
system similar to the IRPT model (maintenance of cell-to-cell contact and
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communication, maintained cellular metabolism and transport) with the benefit of
being able to more completely study how the renal PT handles glucuronide
conjugates.

Again, in addition to the basolateral membrane, the luminal

membrane would have also been intact and functional, providing a much more
dynamic model for studying the transport of AG.
Another important study that would greatly clarify the findings found in the
present study would be to examine the nature of the apparent protein binding of
AG. Whether it could be done immunohistochemically or by other means of
studying protein binding, it would allow for greater understanding as to the
disposition of the AG molecule in the IRPT and RCS model.
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Appendix

Perfusion Buffer A
pH
7.36
Chemical
NaCl
KCl

Concentration
115.0 mM
5.0 mM

NaHCO3

25.0 mM

NaH2PO4

2.0 mM

MgSO4●7H2O
Alanine
Glucose
Deferoxamine
Mannatol
Lactate
Dextran
Penicillin G

1.0 mM
1.0 mM
5.0 mM
0.1 mM
25.0 mM
4.0 mM
0.6 % (w/v)
100 units/ml

CaCl2

1.0 mM

bubble with 95% O2/ 5% CO2 for 30 min

Perfusion Buffer B
Chemical
Collagenase
SBTI

Concentration
130 units/ml
0.01 % (w/v)

diluted in 25 ml Perfusion buffer A
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Incubation Buffer A
pH 7.36
Chemical
NaCl
KCl

Concentration
115.0 mM
5.0 mM

NaHCO3

25.0 mM

NaH2PO4

2.0 mM

MgSO4●7H2O
Alanine
Glucose
Deferoxamine
Malic acid
Butyric acid
Lactate

1.0 mM
1.0 mM
5.0 mM
0.1 mM
5.0 mM
2.0 mM
5.0 mM

CaCl2
Penicillin G

1.0 mM
100 units/ml

bubble with 95% O2/ 5% CO2 for 30 min

Incubation Buffer B
Chemical
Concentration
Collagenase
150 units/ml
SBTI
0.02% (w/v)
BSA
0.2% (w/v)
Dnase
70 units/ml
diluted in 50 ml Incubation buffer A
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Krebs-Henseleit Concentrate (KHB) (10x)
Chemical
NaCl
KCl

Concentration
118.0 mM
4.8 mM

NaHCO3

0.12 mM

MgSO4●7H2O
Hepes

25.0 mM
25.0 mM

bubble with 95% O2/ 5% CO2 for 30 min

Krebs-Henseleit Buffer (1x)
pH 7.36
Chemical
KHB 10x

Amount
20.0 ml

dH2O

180.0 ml

bubble with 95% O2/ 5% CO2 for 30 min
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Transport Buffer #1 (tubules)
295 ± 5 mOsm/kg
Chemical
NaCl

pH 7.4

Concentration
110.0 mM

NaHCO3
KCl

25.0 mM
5.0 mM

NaH2PO4

2.0 mM

MgSO4●7H2O

1.0 mM

CaCl2
Sodium acetate
Glucose
Alanine
Glycine
Lactate
Malic acid
Sodium citrate

1.8 mM
10.0 mM
8.3 mM
5.0 mM
0.9 mM
1.5 mM
1.0 mM
1.0 mM

bubble with 95% O2/ 5% CO2 for 30 min

Transport Buffer #2 (slices)
pH 7.5
Chemical
NaCl
KCl

Concentration
120.0 mM
16.2 mM

CaCl2

1.0 mM

MgSO4●7H2O

1.2 mM

NaH2PO4

10.0 mM

bubble with 95% O2/ 5% CO2 for 30 min
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45% Percoll Density Gradient
pH 7.36
Chemical
KHB 10x

Amount
6.0 ml

dH2O

27.0 ml
27.0 ml

Percoll

bubble with 95% O2/ 5% CO2 for 30 min

mixed in exact order

Alkaline Phosphatase Assay
Procedure 104

Stock substrate solution
40 mg capsule

10 ml H2O

p-Nitrophenol standard solution
0.5 ml p-nitrophenol standard solution
QS to 100 ml with 0.02 N NaOH
0.02 N NaOH
0.8g NaOH

1000 ml H2O
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Hexokinase Assay

Substrate solution (3.24x)
Glucose
0.88 g
MgCl2●6H2O
Na2EDTA
Tris/HCl

1.32 g
0.121 g
5.1 g
100.0 ml adjust pH to 7.6

NADP+ (3.24x)
8.1 mg/ 5.0 ml H2O

ATP (3.24x)
0.267 g/ 3.0 ml H2O

G6PDH (type VII, Sigma)
Stock = 350 units/mg; 332.5 units/ml
Assay:

Chemical
Glucose

Concentration
15.0 mM

MgCl2●6H2O

20.0 mM

Na2EDTA
Tris/HCl
NADP+
ATP
G6PDH

10.0 µM
0.1 M
0.67 mM
2 units/ml
50 mM
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Bradford Reagent
Chemical
Coomassie
Brilliant Blue
95% EtOH
85% Phosphoric
acid
QS to 1L with H2O

Amount
100.0 g
50.0 ml
100.0 ml

p-[glycyl-14C]-aminohippuric acid (PAH)
Stock Solution

50 µCi

1
2

add 375 µl dH2O to bottle (+ 2 drops 1 N NaOH)
transfer to scintillation vial

3

was bottle 1x with 375 µl H2O and transfer to scintillation vial
1.25 ml = 50 µCi/1.25 ml= 40 µCi/ml

Working solution

20µCi/ml

250 µl stock PAH solution
250 µl H2O
500 µl = 20 µCi/ml

Stock cold PAH
14 mM
27.188 mg / 10 ml H2O
several drops of 1N NaOH added
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10µCi/ml
100 µl stock PAH
solution
300 µl
H2O
400 µl = 10 µCi/ml

70 µM working solution
1.25 ml stock 14C-PAH
1.25 ml stock
cold PAH
2.5 ml 7 mM PAH @ 20 µCi/ml

4-acetamidophenyl-ring-UL14C β-D-glucuronide sodium salt (AG)
Stock Solution
1

250 µCi

add 3.95 µl dH2O to bottle
6.25 ml = 250 µCi/6.25 ml= 40 µCi/ml

Working solution

20µCi/ml

250 µl stock AG solution
250 µl dH2O
500 µl = 20 µCi/ml

10µCi/ml
100 µl stock AG
solution
300 µl
dH2O
400 µl = 10 µCi/ml

Assay concentration
1:100 dilution of working solution yields 0.1 or 0.2 µCi/ml
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D-[1-3H(N)]-mannitol (MN)
Stock Solution
1
2
3

250 µCi

add 0.25 ml dH2O to vial
transfer to scintaillation vial labeled stock
wash vial 4x with 0.5 ml dH2O and add to stock
250 µCi/ 2.5 ml = 100 µCi/ml

Working solution

10µCi/ml

50 µl stock MN solution
450 µl dH2O
500 µl = 10 µCi/ml

Assay concentration
1:100 dilution of working solution yields 0.1 or 0.2 µCi/ml

[6,7-3H(N)]-estrone sulfate, ammonium salt (ES)
Stock Solution
50 µCi
1
Stock solution at 50 µCi/ml

Working solution

10µCi/ml

50 µl stock ES solution
2.450 ml dH2O
3 ml = 15 µCi/ml
***standards of working soln.= actually at 20 µCi/ml
Assay concentration
1:100 dilution of working solution yields 0.2 µCi/ml
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Fluorescein 400uM
1.5 mg/ 10 ml H2O

Probenecid 100mM
28.54 mg / 1.0 ml
add 1 N NaOH dropwise until in solution
QS to 1 ml with H2O

p-aminohippuric acid (PAH) 100mM
19.42 mg/ 1 ml
add 1 N NaOH dropwise until in solution
QS to 1 ml with H2O

Ouabain 10mM
1.82 mg/ 250 µl H2O (warmed)
protected from light

Saccharic acid 1,4-lactone 2M
38.0 mg/ 100 µl H2O
20 mM :
30µl 2M stock/3 ml
10 mM :
15µl 2M stock/3 ml
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4-acetamidophenyl-β-D-glucuronide sodium salt (AG)
500 mM
70 mg/ 400 µl H2O

100 mM
35 mg/ 1 ml H2O

50 mM
17.44 mg/ 1 ml H2O

20 mM
80 µl 50 mM AG + 180 µl H2O

Estrone Sulfate (ES)
protected from light

40 mM
4.7 mg/ 360 µl 100% EtOH
warmed

25mM
18.6 mg/ 2 ml 100% EtOH
warmed

10 mM
3.7 mg/ 1 ml 100% EtOH
warmed

Testosterone Glucuronide (TG) 16.7 mM
10 mg/ 1230 µl 66% EtOH

Methylumbelliferyl-β-D-glucuronide 50 mM
8.8 mg/ 500 µl 50% EtOH
warmed
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Dihydroxyepiandrosterone sulfate (DHEAs) 100 mM
3.9 mg/ 100 µl H2O
warmed

Diclofenac (DC)
50 mM
15.8 mg/ 1 ml H2O

20 mM
80 µl 50 mM DC + 180 µl H2O

4-Acetamidophenol (APAP)
50 mM
7.6 mg/ 1 ml H2O

20 mM
80 µl 50 mM APAP + 180 µl H2O

Benzylpenicillin (PG) 100 mM
35.6 mg/ 1 ml H2O

Pentobarbital Sodium 50 mg protein/ml
500 mg/ 10 ml H2O

Heparin
22.7 mg/ 10 ml 0.9% saline
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0.9% Saline
9 g NaCl/ 1L H2O

3M Perchloric Acid
50 ml 70% perchloric acid
qs 250 ml with H2O

Potassium Phosphate Buffer (KH2PO4)monobasic - HPLC
13.6 g/ 1.0 L H2O
pH 6.0, filtered

Solutions for Gel Preparation and Western Blot

†

Solutions were prepared by Dr. Kelley Kiningham

Cell Fractionization
Homogenization Buffer (25 ml)
20 mM HEPES .........................................................................5 ml x 100 mM
5 mM EGTA..............................................................................1.25 ml x 0.1M
10 mM 2-mercaptoethanol (2ME)*...........................................................20 ul
1 ug/1 ml pepstatin ........................................................... 25 ul of (1 mg/1 ml)
1 ug/1 ml leupeptin ........................................................... 20 ul of (1 mg/1 ml)
1 ug/1 ml aprotinin............................................................ 20 ul of (1 mg/1 ml)
1 mM phenylmethylsufonyl fluoride (PMSF) .............................500 ul x10mM
Diluted to 25 ml with deionized water
* 2ME was not included for nonreduced protein samples.
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Gel Preparation
30% Acrylamide, 0.8% Bisacrylamide† (neurotoxic)
60 g acrylamide
1.6 g bisacrylamide
dilute to 200 ml with water
Use 37oC water bath to dissolve solids if necessary; sterile filter into foil
wrapped or brown bottle and store at 4oC.
5X Separation Buffer†
56.76 g TRIS
1.25 g sodium dodecyl sulfate (SDS)
pH to 8.8
Diluted to 250 ml with DI water
5X Stacking Buffer†
37.85 g TRIS
2.5 g SDS
pH to 6.8
Diluted to 500 ml with DI water
10% Ammonium Persulfate (APS) (prepared fresh daily)
0.1 g APS in 1 ml deionized water
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2X Sample Buffer†
0.76 g TRIS (125 mM)
2 g SDS (13.9 mM or 4%)
10 ml Glycerol (20%)
5 ml 2-mercaptoethanol (2ME)* (10%)
pH to 6.8
Diluted to 50 ml with DI water
Bromophenol blue (1-2 mg) added until deep blue color obtained
Sample Buffer was prepared without 2-ME which was added just before use
(1:10). Note: If 2X sample buffer is prepared without 2ME, it can remain at
room temperature.
* 2ME was not included for nonreduced protein samples. DI water was
substituted for 2ME.
Separation Gel

8 % Gel (ml) 12.5% Gel (ml)

5X Separation Buffer

7.0

7.0

30% Acrylamine, 0.8% Bis

9.3

14.6

H2O

18.5

13.2

10% Ammonium Persulfate*

0.15

0.15

TEMED

0.025

0.025

Total

35.0 ml

35.0 ml

N-butanol (~2 ml)
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Stacking Gel

ml

5X Separation Buffer

3.0

30% Acrylamine, 0.8% Bis

1.5

H2O

10.5

10% Ammonium Persulfate*

0.075

TEMED

0.015

After rinsing n-butanol from the set separation gel with a large volume of
water then carefully drying the mold, Stacking Gel was prepared and
poured over the separation gel then left at room temperature for one hour to
set.
10X Electrode Buffer† (Dilute 1:10 prior to use)
30.3 g TRIS (250 mM)
144 g Glycine (1.92 M)
10 g SDS (34.68 mM)
pH to 8.3
Diluted to 1 L with deionized water
Solutions Needed for Western Analysis
Transfer Buffer†
12.12 g TRIS
57.6 g glycine
800 ml methanol
3.2 L distilled water
Solution should be precooled for high voltage transfers.
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Ponceau S†
g Ponceau S
5 ml acetic acid
diute to 100 ml with deionized water
Solution is stored in a brown bottle and may be reused.
10X TBS† (Dilute 1:10 prior to use)
12.12 g TRIS
87.66 g NaCl
pH to 8.0
Dilute to 1 L with deionized water
1X TBST
Add 500 µl Tween-20 to 1 L 1X TBS
Blocking solution (Blotto A)
5% non-fat dry milk in TBST (2.5 mg to 50 ml)
Prepared fresh daily and refrigerated.
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